{"text":"Results from clinical trials evaluating agents such as ixabepilone , albumin-bound paclitaxel , capecitabine , vinorelbine , pemetrexed , and irinotecan are presented .","paragraph":"<h3><u>Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.</u></h3>Resistance to chemotherapeutic agents is a significant obstacle to the effective treatment of metastatic breast cancer (MBC). Anthracycline- and taxane-based regimens are active as first-line treatment for MBC; however, MBC often progresses because of primary or acquired resistance to anthracyclines and taxanes. There are few options for the treatment of patients with anthracycline- and taxane-resistant or taxane-refractory MBC. This article reviews several single agents that have demonstrated activity as treatment for patients with MBC who progress during, or rapidly following, treatment with anthracyclines and taxanes. <b style='color:DodgerBlue;'><i>Results</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>evaluating</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>ixabepilone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>albumin-bound</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>pemetrexed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>presented</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Single-agent <b style='color:Tomato;'><i>capecitabine</i></b> is approved for the treatment of patients after failure of anthracyclines and taxanes. <b style='color:Tomato;'><i>ixabepilone</i></b> has demonstrated efficacy in patients with MBC resistant to multiple chemotherapeutic agents and is the only agent approved by the Food and Drug Administration as monotherapy for anthracycline-, taxane-, and <b style='color:Tomato;'><i>capecitabine</i></b>-resistant MBC. Improved treatment strategies and further evaluation of newer agents may reduce the current burden of treatment-resistant or treatment-refractory MBC.","tokens":[{"text":"Results","start":0,"end":7,"id":0,"ws":true},{"text":"from","start":8,"end":12,"id":1,"ws":true},{"text":"clinical","start":13,"end":21,"id":2,"ws":true},{"text":"trials","start":22,"end":28,"id":3,"ws":true},{"text":"evaluating","start":29,"end":39,"id":4,"ws":true},{"text":"agents","start":40,"end":46,"id":5,"ws":true},{"text":"such","start":47,"end":51,"id":6,"ws":true},{"text":"as","start":52,"end":54,"id":7,"ws":true},{"text":"ixabepilone","start":55,"end":66,"id":8,"ws":true},{"text":",","start":67,"end":68,"id":9,"ws":true},{"text":"albumin-bound","start":69,"end":82,"id":10,"ws":true},{"text":"paclitaxel","start":83,"end":93,"id":11,"ws":true},{"text":",","start":94,"end":95,"id":12,"ws":true},{"text":"capecitabine","start":96,"end":108,"id":13,"ws":true},{"text":",","start":109,"end":110,"id":14,"ws":true},{"text":"vinorelbine","start":111,"end":122,"id":15,"ws":true},{"text":",","start":123,"end":124,"id":16,"ws":true},{"text":"pemetrexed","start":125,"end":135,"id":17,"ws":true},{"text":",","start":136,"end":137,"id":18,"ws":true},{"text":"and","start":138,"end":141,"id":19,"ws":true},{"text":"irinotecan","start":142,"end":152,"id":20,"ws":true},{"text":"are","start":153,"end":156,"id":21,"ws":true},{"text":"presented","start":157,"end":166,"id":22,"ws":true},{"text":".","start":167,"end":168,"id":23,"ws":false}],"spans":[{"start":55,"end":66,"token_start":8,"token_end":8,"label":"DRUG"},{"start":83,"end":93,"token_start":11,"token_end":11,"label":"DRUG"},{"start":96,"end":108,"token_start":13,"token_end":13,"label":"DRUG"},{"start":111,"end":122,"token_start":15,"token_end":15,"label":"DRUG"},{"start":125,"end":135,"token_start":17,"token_end":17,"label":"DRUG"},{"start":142,"end":152,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19675449/","_input_hash":234088543,"_task_hash":2101921619,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The clinical studies provide evidence that combined fluticasone/formoterol is more efficacious than fluticasone or formoterol given alone , and provides similar improvements in lung function to fluticasone ( Flixotide ( \u00ae ) ) and formoterol ( Foradil ( \u00ae ) ) administered concurrently .","paragraph":"<h3><u>[A new fixed dose combination of fluticasone and formoterol in a pressurised metered-dose inhaler for the treatment of asthma].</u></h3>The combination of an inhaled corticosteroid and a long acting beta-2 agonist is indicated for the regular treatment of persistent moderate-to-severe asthmatics whose asthma is not controlled by inhaled corticosteroids and the occasional use of a short acting beta-2 agonist. The aim of this review is to give an overview of the rationale of combining <b style='color:Tomato;'><i>formoterol</i></b> and <b style='color:Tomato;'><i>fluticasone</i></b> and to analyze the clinical data concerning a new fixed combination of <b style='color:Tomato;'><i>fluticasone</i></b> and <b style='color:Tomato;'><i>formoterol</i></b> in a pressurised metered-dose inhaler with a dose counter (Flutiform(\u00ae)) that was approved for the treatment of asthma in France in 2013. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>studies</i></b> <b style='color:DodgerBlue;'><i>provide</i></b> <b style='color:DodgerBlue;'><i>evidence</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>fluticasone/formoterol</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>efficacious</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>fluticasone</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>formoterol</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>provides</i></b> <b style='color:DodgerBlue;'><i>similar</i></b> <b style='color:DodgerBlue;'><i>improvements</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>lung</i></b> <b style='color:DodgerBlue;'><i>function</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>fluticasone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Flixotide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>\u00ae</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>formoterol</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>Foradil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>\u00ae</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>administered</i></b> <b style='color:DodgerBlue;'><i>concurrently</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of <b style='color:Tomato;'><i>fluticasone</i></b>/<b style='color:Tomato;'><i>formoterol</i></b> gave a more rapid bronchodilatation than the combination <b style='color:Tomato;'><i>fluticasone</i></b>/<b style='color:Tomato;'><i>salmeterol</i></b>. As a whole, the combination of <b style='color:Tomato;'><i>fluticasone</i></b>/<b style='color:Tomato;'><i>formoterol</i></b> had similar efficacy and tolerability profiles to the combinations of either <b style='color:Tomato;'><i>bu<b style='color:Tomato;'><i>desonide</i></b></i></b>/<b style='color:Tomato;'><i>formoterol</i></b> or <b style='color:Tomato;'><i>fluticasone</i></b>/<b style='color:Tomato;'><i>salmeterol</i></b>.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"clinical","start":4,"end":12,"id":1,"ws":true},{"text":"studies","start":13,"end":20,"id":2,"ws":true},{"text":"provide","start":21,"end":28,"id":3,"ws":true},{"text":"evidence","start":29,"end":37,"id":4,"ws":true},{"text":"that","start":38,"end":42,"id":5,"ws":true},{"text":"combined","start":43,"end":51,"id":6,"ws":true},{"text":"fluticasone/formoterol","start":52,"end":74,"id":7,"ws":true},{"text":"is","start":75,"end":77,"id":8,"ws":true},{"text":"more","start":78,"end":82,"id":9,"ws":true},{"text":"efficacious","start":83,"end":94,"id":10,"ws":true},{"text":"than","start":95,"end":99,"id":11,"ws":true},{"text":"fluticasone","start":100,"end":111,"id":12,"ws":true},{"text":"or","start":112,"end":114,"id":13,"ws":true},{"text":"formoterol","start":115,"end":125,"id":14,"ws":true},{"text":"given","start":126,"end":131,"id":15,"ws":true},{"text":"alone","start":132,"end":137,"id":16,"ws":true},{"text":",","start":138,"end":139,"id":17,"ws":true},{"text":"and","start":140,"end":143,"id":18,"ws":true},{"text":"provides","start":144,"end":152,"id":19,"ws":true},{"text":"similar","start":153,"end":160,"id":20,"ws":true},{"text":"improvements","start":161,"end":173,"id":21,"ws":true},{"text":"in","start":174,"end":176,"id":22,"ws":true},{"text":"lung","start":177,"end":181,"id":23,"ws":true},{"text":"function","start":182,"end":190,"id":24,"ws":true},{"text":"to","start":191,"end":193,"id":25,"ws":true},{"text":"fluticasone","start":194,"end":205,"id":26,"ws":true},{"text":"(","start":206,"end":207,"id":27,"ws":true},{"text":"Flixotide","start":208,"end":217,"id":28,"ws":true},{"text":"(","start":218,"end":219,"id":29,"ws":true},{"text":"\u00ae","start":220,"end":221,"id":30,"ws":true},{"text":")","start":222,"end":223,"id":31,"ws":true},{"text":")","start":224,"end":225,"id":32,"ws":true},{"text":"and","start":226,"end":229,"id":33,"ws":true},{"text":"formoterol","start":230,"end":240,"id":34,"ws":true},{"text":"(","start":241,"end":242,"id":35,"ws":true},{"text":"Foradil","start":243,"end":250,"id":36,"ws":true},{"text":"(","start":251,"end":252,"id":37,"ws":true},{"text":"\u00ae","start":253,"end":254,"id":38,"ws":true},{"text":")","start":255,"end":256,"id":39,"ws":true},{"text":")","start":257,"end":258,"id":40,"ws":true},{"text":"administered","start":259,"end":271,"id":41,"ws":true},{"text":"concurrently","start":272,"end":284,"id":42,"ws":true},{"text":".","start":285,"end":286,"id":43,"ws":false}],"spans":[{"start":100,"end":111,"token_start":12,"token_end":12,"label":"DRUG"},{"start":115,"end":125,"token_start":14,"token_end":14,"label":"DRUG"},{"start":194,"end":205,"token_start":26,"token_end":26,"label":"DRUG"},{"start":230,"end":240,"token_start":34,"token_end":34,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25391505/","_input_hash":1811966118,"_task_hash":671597530,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":26,"child":34,"head_span":{"start":194,"end":205,"token_start":26,"token_end":26,"label":"DRUG"},"child_span":{"start":230,"end":240,"token_start":34,"token_end":34,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The aim of this study was to evaluate the in vitro effect of single antibiotic ( ciprofloxacin , ceftazidime , or ampicillin ) treatment on adherence of Escherichia coli and Enterococcus to plastic stents .","paragraph":"<h3><u>In vitro evaluation of antibiotic prophylaxis in the prevention of biliary stent blockage.</u></h3>Bacterial adherence and biofilm formation are important factors in the blockage of biliary stents. Clinical studies with oral antibiotic prophylaxis to prevent stent blockage have produced conflicting results. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>antibiotic</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>ciprofloxacin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>ceftazidime</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>ampicillin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>adherence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>Escherichia</i></b> <b style='color:DodgerBlue;'><i>coli</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Enterococcus</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>plastic</i></b> <b style='color:DodgerBlue;'><i>stents</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Selected clinical isolates of E coli and Enterococcus were perfused through a modified Robbins device containing segments of polyethylene stents. The stents were removed daily and the number of bacteria attached was measured. The effect of antibiotic treatment on bacterial adherence was tested by the perfusion of individual antibiotics into separate modified Robbins devices using a side-arm adaptor and the results were compared with saline controls. ### results Compared with the saline controls, <b style='color:Tomato;'><i>ciprofloxacin</i></b> and <b style='color:Tomato;'><i>ceftazidime</i></b> caused a 10- to 100-fold reduction in the number of E coli attached to the stents, whereas <b style='color:Tomato;'><i>ampicillin</i></b> had no effect on adherence of E coli. <b style='color:Tomato;'><i>ampicillin</i></b> caused a 5- to 10-fold reduction in Enterococcus adherence but there was no change with <b style='color:Tomato;'><i>ceftazidime</i></b>. Sustained reduction in E coli adherence was observed with prolonged <b style='color:Tomato;'><i>ciprofloxacin</i></b> perfusion. ### conclusion Timely treatment with appropriate antibiotics reduced bacterial adherence in vitro and may be potentially beneficial in the prevention of stent blockage.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"this","start":11,"end":15,"id":3,"ws":true},{"text":"study","start":16,"end":21,"id":4,"ws":true},{"text":"was","start":22,"end":25,"id":5,"ws":true},{"text":"to","start":26,"end":28,"id":6,"ws":true},{"text":"evaluate","start":29,"end":37,"id":7,"ws":true},{"text":"the","start":38,"end":41,"id":8,"ws":true},{"text":"in","start":42,"end":44,"id":9,"ws":true},{"text":"vitro","start":45,"end":50,"id":10,"ws":true},{"text":"effect","start":51,"end":57,"id":11,"ws":true},{"text":"of","start":58,"end":60,"id":12,"ws":true},{"text":"single","start":61,"end":67,"id":13,"ws":true},{"text":"antibiotic","start":68,"end":78,"id":14,"ws":true},{"text":"(","start":79,"end":80,"id":15,"ws":true},{"text":"ciprofloxacin","start":81,"end":94,"id":16,"ws":true},{"text":",","start":95,"end":96,"id":17,"ws":true},{"text":"ceftazidime","start":97,"end":108,"id":18,"ws":true},{"text":",","start":109,"end":110,"id":19,"ws":true},{"text":"or","start":111,"end":113,"id":20,"ws":true},{"text":"ampicillin","start":114,"end":124,"id":21,"ws":true},{"text":")","start":125,"end":126,"id":22,"ws":true},{"text":"treatment","start":127,"end":136,"id":23,"ws":true},{"text":"on","start":137,"end":139,"id":24,"ws":true},{"text":"adherence","start":140,"end":149,"id":25,"ws":true},{"text":"of","start":150,"end":152,"id":26,"ws":true},{"text":"Escherichia","start":153,"end":164,"id":27,"ws":true},{"text":"coli","start":165,"end":169,"id":28,"ws":true},{"text":"and","start":170,"end":173,"id":29,"ws":true},{"text":"Enterococcus","start":174,"end":186,"id":30,"ws":true},{"text":"to","start":187,"end":189,"id":31,"ws":true},{"text":"plastic","start":190,"end":197,"id":32,"ws":true},{"text":"stents","start":198,"end":204,"id":33,"ws":true},{"text":".","start":205,"end":206,"id":34,"ws":false}],"spans":[{"start":81,"end":94,"token_start":16,"token_end":16,"label":"DRUG"},{"start":97,"end":108,"token_start":18,"token_end":18,"label":"DRUG"},{"start":114,"end":124,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10699774/","_input_hash":84121731,"_task_hash":-1431098532,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Paclitaxel and docetaxel as single agents have yielded overall response rates of 7 % to 56 % , depending on whether the patients have received prior chemotherapy for metastatic disease .","paragraph":"<h3><u>Current and future perspectives in advanced bladder cancer: is there a new standard?</u></h3>The <b style='color:Tomato;'><i>methotrexate</i></b>/<b style='color:Tomato;'><i>vinblastine</i></b>/<b style='color:Tomato;'><i>doxorubicin</i></b>/cisplatin (MVAC) regimen has been the standard treatment in patients with locally advanced and metastatic urothelial cancer for the past 15 years. The minimal or moderate survival benefit-depending on prognostic features-and the severe toxicity associated with the MVAC regimen have made the search for new drugs and drug combinations of utmost importance to increase efficacy and/or decrease toxicity. In this respect, the taxanes and <b style='color:Tomato;'><i>gemcitabine</i></b> are promising new drugs. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>single</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>yielded</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>response</i></b> <b style='color:DodgerBlue;'><i>rates</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>7</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>56</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>depending</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>whether</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The combination of <b style='color:Tomato;'><i>paclitaxel</i></b> and cisplatin has been explored in three studies with a total of 104 evaluable patients, a pooled overall response (OR) rate of 61%, and a complete response (CR) rate of 20%. There are two studies of <b style='color:Tomato;'><i>docetaxel</i></b> and cisplatin with a total of 91 evaluable patients, an OR rate of 54%, and a CR rate of 16%. The OR rate for <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>carboplatin</i></b> in six studies was 43%, with a CR rate of 13%; however, the reported median survival was only 8.5 to 9.5 months. The OR rate for single-agent <b style='color:Tomato;'><i>gemcitabine</i></b> based on five studies was 26%, with a CR rate of 9%, which was apparently independent of whether the patients had received prior chemotherapy. The OR rate for <b style='color:Tomato;'><i>gemcitabine</i></b> and cisplatin in four phase II studies ranged from 41% to 57%, with a CR rate of 15% to 22% and a median survival of 12.5 to 14.3 months. Based on the encouraging results for the combination of <b style='color:Tomato;'><i>gemcitabine</i></b> and cisplatin (GC), a randomized phase III trial comparing GC and MVAC was begun in late 1996. This study of 405 randomized patients showed that the two regimens were associated with similar response rates, time to progression, and overall survival, whereas GC was associated with less toxicity than MVAC. On the basis of this superior risk-benefit ratio, the GC regimen should be favored as a new standard treatment in patients with locally advanced and metastatic urothelial cancer. Other promising combinations include <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b>, with or without cisplatin, and the combination of <b style='color:Tomato;'><i>ifosfamide</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, and cisplatin. The triple combination of <b style='color:Tomato;'><i>gemcitabine</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b>, and cisplatin has yielded an OR rate of 78%, a CR rate of 28%, and a median survival of 24 months. An international phase III trial comparing this triple combination with GC in patients with locally advanced and metastatic urothelial cancer has now been initiated.","tokens":[{"text":"Paclitaxel","start":0,"end":10,"id":0,"ws":true},{"text":"and","start":11,"end":14,"id":1,"ws":true},{"text":"docetaxel","start":15,"end":24,"id":2,"ws":true},{"text":"as","start":25,"end":27,"id":3,"ws":true},{"text":"single","start":28,"end":34,"id":4,"ws":true},{"text":"agents","start":35,"end":41,"id":5,"ws":true},{"text":"have","start":42,"end":46,"id":6,"ws":true},{"text":"yielded","start":47,"end":54,"id":7,"ws":true},{"text":"overall","start":55,"end":62,"id":8,"ws":true},{"text":"response","start":63,"end":71,"id":9,"ws":true},{"text":"rates","start":72,"end":77,"id":10,"ws":true},{"text":"of","start":78,"end":80,"id":11,"ws":true},{"text":"7","start":81,"end":82,"id":12,"ws":true},{"text":"%","start":83,"end":84,"id":13,"ws":true},{"text":"to","start":85,"end":87,"id":14,"ws":true},{"text":"56","start":88,"end":90,"id":15,"ws":true},{"text":"%","start":91,"end":92,"id":16,"ws":true},{"text":",","start":93,"end":94,"id":17,"ws":true},{"text":"depending","start":95,"end":104,"id":18,"ws":true},{"text":"on","start":105,"end":107,"id":19,"ws":true},{"text":"whether","start":108,"end":115,"id":20,"ws":true},{"text":"the","start":116,"end":119,"id":21,"ws":true},{"text":"patients","start":120,"end":128,"id":22,"ws":true},{"text":"have","start":129,"end":133,"id":23,"ws":true},{"text":"received","start":134,"end":142,"id":24,"ws":true},{"text":"prior","start":143,"end":148,"id":25,"ws":true},{"text":"chemotherapy","start":149,"end":161,"id":26,"ws":true},{"text":"for","start":162,"end":165,"id":27,"ws":true},{"text":"metastatic","start":166,"end":176,"id":28,"ws":true},{"text":"disease","start":177,"end":184,"id":29,"ws":true},{"text":".","start":185,"end":186,"id":30,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/11894002/","_input_hash":120739995,"_task_hash":-239446350,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The most effective treatment regimens for advanced nonseminomatous testicular tumors employ vinblastine , CDDP and bleomycin and adjunctive surgery .","paragraph":"<h3><u>[Preoperative chemotherapy of testicular cancer and Wilm's tumor].</u></h3>Of the various urogenital malignancies, preoperative chemotherapy is most effective for testicular cancer and Wilms' tumor. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>nonseminomatous</i></b> <b style='color:DodgerBlue;'><i>testicular</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>employ</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>CDDP</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bleomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>adjunctive</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Another effective chemotherapy regimen is combination of <b style='color:Tomato;'><i>vinblastine</i></b>, actinomycin D, <b style='color:Tomato;'><i>bleomycin</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b> and CDDP presented by MSKCC. Available pretreatment with 4 courses of platinum, <b style='color:Tomato;'><i>vinblastine</i></b> and <b style='color:Tomato;'><i>bleomycin</i></b> before any surgical treatment in those with massive bulk metastatic disease seems to provide the most effective cytoreduction and best survival. Donohue has shown that in a primary chemotherapy group, there is only 20% active carcinoma after primary chemotherapy, whereas in a salvage chemotherapy group there is approximately 50% active carcinoma at surgery. It must therefore be emphasized that complete remission should be obtained by primary chemotherapy and adjunctive surgery. In Wilms' tumor preoperative chemotherapy with <b style='color:Tomato;'><i>vincristine</i></b> and actinomycin D should be given.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"most","start":4,"end":8,"id":1,"ws":true},{"text":"effective","start":9,"end":18,"id":2,"ws":true},{"text":"treatment","start":19,"end":28,"id":3,"ws":true},{"text":"regimens","start":29,"end":37,"id":4,"ws":true},{"text":"for","start":38,"end":41,"id":5,"ws":true},{"text":"advanced","start":42,"end":50,"id":6,"ws":true},{"text":"nonseminomatous","start":51,"end":66,"id":7,"ws":true},{"text":"testicular","start":67,"end":77,"id":8,"ws":true},{"text":"tumors","start":78,"end":84,"id":9,"ws":true},{"text":"employ","start":85,"end":91,"id":10,"ws":true},{"text":"vinblastine","start":92,"end":103,"id":11,"ws":true},{"text":",","start":104,"end":105,"id":12,"ws":true},{"text":"CDDP","start":106,"end":110,"id":13,"ws":true},{"text":"and","start":111,"end":114,"id":14,"ws":true},{"text":"bleomycin","start":115,"end":124,"id":15,"ws":true},{"text":"and","start":125,"end":128,"id":16,"ws":true},{"text":"adjunctive","start":129,"end":139,"id":17,"ws":true},{"text":"surgery","start":140,"end":147,"id":18,"ws":true},{"text":".","start":148,"end":149,"id":19,"ws":false}],"spans":[{"start":92,"end":103,"token_start":11,"token_end":11,"label":"DRUG"},{"start":115,"end":124,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/2581512/","_input_hash":1927771666,"_task_hash":-259598406,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":11,"child":15,"head_span":{"start":92,"end":103,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":115,"end":124,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen : a TransATAC study .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Prediction</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>distant</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>using</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>21-gene</i></b> <b style='color:DodgerBlue;'><i>recurrence</i></b> <b style='color:DodgerBlue;'><i>score</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>node-negative</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>node-positive</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>TransATAC</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>PURPOSE To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in the <b style='color:Tomato;'><i>tamoxifen</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b> arms of the Arimidex, <b style='color:Tomato;'><i>tamoxifen</i></b>, Alone or in Combination (ATAC) Trial. PATIENTS AND METHODS RNA was extracted from 1,372 tumor blocks from postmenopausal patients with hormone receptor-positive primary breast cancer in the monotherapy arms of ATAC. Twenty-one genes were assessed by quantitative reverse transcriptase polymerase chain reaction, and the RS was calculated. Cox proportional hazards models assessed the value of adding RS to a model with clinical variables (age, tumor size, grade, and treatment) in node-negative (N0) and node-positive (N+) women. RESULTS Reportable scores were available from 1,231 evaluable patients (N0, n = 872; N+, n = 306; and node status unknown, n = 53); 72, 74, and six DRs occurred in N0, N+, and node status unknown patients, respectively. For both N0 and N+ patients, RS was significantly associated with time to DR in multivariate analyses (P < .001 for N0 and P = .002 for N+). RS also showed significant prognostic value beyond that provided by Adjuvant! Online (P < .001). Nine-year DR rates in low (RS < 18), intermediate (RS = 18 to 30), and high RS (RS > or = 31) groups were 4%, 12%, and 25%, respectively, in N0 patients and 17%, 28%, and 49%, respectively, in N+ patients. The prognostic value of RS was similar in <b style='color:Tomato;'><i>anastrozole</i></b>- and <b style='color:Tomato;'><i>tamoxifen</i></b>-treated patients. CONCLUSION This study confirmed the performance of RS in postmenopausal HR+ patients treated with <b style='color:Tomato;'><i>tamoxifen</i></b> in a large contemporary population and demonstrated that RS is an independent predictor of DR in N0 and N+ hormone receptor-positive patients treated with <b style='color:Tomato;'><i>anastrozole</i></b>, adding value to estimates with standard clinicopathologic features.","tokens":[{"text":"Prediction","start":0,"end":10,"id":0,"ws":true},{"text":"of","start":11,"end":13,"id":1,"ws":true},{"text":"risk","start":14,"end":18,"id":2,"ws":true},{"text":"of","start":19,"end":21,"id":3,"ws":true},{"text":"distant","start":22,"end":29,"id":4,"ws":true},{"text":"recurrence","start":30,"end":40,"id":5,"ws":true},{"text":"using","start":41,"end":46,"id":6,"ws":true},{"text":"the","start":47,"end":50,"id":7,"ws":true},{"text":"21-gene","start":51,"end":58,"id":8,"ws":true},{"text":"recurrence","start":59,"end":69,"id":9,"ws":true},{"text":"score","start":70,"end":75,"id":10,"ws":true},{"text":"in","start":76,"end":78,"id":11,"ws":true},{"text":"node-negative","start":79,"end":92,"id":12,"ws":true},{"text":"and","start":93,"end":96,"id":13,"ws":true},{"text":"node-positive","start":97,"end":110,"id":14,"ws":true},{"text":"postmenopausal","start":111,"end":125,"id":15,"ws":true},{"text":"patients","start":126,"end":134,"id":16,"ws":true},{"text":"with","start":135,"end":139,"id":17,"ws":true},{"text":"breast","start":140,"end":146,"id":18,"ws":true},{"text":"cancer","start":147,"end":153,"id":19,"ws":true},{"text":"treated","start":154,"end":161,"id":20,"ws":true},{"text":"with","start":162,"end":166,"id":21,"ws":true},{"text":"anastrozole","start":167,"end":178,"id":22,"ws":true},{"text":"or","start":179,"end":181,"id":23,"ws":true},{"text":"tamoxifen","start":182,"end":191,"id":24,"ws":true},{"text":":","start":192,"end":193,"id":25,"ws":true},{"text":"a","start":194,"end":195,"id":26,"ws":true},{"text":"TransATAC","start":196,"end":205,"id":27,"ws":true},{"text":"study","start":206,"end":211,"id":28,"ws":true},{"text":".","start":212,"end":213,"id":29,"ws":false}],"spans":[{"start":167,"end":178,"token_start":22,"token_end":22,"label":"DRUG"},{"start":182,"end":191,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20212256/","_input_hash":1790719554,"_task_hash":-1109752328,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":22,"child":24,"head_span":{"start":167,"end":178,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":182,"end":191,"token_start":24,"token_end":24,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"When novel DMARDs were used as monotherapies , greater ACR20/50/70 responses were observed with tocilizumab than with anti-tumor necrosis factor agents ( aTNF ) or tofacitinib .","paragraph":"<h3><u>Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis.</u></h3>Given the availability of a number of alternative biologic treatment options and other novel disease-modifying antirheumatic drugs (DMARDs) for the treatment of patients with rheumatoid arthritis (RA), clinicians are faced with an increasingly challenging choice regarding optimal treatment. Biologics are usually combined with traditional DMARDs, primarily <b style='color:Tomato;'><i>methotrexate</i></b> (MTX), but some biologics and <b style='color:Tomato;'><i>tofacitinib</i></b> (together referred to in this article as novel DMARDs) have been shown to be efficacious as monotherapy as well. In real-world practice, approximately one-third of RA patients receiving biologics are on monotherapy, primarily because of intolerance of, or noncompliance with, MTX. Limited data, however, are available analyzing the effectiveness of monotherapy compared with combination therapy across novel DMARDs. ### objective To compare American College of Rheumatology (ACR) responses to approved novel DMARDs used as monotherapy or as combination therapy with <b style='color:Tomato;'><i>methotrexate</i></b> (MTX) at 24 weeks in RA patients who have shown inadequate response to conventional DMARDs (DMARD-IR). ### methods Through a systematic review of the literature, we identified randomized controlled trials that assessed approved novel DMARDs used as monotherapy or as combination therapy with MTX in DMARD-IR RA patients. Twenty-eight RCTs were identified that evaluated <b style='color:Tomato;'><i>abatacept</i></b>, <b style='color:Tomato;'><i>anakinra</i></b>, <b style='color:Tomato;'><i>adalimumab</i></b>, <b style='color:Tomato;'><i>certolizumab pegol</i></b>, <b style='color:Tomato;'><i>etanercept</i></b>, <b style='color:Tomato;'><i>golimumab</i></b>, <b style='color:Tomato;'><i>infliximab</i></b>, <b style='color:Tomato;'><i>tocilizumab</i></b>, or <b style='color:Tomato;'><i>tofacitinib</i></b>. ACR responses at 24 weeks were extracted and combined by means of Bayesian network meta-analyses. ### results With the exception of <b style='color:Tomato;'><i>anakinra</i></b> plus MTX, which was less efficacious, most novel DMARDs, when used in combination with MTX, demonstrated comparable ACR responses. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>novel</i></b> <b style='color:DodgerBlue;'><i>DMARDs</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>monotherapies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>greater</i></b> <b style='color:DodgerBlue;'><i>ACR20/50/70</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>observed</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tocilizumab</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>anti-tumor</i></b> <b style='color:DodgerBlue;'><i>necrosis</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>aTNF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>tofacitinib</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Furthermore, ACR20/50/70 responses with <b style='color:Tomato;'><i>tocilizumab</i></b> plus MTX were similar to those with <b style='color:Tomato;'><i>tocilizumab</i></b> monotherapy (odds ratio [OR] for the indirect comparison\u2009=\u20091.08, 95% credible interval [CrI]\u2009=\u20090.40-2.84; OR\u2009=\u20091.24, CrI\u2009=\u20090.44-3.61; OR\u2009=\u20090.95, CrI\u2009=\u20090.33-2.72, respectively), whereas greater responses were observed with aTNF plus MTX than with aTNF monotherapy (OR\u2009=\u20092.41, CrI\u2009=\u20090.51-11.61; OR\u2009=\u20092.85, CrI\u2009=\u20090.51-17.67; OR\u2009=\u20091.28, CrI\u2009=\u20090.21-8.42, respectively). Relative efficacy estimates for the indirect comparison of <b style='color:Tomato;'><i>tofacitinib</i></b> plus MTX with <b style='color:Tomato;'><i>tofacitinib</i></b> monotherapy were very uncertain. ### conclusions Results suggest that in combination with MTX most of the available novel DMARDs have similar levels of efficacy in DMARD-IR patients. As monotherapy, however, <b style='color:Tomato;'><i>tocilizumab</i></b> displayed higher ACR responses than aTNF or <b style='color:Tomato;'><i>tofacitinib</i></b>. ACR responses with <b style='color:Tomato;'><i>tocilizumab</i></b> plus MTX were similar to those with <b style='color:Tomato;'><i>tocilizumab</i></b> as monotherapy, whereas aTNF in combination with MTX demonstrated greater ACR responses than aTNF as monotherapy.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"novel","start":5,"end":10,"id":1,"ws":true},{"text":"DMARDs","start":11,"end":17,"id":2,"ws":true},{"text":"were","start":18,"end":22,"id":3,"ws":true},{"text":"used","start":23,"end":27,"id":4,"ws":true},{"text":"as","start":28,"end":30,"id":5,"ws":true},{"text":"monotherapies","start":31,"end":44,"id":6,"ws":true},{"text":",","start":45,"end":46,"id":7,"ws":true},{"text":"greater","start":47,"end":54,"id":8,"ws":true},{"text":"ACR20/50/70","start":55,"end":66,"id":9,"ws":true},{"text":"responses","start":67,"end":76,"id":10,"ws":true},{"text":"were","start":77,"end":81,"id":11,"ws":true},{"text":"observed","start":82,"end":90,"id":12,"ws":true},{"text":"with","start":91,"end":95,"id":13,"ws":true},{"text":"tocilizumab","start":96,"end":107,"id":14,"ws":true},{"text":"than","start":108,"end":112,"id":15,"ws":true},{"text":"with","start":113,"end":117,"id":16,"ws":true},{"text":"anti-tumor","start":118,"end":128,"id":17,"ws":true},{"text":"necrosis","start":129,"end":137,"id":18,"ws":true},{"text":"factor","start":138,"end":144,"id":19,"ws":true},{"text":"agents","start":145,"end":151,"id":20,"ws":true},{"text":"(","start":152,"end":153,"id":21,"ws":true},{"text":"aTNF","start":154,"end":158,"id":22,"ws":true},{"text":")","start":159,"end":160,"id":23,"ws":true},{"text":"or","start":161,"end":163,"id":24,"ws":true},{"text":"tofacitinib","start":164,"end":175,"id":25,"ws":true},{"text":".","start":176,"end":177,"id":26,"ws":false}],"spans":[{"start":96,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},{"start":164,"end":175,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25943002/","_input_hash":-768717398,"_task_hash":930325306,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"27 patients suffering from disseminated carcinoma of the breast with at least two visceral metastases , and two had become resistant to conventional chemotherpy and hormones , received a combination of , in the present trial , vincristine followed by cyclophosphamide with 5-fluoro-uracil .","paragraph":"<h3><u>[Chemotherapeutic combinations of mutually potentializing drugs. 1-Application to the treatment of breast cancers].</u></h3> <b style='color:DodgerBlue;'><i>27</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>suffering</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>disseminated</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>visceral</i></b> <b style='color:DodgerBlue;'><i>metastases</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>had</i></b> <b style='color:DodgerBlue;'><i>become</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>conventional</i></b> <b style='color:DodgerBlue;'><i>chemotherpy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>hormones</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>5-fluoro-uracil</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Chemotherapy was administered intermittently: each cycle of treatment lasted 6 days and was followed by a period without treatment of 25 days. Haematological tolerance was satisfactory. No serious incidents occurred during two years use of the combination. 20 out of 27 patients showed objective tumour regression of more than 50 p.cent lasting for more than 6 months, whilst 9 showed apparent complete regression of the malignant lesions. There was one complete failure. Chemotherapy was continued in all cases after regression of the neoplastic process was obtained.","tokens":[{"text":"27","start":0,"end":2,"id":0,"ws":true},{"text":"patients","start":3,"end":11,"id":1,"ws":true},{"text":"suffering","start":12,"end":21,"id":2,"ws":true},{"text":"from","start":22,"end":26,"id":3,"ws":true},{"text":"disseminated","start":27,"end":39,"id":4,"ws":true},{"text":"carcinoma","start":40,"end":49,"id":5,"ws":true},{"text":"of","start":50,"end":52,"id":6,"ws":true},{"text":"the","start":53,"end":56,"id":7,"ws":true},{"text":"breast","start":57,"end":63,"id":8,"ws":true},{"text":"with","start":64,"end":68,"id":9,"ws":true},{"text":"at","start":69,"end":71,"id":10,"ws":true},{"text":"least","start":72,"end":77,"id":11,"ws":true},{"text":"two","start":78,"end":81,"id":12,"ws":true},{"text":"visceral","start":82,"end":90,"id":13,"ws":true},{"text":"metastases","start":91,"end":101,"id":14,"ws":true},{"text":",","start":102,"end":103,"id":15,"ws":true},{"text":"and","start":104,"end":107,"id":16,"ws":true},{"text":"two","start":108,"end":111,"id":17,"ws":true},{"text":"had","start":112,"end":115,"id":18,"ws":true},{"text":"become","start":116,"end":122,"id":19,"ws":true},{"text":"resistant","start":123,"end":132,"id":20,"ws":true},{"text":"to","start":133,"end":135,"id":21,"ws":true},{"text":"conventional","start":136,"end":148,"id":22,"ws":true},{"text":"chemotherpy","start":149,"end":160,"id":23,"ws":true},{"text":"and","start":161,"end":164,"id":24,"ws":true},{"text":"hormones","start":165,"end":173,"id":25,"ws":true},{"text":",","start":174,"end":175,"id":26,"ws":true},{"text":"received","start":176,"end":184,"id":27,"ws":true},{"text":"a","start":185,"end":186,"id":28,"ws":true},{"text":"combination","start":187,"end":198,"id":29,"ws":true},{"text":"of","start":199,"end":201,"id":30,"ws":true},{"text":",","start":202,"end":203,"id":31,"ws":true},{"text":"in","start":204,"end":206,"id":32,"ws":true},{"text":"the","start":207,"end":210,"id":33,"ws":true},{"text":"present","start":211,"end":218,"id":34,"ws":true},{"text":"trial","start":219,"end":224,"id":35,"ws":true},{"text":",","start":225,"end":226,"id":36,"ws":true},{"text":"vincristine","start":227,"end":238,"id":37,"ws":true},{"text":"followed","start":239,"end":247,"id":38,"ws":true},{"text":"by","start":248,"end":250,"id":39,"ws":true},{"text":"cyclophosphamide","start":251,"end":267,"id":40,"ws":true},{"text":"with","start":268,"end":272,"id":41,"ws":true},{"text":"5-fluoro-uracil","start":273,"end":288,"id":42,"ws":true},{"text":".","start":289,"end":290,"id":43,"ws":false}],"spans":[{"start":227,"end":238,"token_start":37,"token_end":37,"label":"DRUG"},{"start":251,"end":267,"token_start":40,"token_end":40,"label":"DRUG"},{"start":273,"end":288,"token_start":42,"token_end":42,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/1129034/","_input_hash":355587438,"_task_hash":-1711097268,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":37,"child":40,"head_span":{"start":227,"end":238,"token_start":37,"token_end":37,"label":"DRUG"},"child_span":{"start":251,"end":267,"token_start":40,"token_end":40,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":42,"child":40,"head_span":{"start":273,"end":288,"token_start":42,"token_end":42,"label":"DRUG"},"child_span":{"start":251,"end":267,"token_start":40,"token_end":40,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Paclitaxel showed synergistic anti-proliferative impacts with fulvestrant .","paragraph":"<h3><u>Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer.</u></h3>To investigate the prognostic role of the estrogen receptor (ER) in gastric cancer (GC) patients, tumor tissues from 932 patients with advanced GC were assessed for ER expression using immunohistochemistry, and their clinicopathologic features were evaluated. Forty patients (4.3%) had ER expression and they were more frequently associated with diffuse type gastric cancer and shorter disease free survival. Furthermore, we carried out in vitro analysis to evaluate the effect of ER modulation on the proliferation of GC cell lines. Estradiol enhanced proliferation of ER positive GC cells while it did not show any effect on ER negative GC cells. When ER was inhibited by <b style='color:Tomato;'><i>fulvestrant</i></b> and ER siRNA, estradiol-induced proliferation of ER positive GC cell was suppressed. <b style='color:MediumOrchid;'><i>Paclitaxel</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>anti-proliferative</i></b> <b style='color:DodgerBlue;'><i>impacts</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>fulvestrant</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Suppressing ER by <b style='color:Tomato;'><i>fulvestrant</i></b>, <b style='color:Tomato;'><i>paclitaxel</i></b> and ER siRNA showed increased expression of E-cadherin, which is a crucial factor in diffuse-type carcinogenesis.","tokens":[{"text":"Paclitaxel","start":0,"end":10,"id":0,"ws":true},{"text":"showed","start":11,"end":17,"id":1,"ws":true},{"text":"synergistic","start":18,"end":29,"id":2,"ws":true},{"text":"anti-proliferative","start":30,"end":48,"id":3,"ws":true},{"text":"impacts","start":49,"end":56,"id":4,"ws":true},{"text":"with","start":57,"end":61,"id":5,"ws":true},{"text":"fulvestrant","start":62,"end":73,"id":6,"ws":true},{"text":".","start":74,"end":75,"id":7,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":62,"end":73,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25534230/","_input_hash":1047854151,"_task_hash":-1333371023,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":0,"child":6,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":62,"end":73,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"We previously demonstrated that the combination of oral estramustine ( 15 mg/kg/day ) and oral etoposide ( 50 mg/m2/day ) is effective first-line therapy for the treatment of hormone refractory prostate cancer .","paragraph":"<h3><u>A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.</u></h3> <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>estramustine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>15</i></b> <b style='color:DodgerBlue;'><i>mg/kg/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>oral</i></b> <b style='color:MediumOrchid;'><i>etoposide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg/m2/day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>hormone</i></b> <b style='color:DodgerBlue;'><i>refractory</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We initiated a new Phase II trial utilizing a lower dose of <b style='color:Tomato;'><i>estramustine</i></b> (10 mg/kg/day) and allowing previous chemotherapy treatment. ### methods <b style='color:Tomato;'><i>estramustine</i></b> (10 mg/kg/day) and <b style='color:Tomato;'><i>etoposide</i></b> (50 mg/m2/day) were administered orally for 21 of 28 days. Sixty-two patients were enrolled with a minimum of 26 weeks of follow-up. ### results Of 15 patients with measurable soft tissue disease, 8 (53%) had a partial response (PR). Seven of these 8 patients also demonstrated a decrease in baseline prostate-specific antigen (PSA) of more than 50%. The median survival of all patients was 56 weeks. Of 47 patients with disease limited to the bone, 16 (34%) had a PR to therapy based on decrease in pretreatment PSA of more than 50%. Overall, 24 (39%) of 62 patients demonstrated a decrease in pretreatment PSA levels of at least 50% from baseline. Twenty-two patients received previous chemotherapy. There were no differences in survival or disease response in patients treated with previous chemotherapy compared with untreated patients. Pretreatment hemoglobin, PSA, alkaline phosphatase and lactate dehydrogenase levels were not significant prognostic factors, but performance status was an important predictor of survival. ### conclusions We conclude that the combination of oral <b style='color:Tomato;'><i>estramustine</i></b> (10 mg/kg/day) and oral <b style='color:Tomato;'><i>etoposide</i></b> (50 mg/m2/day) is an active regimen for hormone refractory prostate cancer.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"previously","start":3,"end":13,"id":1,"ws":true},{"text":"demonstrated","start":14,"end":26,"id":2,"ws":true},{"text":"that","start":27,"end":31,"id":3,"ws":true},{"text":"the","start":32,"end":35,"id":4,"ws":true},{"text":"combination","start":36,"end":47,"id":5,"ws":true},{"text":"of","start":48,"end":50,"id":6,"ws":true},{"text":"oral","start":51,"end":55,"id":7,"ws":true},{"text":"estramustine","start":56,"end":68,"id":8,"ws":true},{"text":"(","start":69,"end":70,"id":9,"ws":true},{"text":"15","start":71,"end":73,"id":10,"ws":true},{"text":"mg/kg/day","start":74,"end":83,"id":11,"ws":true},{"text":")","start":84,"end":85,"id":12,"ws":true},{"text":"and","start":86,"end":89,"id":13,"ws":true},{"text":"oral","start":90,"end":94,"id":14,"ws":true},{"text":"etoposide","start":95,"end":104,"id":15,"ws":true},{"text":"(","start":105,"end":106,"id":16,"ws":true},{"text":"50","start":107,"end":109,"id":17,"ws":true},{"text":"mg/m2/day","start":110,"end":119,"id":18,"ws":true},{"text":")","start":120,"end":121,"id":19,"ws":true},{"text":"is","start":122,"end":124,"id":20,"ws":true},{"text":"effective","start":125,"end":134,"id":21,"ws":true},{"text":"first-line","start":135,"end":145,"id":22,"ws":true},{"text":"therapy","start":146,"end":153,"id":23,"ws":true},{"text":"for","start":154,"end":157,"id":24,"ws":true},{"text":"the","start":158,"end":161,"id":25,"ws":true},{"text":"treatment","start":162,"end":171,"id":26,"ws":true},{"text":"of","start":172,"end":174,"id":27,"ws":true},{"text":"hormone","start":175,"end":182,"id":28,"ws":true},{"text":"refractory","start":183,"end":193,"id":29,"ws":true},{"text":"prostate","start":194,"end":202,"id":30,"ws":true},{"text":"cancer","start":203,"end":209,"id":31,"ws":true},{"text":".","start":210,"end":211,"id":32,"ws":false}],"spans":[{"start":56,"end":68,"token_start":8,"token_end":8,"label":"DRUG"},{"start":95,"end":104,"token_start":15,"token_end":15,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9301705/","_input_hash":769126920,"_task_hash":-953504087,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":8,"child":15,"head_span":{"start":56,"end":68,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":95,"end":104,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Therapy consisted of bendamustine ( 70 mg/m(2 ) ) for 2 consecutive days every 28 days , and ofatumumab 300 mg on day 1 and 1000 mg on day 8 during the first cycle , and 1000 mg on day 1 subsequently .","paragraph":"<h3><u>Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.</u></h3>We conducted a phase II, noncomparative, open-label, multicenter GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) study (CLL0809) to assess the efficacy and safety of <b style='color:Tomato;'><i>bendamustine</i></b> in combination with <b style='color:Tomato;'><i>ofatumumab</i></b> (BendOfa) in relapsed/refractory chronic lymphocytic leukemia (CLL). Forty-seven patients from 14 centers were evaluated. <b style='color:DodgerBlue;'><i>Therapy</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>bendamustine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>70</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>28</i></b> <b style='color:DodgerBlue;'><i>days</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ofatumumab</i></b> <b style='color:DodgerBlue;'><i>300</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>8</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>cycle</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>1000</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>subsequently</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Treatment was administered up to six cycles. The overall response rate (ORR), as per intention-to-treat analysis, was 72.3% (95% confidence of interval (CI), 57-84%), with 17% complete responses. After a median follow-up of 24.2 months, the overall survival was 83.6% (95% CI, 73.0-95.7%) and the progression-free survival (PFS) was 49.6% (95% CI, 35.9-68.6%). The median PFS was 23.6 months. Univariate and multivariate analyses were used to identify clinical and biological characteristics associated with ORR and PFS. Myelosuppression was the most common toxicity; grade \u22653 neutropenia was observed in 61.7% of patients; however, grade \u22653 infections occurred in 6% of patients. BendOfa is feasible and effective in relapsed/refractory CLL patients, including patients with high-risk clinical and biological features.","tokens":[{"text":"Therapy","start":0,"end":7,"id":0,"ws":true},{"text":"consisted","start":8,"end":17,"id":1,"ws":true},{"text":"of","start":18,"end":20,"id":2,"ws":true},{"text":"bendamustine","start":21,"end":33,"id":3,"ws":true},{"text":"(","start":34,"end":35,"id":4,"ws":true},{"text":"70","start":36,"end":38,"id":5,"ws":true},{"text":"mg/m(2","start":39,"end":45,"id":6,"ws":true},{"text":")","start":46,"end":47,"id":7,"ws":true},{"text":")","start":48,"end":49,"id":8,"ws":true},{"text":"for","start":50,"end":53,"id":9,"ws":true},{"text":"2","start":54,"end":55,"id":10,"ws":true},{"text":"consecutive","start":56,"end":67,"id":11,"ws":true},{"text":"days","start":68,"end":72,"id":12,"ws":true},{"text":"every","start":73,"end":78,"id":13,"ws":true},{"text":"28","start":79,"end":81,"id":14,"ws":true},{"text":"days","start":82,"end":86,"id":15,"ws":true},{"text":",","start":87,"end":88,"id":16,"ws":true},{"text":"and","start":89,"end":92,"id":17,"ws":true},{"text":"ofatumumab","start":93,"end":103,"id":18,"ws":true},{"text":"300","start":104,"end":107,"id":19,"ws":true},{"text":"mg","start":108,"end":110,"id":20,"ws":true},{"text":"on","start":111,"end":113,"id":21,"ws":true},{"text":"day","start":114,"end":117,"id":22,"ws":true},{"text":"1","start":118,"end":119,"id":23,"ws":true},{"text":"and","start":120,"end":123,"id":24,"ws":true},{"text":"1000","start":124,"end":128,"id":25,"ws":true},{"text":"mg","start":129,"end":131,"id":26,"ws":true},{"text":"on","start":132,"end":134,"id":27,"ws":true},{"text":"day","start":135,"end":138,"id":28,"ws":true},{"text":"8","start":139,"end":140,"id":29,"ws":true},{"text":"during","start":141,"end":147,"id":30,"ws":true},{"text":"the","start":148,"end":151,"id":31,"ws":true},{"text":"first","start":152,"end":157,"id":32,"ws":true},{"text":"cycle","start":158,"end":163,"id":33,"ws":true},{"text":",","start":164,"end":165,"id":34,"ws":true},{"text":"and","start":166,"end":169,"id":35,"ws":true},{"text":"1000","start":170,"end":174,"id":36,"ws":true},{"text":"mg","start":175,"end":177,"id":37,"ws":true},{"text":"on","start":178,"end":180,"id":38,"ws":true},{"text":"day","start":181,"end":184,"id":39,"ws":true},{"text":"1","start":185,"end":186,"id":40,"ws":true},{"text":"subsequently","start":187,"end":199,"id":41,"ws":true},{"text":".","start":200,"end":201,"id":42,"ws":false}],"spans":[{"start":21,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},{"start":93,"end":103,"token_start":18,"token_end":18,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24220274/","_input_hash":-946523501,"_task_hash":648212012,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":3,"child":18,"head_span":{"start":21,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":93,"end":103,"token_start":18,"token_end":18,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"All consecutive patients with advanced BTC received the GEMOX regimen in a setting outside a study : gemcitabine 1,000 mg/m(2 ) on day 1 , and oxaliplatin 100 mg/m(2 ) on day 2 , treatment repeated every 2 weeks until progression or unacceptable toxicity .","paragraph":"<h3><u>Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma.</u></h3>The combination <b style='color:Tomato;'><i>gemcitabine</i></b>-<b style='color:Tomato;'><i>oxaliplatin</i></b> (GEMOX) is frequently used in patients with advanced biliary tract carcinoma (BTC). However, this is only based on phase II studies performed in selected patients.We assessed the efficacy and safety of the GEMOX regimen in non-selected patients with advanced BTC. ### methods <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>BTC</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>GEMOX</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>outside</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>1,000</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>oxaliplatin</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>mg/m(2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>repeated</i></b> <b style='color:DodgerBlue;'><i>every</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>until</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>unacceptable</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Forty-four patients were enrolled. ### efficacy 1 complete and 6 partial responses (objective response rate = 16.3%), 18 tumour stabilizations (41.9%, disease control rate = 58.1%), median progression-free survival was 5.0 months and median overall survival was 11.0 months. ### toxicity grade 3 neuropathy in 4 patients, grade 3 asthenia in 5 patients. ### conclusion The GEMOX combination was well tolerated, with a modest activity in non-selected patients with advanced BTC. This regimen should be compared to the new standard <b style='color:Tomato;'><i>gemcitabine</i></b>-cisplatin combination.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"consecutive","start":4,"end":15,"id":1,"ws":true},{"text":"patients","start":16,"end":24,"id":2,"ws":true},{"text":"with","start":25,"end":29,"id":3,"ws":true},{"text":"advanced","start":30,"end":38,"id":4,"ws":true},{"text":"BTC","start":39,"end":42,"id":5,"ws":true},{"text":"received","start":43,"end":51,"id":6,"ws":true},{"text":"the","start":52,"end":55,"id":7,"ws":true},{"text":"GEMOX","start":56,"end":61,"id":8,"ws":true},{"text":"regimen","start":62,"end":69,"id":9,"ws":true},{"text":"in","start":70,"end":72,"id":10,"ws":true},{"text":"a","start":73,"end":74,"id":11,"ws":true},{"text":"setting","start":75,"end":82,"id":12,"ws":true},{"text":"outside","start":83,"end":90,"id":13,"ws":true},{"text":"a","start":91,"end":92,"id":14,"ws":true},{"text":"study","start":93,"end":98,"id":15,"ws":true},{"text":":","start":99,"end":100,"id":16,"ws":true},{"text":"gemcitabine","start":101,"end":112,"id":17,"ws":true},{"text":"1,000","start":113,"end":118,"id":18,"ws":true},{"text":"mg/m(2","start":119,"end":125,"id":19,"ws":true},{"text":")","start":126,"end":127,"id":20,"ws":true},{"text":"on","start":128,"end":130,"id":21,"ws":true},{"text":"day","start":131,"end":134,"id":22,"ws":true},{"text":"1","start":135,"end":136,"id":23,"ws":true},{"text":",","start":137,"end":138,"id":24,"ws":true},{"text":"and","start":139,"end":142,"id":25,"ws":true},{"text":"oxaliplatin","start":143,"end":154,"id":26,"ws":true},{"text":"100","start":155,"end":158,"id":27,"ws":true},{"text":"mg/m(2","start":159,"end":165,"id":28,"ws":true},{"text":")","start":166,"end":167,"id":29,"ws":true},{"text":"on","start":168,"end":170,"id":30,"ws":true},{"text":"day","start":171,"end":174,"id":31,"ws":true},{"text":"2","start":175,"end":176,"id":32,"ws":true},{"text":",","start":177,"end":178,"id":33,"ws":true},{"text":"treatment","start":179,"end":188,"id":34,"ws":true},{"text":"repeated","start":189,"end":197,"id":35,"ws":true},{"text":"every","start":198,"end":203,"id":36,"ws":true},{"text":"2","start":204,"end":205,"id":37,"ws":true},{"text":"weeks","start":206,"end":211,"id":38,"ws":true},{"text":"until","start":212,"end":217,"id":39,"ws":true},{"text":"progression","start":218,"end":229,"id":40,"ws":true},{"text":"or","start":230,"end":232,"id":41,"ws":true},{"text":"unacceptable","start":233,"end":245,"id":42,"ws":true},{"text":"toxicity","start":246,"end":254,"id":43,"ws":true},{"text":".","start":255,"end":256,"id":44,"ws":false}],"spans":[{"start":101,"end":112,"token_start":17,"token_end":17,"label":"DRUG"},{"start":143,"end":154,"token_start":26,"token_end":26,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/20551640/","_input_hash":1963669052,"_task_hash":462076968,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":["POS11"],"answer":"accept"}
{"text":"Recent randomized controlled trials ( RCT ) have failed to demonstrate the efficacy of widely used therapies , such as rituximab plus intravenous immunoglobulin or proteasome inhibition ( bortezomib ) , reinforcing a great need for new therapeutic concepts .","paragraph":"<h3><u>Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.</u></h3>Late antibody-mediated rejection (ABMR) triggered by donor-specific antibodies (DSA) is a cardinal cause of kidney allograft dysfunction and loss. Diagnostic criteria for this rejection type are well established, but effective treatment remains a major challenge. <b style='color:DodgerBlue;'><i>Recent</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>controlled</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RCT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>failed</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>demonstrate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>widely</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>therapies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>such</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>immunoglobulin</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>proteasome</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>reinforcing</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>great</i></b> <b style='color:DodgerBlue;'><i>need</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>concepts</i></b> <b style='color:DodgerBlue;'><i>.</i></b> One promising target in this context may be interleukin-6 (IL-6), a pleiotropic cytokine known to play an important role in inflammation and adaptive immunity. ### methods This investigator-driven RCT was designed to assess the safety and efficacy of <b style='color:Tomato;'><i>clazakizumab</i></b>, a genetically engineered humanized monoclonal antibody directed against IL-6. The study will include 20 DSA-positive kidney allograft recipients diagnosed with ABMR \u2265\u2009365\u2009days after transplantation. Participants will be recruited at two study sites in Austria and Germany (Medical University of Vienna; Charit\u00e9 University Medicine Berlin). First, patients will enter a three-month double-blind RCT (1,1 randomization, stratification according to ABMR phenotype and study site) and will receive either <b style='color:Tomato;'><i>clazakizumab</i></b> (subcutaneous administration of 25\u2009mg in monthly intervals) or placebo. In a second open-label part of the trial (months 4-12), all patients will receive <b style='color:Tomato;'><i>clazakizumab</i></b> at 25\u2009mg every month. The primary endpoint is safety and tolerability. Secondary endpoints are the pharmacokinetics and pharmacodynamics of <b style='color:Tomato;'><i>clazakizumab</i></b>, its effect on drug metabolism in the liver, DSA characteristics, morphological ABMR lesions and molecular gene expression patterns in three- and 12-month protocol biopsies, serum/urinary biomarkers of inflammation and endothelial activation/injury, Torque Teno viral load as a measure of overall immunosuppression, kidney function, urinary protein excretion, as well as transplant and patient survival. ### discussion Currently, there is no treatment proven to be effective in halting the progression of late ABMR. Based on the hypothesis that antagonizing the effects of IL-6 improves the outcome of DSA-positive late ABMR by counteracting DSA-triggered inflammation and B cell/plasma cell-driven alloimmunity, we suggest that our trial has the potential to provide proof of concept of a novel treatment of this type of rejection. ### Trial Registration ClinicalTrials.gov, NCT03444103 . Registered on 23 February 2018 (retrospective registration).","tokens":[{"text":"Recent","start":0,"end":6,"id":0,"ws":true},{"text":"randomized","start":7,"end":17,"id":1,"ws":true},{"text":"controlled","start":18,"end":28,"id":2,"ws":true},{"text":"trials","start":29,"end":35,"id":3,"ws":true},{"text":"(","start":36,"end":37,"id":4,"ws":true},{"text":"RCT","start":38,"end":41,"id":5,"ws":true},{"text":")","start":42,"end":43,"id":6,"ws":true},{"text":"have","start":44,"end":48,"id":7,"ws":true},{"text":"failed","start":49,"end":55,"id":8,"ws":true},{"text":"to","start":56,"end":58,"id":9,"ws":true},{"text":"demonstrate","start":59,"end":70,"id":10,"ws":true},{"text":"the","start":71,"end":74,"id":11,"ws":true},{"text":"efficacy","start":75,"end":83,"id":12,"ws":true},{"text":"of","start":84,"end":86,"id":13,"ws":true},{"text":"widely","start":87,"end":93,"id":14,"ws":true},{"text":"used","start":94,"end":98,"id":15,"ws":true},{"text":"therapies","start":99,"end":108,"id":16,"ws":true},{"text":",","start":109,"end":110,"id":17,"ws":true},{"text":"such","start":111,"end":115,"id":18,"ws":true},{"text":"as","start":116,"end":118,"id":19,"ws":true},{"text":"rituximab","start":119,"end":128,"id":20,"ws":true},{"text":"plus","start":129,"end":133,"id":21,"ws":true},{"text":"intravenous","start":134,"end":145,"id":22,"ws":true},{"text":"immunoglobulin","start":146,"end":160,"id":23,"ws":true},{"text":"or","start":161,"end":163,"id":24,"ws":true},{"text":"proteasome","start":164,"end":174,"id":25,"ws":true},{"text":"inhibition","start":175,"end":185,"id":26,"ws":true},{"text":"(","start":186,"end":187,"id":27,"ws":true},{"text":"bortezomib","start":188,"end":198,"id":28,"ws":true},{"text":")","start":199,"end":200,"id":29,"ws":true},{"text":",","start":201,"end":202,"id":30,"ws":true},{"text":"reinforcing","start":203,"end":214,"id":31,"ws":true},{"text":"a","start":215,"end":216,"id":32,"ws":true},{"text":"great","start":217,"end":222,"id":33,"ws":true},{"text":"need","start":223,"end":227,"id":34,"ws":true},{"text":"for","start":228,"end":231,"id":35,"ws":true},{"text":"new","start":232,"end":235,"id":36,"ws":true},{"text":"therapeutic","start":236,"end":247,"id":37,"ws":true},{"text":"concepts","start":248,"end":256,"id":38,"ws":true},{"text":".","start":257,"end":258,"id":39,"ws":false}],"spans":[{"start":119,"end":128,"token_start":20,"token_end":20,"label":"DRUG"},{"start":134,"end":160,"token_start":22,"token_end":23,"label":"DRUG"},{"start":188,"end":198,"token_start":28,"token_end":28,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30635033/","_input_hash":-623695755,"_task_hash":-1489410173,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":20,"child":23,"head_span":{"start":119,"end":128,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":134,"end":160,"token_start":22,"token_end":23,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"},{"head":20,"child":28,"head_span":{"start":119,"end":128,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":188,"end":198,"token_start":28,"token_end":28,"label":"DRUG"},"color":"#ffdaf9","label":"NEG2"}],"radio":["NEG10","NEG20"],"answer":"accept"}
{"text":"The experimental protocol was as follows : ( 1 ) at time zero , intravenous infusion of ritodrine was begun ; ( 2 ) at 120 min , 2 % lidocaine was given epidurally to achieve a sensory level of at least T6 ; and ( 3 ) at 135 min , an intravenous bolus of either ephedrine , phenylephrine , or normal saline-control was given , followed by a continuous intravenous infusion of the same agent for 30 min .","paragraph":"<h3><u>Ephedrine remains the vasopressor of choice for treatment of hypotension during ritodrine infusion and epidural anesthesia.</u></h3>Historically, ephedrine has been the vasopressor of choice for treatment of most cases of hypotension in obstetric patients. However, the choice of vasopressor in the parturient receiving a beta-adrenergic agent for tocolysis has not been evaluated extensively. The current study evaluated whether ephedrine or <b style='color:Tomato;'><i>phenylephrine</i></b> better restores uterine blood flow and fetal oxygenation during <b style='color:Tomato;'><i>ritodrine</i></b> infusion and epidural anesthesia-induced hypotension in gravid ewes. ### methods Fourteen chronically instrumented gravid ewes between 0.8 and 0.9 timed gestational age were used. On separate days, each animal underwent the experimental protocol with one of three agents: ephedrine, <b style='color:Tomato;'><i>phenylephrine</i></b>, and normal saline-control. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>follows</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>zero</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>ritodrine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>begun</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>2</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>epidurally</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>achieve</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>sensory</i></b> <b style='color:DodgerBlue;'><i>level</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>least</i></b> <b style='color:DodgerBlue;'><i>T6</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>135</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>bolus</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:DodgerBlue;'><i>ephedrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>phenylephrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>normal</i></b> <b style='color:DodgerBlue;'><i>saline-control</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>continuous</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:DodgerBlue;'><i>infusion</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>same</i></b> <b style='color:DodgerBlue;'><i>agent</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>30</i></b> <b style='color:DodgerBlue;'><i>min</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In the ephedrine and <b style='color:Tomato;'><i>phenylephrine</i></b> experiments, the rate of infusion was adjusted to maintain maternal mean arterial pressure close to baseline. ### results <b style='color:Tomato;'><i>ritodrine</i></b> infusion alone significantly increased maternal heart rate and cardiac output in all three groups. Epidural anesthesia during <b style='color:Tomato;'><i>ritodrine</i></b> infusion significantly decreased maternal mean arterial pressure, heart rate, cardiac output, uterine blood flow, and fetal arterial oxygen tension for each of the three groups. Both ephedrine and <b style='color:Tomato;'><i>phenylephrine</i></b> restored maternal mean arterial pressure to baseline, as designed. Ephedrine significantly increased uterine blood flow and fetal arterial oxygen tension when compared with normal saline--control, but <b style='color:Tomato;'><i>phenylephrine</i></b> did not. <b style='color:Tomato;'><i>phenylephrine</i></b> significantly increased uterine vascular resistance when compared with normal saline--control, but ephedrine did not. ### conclusions Although ephedrine and <b style='color:Tomato;'><i>phenylephrine</i></b> provided similar restoration of maternal mean arterial pressure, ephedrine was superior to <b style='color:Tomato;'><i>phenylephrine</i></b> in restoring uterine blood flow during <b style='color:Tomato;'><i>ritodrine</i></b> infusion and epidural anesthesia-induced hypotension in gravid ewes. Also, ephedrine, but not <b style='color:Tomato;'><i>phenylephrine</i></b>, significantly improved fetal oxygenation, when compared to normal saline--control.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"experimental","start":4,"end":16,"id":1,"ws":true},{"text":"protocol","start":17,"end":25,"id":2,"ws":true},{"text":"was","start":26,"end":29,"id":3,"ws":true},{"text":"as","start":30,"end":32,"id":4,"ws":true},{"text":"follows","start":33,"end":40,"id":5,"ws":true},{"text":":","start":41,"end":42,"id":6,"ws":true},{"text":"(","start":43,"end":44,"id":7,"ws":true},{"text":"1","start":45,"end":46,"id":8,"ws":true},{"text":")","start":47,"end":48,"id":9,"ws":true},{"text":"at","start":49,"end":51,"id":10,"ws":true},{"text":"time","start":52,"end":56,"id":11,"ws":true},{"text":"zero","start":57,"end":61,"id":12,"ws":true},{"text":",","start":62,"end":63,"id":13,"ws":true},{"text":"intravenous","start":64,"end":75,"id":14,"ws":true},{"text":"infusion","start":76,"end":84,"id":15,"ws":true},{"text":"of","start":85,"end":87,"id":16,"ws":true},{"text":"ritodrine","start":88,"end":97,"id":17,"ws":true},{"text":"was","start":98,"end":101,"id":18,"ws":true},{"text":"begun","start":102,"end":107,"id":19,"ws":true},{"text":";","start":108,"end":109,"id":20,"ws":true},{"text":"(","start":110,"end":111,"id":21,"ws":true},{"text":"2","start":112,"end":113,"id":22,"ws":true},{"text":")","start":114,"end":115,"id":23,"ws":true},{"text":"at","start":116,"end":118,"id":24,"ws":true},{"text":"120","start":119,"end":122,"id":25,"ws":true},{"text":"min","start":123,"end":126,"id":26,"ws":true},{"text":",","start":127,"end":128,"id":27,"ws":true},{"text":"2","start":129,"end":130,"id":28,"ws":true},{"text":"%","start":131,"end":132,"id":29,"ws":true},{"text":"lidocaine","start":133,"end":142,"id":30,"ws":true},{"text":"was","start":143,"end":146,"id":31,"ws":true},{"text":"given","start":147,"end":152,"id":32,"ws":true},{"text":"epidurally","start":153,"end":163,"id":33,"ws":true},{"text":"to","start":164,"end":166,"id":34,"ws":true},{"text":"achieve","start":167,"end":174,"id":35,"ws":true},{"text":"a","start":175,"end":176,"id":36,"ws":true},{"text":"sensory","start":177,"end":184,"id":37,"ws":true},{"text":"level","start":185,"end":190,"id":38,"ws":true},{"text":"of","start":191,"end":193,"id":39,"ws":true},{"text":"at","start":194,"end":196,"id":40,"ws":true},{"text":"least","start":197,"end":202,"id":41,"ws":true},{"text":"T6","start":203,"end":205,"id":42,"ws":true},{"text":";","start":206,"end":207,"id":43,"ws":true},{"text":"and","start":208,"end":211,"id":44,"ws":true},{"text":"(","start":212,"end":213,"id":45,"ws":true},{"text":"3","start":214,"end":215,"id":46,"ws":true},{"text":")","start":216,"end":217,"id":47,"ws":true},{"text":"at","start":218,"end":220,"id":48,"ws":true},{"text":"135","start":221,"end":224,"id":49,"ws":true},{"text":"min","start":225,"end":228,"id":50,"ws":true},{"text":",","start":229,"end":230,"id":51,"ws":true},{"text":"an","start":231,"end":233,"id":52,"ws":true},{"text":"intravenous","start":234,"end":245,"id":53,"ws":true},{"text":"bolus","start":246,"end":251,"id":54,"ws":true},{"text":"of","start":252,"end":254,"id":55,"ws":true},{"text":"either","start":255,"end":261,"id":56,"ws":true},{"text":"ephedrine","start":262,"end":271,"id":57,"ws":true},{"text":",","start":272,"end":273,"id":58,"ws":true},{"text":"phenylephrine","start":274,"end":287,"id":59,"ws":true},{"text":",","start":288,"end":289,"id":60,"ws":true},{"text":"or","start":290,"end":292,"id":61,"ws":true},{"text":"normal","start":293,"end":299,"id":62,"ws":true},{"text":"saline-control","start":300,"end":314,"id":63,"ws":true},{"text":"was","start":315,"end":318,"id":64,"ws":true},{"text":"given","start":319,"end":324,"id":65,"ws":true},{"text":",","start":325,"end":326,"id":66,"ws":true},{"text":"followed","start":327,"end":335,"id":67,"ws":true},{"text":"by","start":336,"end":338,"id":68,"ws":true},{"text":"a","start":339,"end":340,"id":69,"ws":true},{"text":"continuous","start":341,"end":351,"id":70,"ws":true},{"text":"intravenous","start":352,"end":363,"id":71,"ws":true},{"text":"infusion","start":364,"end":372,"id":72,"ws":true},{"text":"of","start":373,"end":375,"id":73,"ws":true},{"text":"the","start":376,"end":379,"id":74,"ws":true},{"text":"same","start":380,"end":384,"id":75,"ws":true},{"text":"agent","start":385,"end":390,"id":76,"ws":true},{"text":"for","start":391,"end":394,"id":77,"ws":true},{"text":"30","start":395,"end":397,"id":78,"ws":true},{"text":"min","start":398,"end":401,"id":79,"ws":true},{"text":".","start":402,"end":403,"id":80,"ws":false}],"spans":[{"start":88,"end":97,"token_start":17,"token_end":17,"label":"DRUG"},{"start":133,"end":142,"token_start":30,"token_end":30,"label":"DRUG"},{"start":274,"end":287,"token_start":59,"token_end":59,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8017645/","_input_hash":990949207,"_task_hash":1588274997,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":17,"child":30,"head_span":{"start":88,"end":97,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":133,"end":142,"token_start":30,"token_end":30,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":57,"child":30,"head_span":{"start":262,"end":271,"token_start":57,"token_end":57,"label":null},"child_span":{"start":133,"end":142,"token_start":30,"token_end":30,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":17,"child":30,"head_span":{"start":88,"end":97,"token_start":17,"token_end":17,"label":"DRUG"},"child_span":{"start":133,"end":142,"token_start":30,"token_end":30,"label":"DRUG"},"color":"#ffd882","label":"POS2"},{"head":59,"child":30,"head_span":{"start":274,"end":287,"token_start":59,"token_end":59,"label":"DRUG"},"child_span":{"start":133,"end":142,"token_start":30,"token_end":30,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>busulfan</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>conditioning</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>allogeneic</i></b> <b style='color:DodgerBlue;'><i>stem</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>transplant</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>matched</i></b> <b style='color:DodgerBlue;'><i>siblings</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>unrelated</i></b> <b style='color:DodgerBlue;'><i>donors</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>myeloid</i></b> <b style='color:DodgerBlue;'><i>leukemia</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3><b style='color:Tomato;'><i>busulfan</i></b> plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> (BuCy) is the traditional conditioning regimen for allogeneic stem cell transplant (allo-SCT) for young, fit patients with acute myeloid leukemia (AML). The <b style='color:Tomato;'><i>thiotepa</i></b>-<b style='color:Tomato;'><i>busulfan</i></b>-<b style='color:Tomato;'><i>fludarabine</i></b> (TBF) protocol has recently demonstrated promising outcome in cord blood and haploidentical SCT; however, there is limited evidence about this regimen in transplant from matched siblings (MSD) and unrelated donors (UD). We retrospectively compared outcomes of 2523 patients aged 18-50 with AML in remission, undergoing transplant from MSD or UD prepared with either TBF or BuCy conditioning. A 1:3 pair-matched analysis was performed: 146 patients receiving TBF were compared with 438 patients receiving BuCy. Relapse risk was significantly lower in the TBF when compared with BuCy group (HR 0.6, P\u2009=\u2009.02), while NRM did not differ. No significant difference was observed in LFS and OS between the two regimens. TBF was associated with a trend towards higher risk of grades III-IV aGVHD (HR 1.8, P\u2009=\u2009.06) and inferior cGVHD (HR 0.7, P\u2009=\u2009.04) when compared with BuCy. In patients undergoing transplant in first remission, the advantage for TBF in terms of relapse was more evident (HR 0.4, P\u2009=\u2009.02), leading to a trend for better LFS in favor of TBF (HR 0.7, P\u2009=\u2009.10), while OS did not differ between the two cohorts. In conclusion, TBF represents a valid myeloablative conditioning regimen providing significantly lower relapse and similar survival when compared with BuCy. Patients in first remission appear to gain the most from this protocol, as in this subgroup a tendency for better LFS was observed when compared with BuCy.","tokens":[{"text":"compared","start":0,"end":8,"id":0,"ws":true},{"text":"to","start":9,"end":11,"id":1,"ws":true},{"text":"busulfan","start":12,"end":20,"id":2,"ws":true},{"text":"and","start":21,"end":24,"id":3,"ws":true},{"text":"cyclophosphamide","start":25,"end":41,"id":4,"ws":true},{"text":"as","start":42,"end":44,"id":5,"ws":true},{"text":"conditioning","start":45,"end":57,"id":6,"ws":true},{"text":"regimen","start":58,"end":65,"id":7,"ws":true},{"text":"for","start":66,"end":69,"id":8,"ws":true},{"text":"allogeneic","start":70,"end":80,"id":9,"ws":true},{"text":"stem","start":81,"end":85,"id":10,"ws":true},{"text":"cell","start":86,"end":90,"id":11,"ws":true},{"text":"transplant","start":91,"end":101,"id":12,"ws":true},{"text":"from","start":102,"end":106,"id":13,"ws":true},{"text":"matched","start":107,"end":114,"id":14,"ws":true},{"text":"siblings","start":115,"end":123,"id":15,"ws":true},{"text":"and","start":124,"end":127,"id":16,"ws":true},{"text":"unrelated","start":128,"end":137,"id":17,"ws":true},{"text":"donors","start":138,"end":144,"id":18,"ws":true},{"text":"for","start":145,"end":148,"id":19,"ws":true},{"text":"acute","start":149,"end":154,"id":20,"ws":true},{"text":"myeloid","start":155,"end":162,"id":21,"ws":true},{"text":"leukemia","start":163,"end":171,"id":22,"ws":true},{"text":".","start":172,"end":173,"id":23,"ws":false}],"spans":[{"start":12,"end":20,"token_start":2,"token_end":2,"label":"DRUG"},{"start":25,"end":41,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30033639/","_input_hash":1876764133,"_task_hash":-612169712,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":12,"end":20,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":25,"end":41,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The aim of this study was to find an experimental model of a donor-recipient rat strain combination that , under triple drug immunosuppressive treatment ( methylprednisolone , cyclosporine , and azathioprine ) , would develop chronic rejection within a few weeks .","paragraph":"<h3><u>An experimental model of chronic renal allograft rejection in the rat using triple drug immunosuppression.</u></h3>Chronic rejection is a major problem in renal transplantation. Various experimental models have been developed to study vasculopathy of chronic rejection. However, animal models resembling the clinical situation of renal transplantation with combination therapy of basic immunosuppression are not available. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>find</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>experimental</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>donor-recipient</i></b> <b style='color:DodgerBlue;'><i>rat</i></b> <b style='color:DodgerBlue;'><i>strain</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>under</i></b> <b style='color:DodgerBlue;'><i>triple</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>immunosuppressive</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>azathioprine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>would</i></b> <b style='color:DodgerBlue;'><i>develop</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>rejection</i></b> <b style='color:DodgerBlue;'><i>within</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>few</i></b> <b style='color:DodgerBlue;'><i>weeks</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods Renal transplantations were performed in strain combinations of DA-->AO, PVG-->BN, and DA-->BN. In each group, 5-8 animals received triple drug treatment of <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> (2 mg/kg), <b style='color:Tomato;'><i>azathioprine</i></b> (2 mg/kg), and <b style='color:Tomato;'><i>cyclosporin</i></b>e (5 mg/kg) daily, 5-10 animals were left without treatment, and 6 syngenic transplantations were performed. The grafts were monitored with ultrasound-guided fine needle aspiration biopsies to quantify the inflammation in the graft. Graft histology was performed in parallel and quantified by using the chronic allograft damage index (CADI). ### results In nonimmunosuppressed animals, irreversible acute rejection with a high peak of inflammation appeared in every strain combination within 5-8 days. In triple drug-treated rats, the DA-->AO combination demonstrated a prolonged acute rejection but no characteristic chronic changes, and the PVG-->BN combination showed practically no inflammation and did not develop any signs of chronic rejection within 60 days (CADI: 2.7+/-2.1), but the DA-->BN combination showed an early, mild inflammatory response 5-7 days after transplantation and developed chronic rejection within 40-60 days after transplantation (CADI: 7.9+/-3.1). Syngenic animals showed no inflammation or histological alterations (CADI: 1.7+/-2.0). ### conclusions In conclusion, in the DA-->BN combination with triple drug treatment, early mild inflammation was followed by the development of chronic rejection and can be used as an experimental model that resembles the clinical situation in renal transplantation.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"this","start":11,"end":15,"id":3,"ws":true},{"text":"study","start":16,"end":21,"id":4,"ws":true},{"text":"was","start":22,"end":25,"id":5,"ws":true},{"text":"to","start":26,"end":28,"id":6,"ws":true},{"text":"find","start":29,"end":33,"id":7,"ws":true},{"text":"an","start":34,"end":36,"id":8,"ws":true},{"text":"experimental","start":37,"end":49,"id":9,"ws":true},{"text":"model","start":50,"end":55,"id":10,"ws":true},{"text":"of","start":56,"end":58,"id":11,"ws":true},{"text":"a","start":59,"end":60,"id":12,"ws":true},{"text":"donor-recipient","start":61,"end":76,"id":13,"ws":true},{"text":"rat","start":77,"end":80,"id":14,"ws":true},{"text":"strain","start":81,"end":87,"id":15,"ws":true},{"text":"combination","start":88,"end":99,"id":16,"ws":true},{"text":"that","start":100,"end":104,"id":17,"ws":true},{"text":",","start":105,"end":106,"id":18,"ws":true},{"text":"under","start":107,"end":112,"id":19,"ws":true},{"text":"triple","start":113,"end":119,"id":20,"ws":true},{"text":"drug","start":120,"end":124,"id":21,"ws":true},{"text":"immunosuppressive","start":125,"end":142,"id":22,"ws":true},{"text":"treatment","start":143,"end":152,"id":23,"ws":true},{"text":"(","start":153,"end":154,"id":24,"ws":true},{"text":"methylprednisolone","start":155,"end":173,"id":25,"ws":true},{"text":",","start":174,"end":175,"id":26,"ws":true},{"text":"cyclosporine","start":176,"end":188,"id":27,"ws":true},{"text":",","start":189,"end":190,"id":28,"ws":true},{"text":"and","start":191,"end":194,"id":29,"ws":true},{"text":"azathioprine","start":195,"end":207,"id":30,"ws":true},{"text":")","start":208,"end":209,"id":31,"ws":true},{"text":",","start":210,"end":211,"id":32,"ws":true},{"text":"would","start":212,"end":217,"id":33,"ws":true},{"text":"develop","start":218,"end":225,"id":34,"ws":true},{"text":"chronic","start":226,"end":233,"id":35,"ws":true},{"text":"rejection","start":234,"end":243,"id":36,"ws":true},{"text":"within","start":244,"end":250,"id":37,"ws":true},{"text":"a","start":251,"end":252,"id":38,"ws":true},{"text":"few","start":253,"end":256,"id":39,"ws":true},{"text":"weeks","start":257,"end":262,"id":40,"ws":true},{"text":".","start":263,"end":264,"id":41,"ws":false}],"spans":[{"start":155,"end":173,"token_start":25,"token_end":25,"label":"DRUG"},{"start":176,"end":188,"token_start":27,"token_end":27,"label":"DRUG"},{"start":195,"end":207,"token_start":30,"token_end":30,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9448142/","_input_hash":-1433669124,"_task_hash":-654271239,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":25,"child":27,"head_span":{"start":155,"end":173,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":176,"end":188,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":30,"child":27,"head_span":{"start":195,"end":207,"token_start":30,"token_end":30,"label":"DRUG"},"child_span":{"start":176,"end":188,"token_start":27,"token_end":27,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11","NEG11"],"answer":"accept"}
{"text":"In FOLL05 trial , R-CHOP was compared with R-CVP ( cyclophosphamide , vincristine , prednisone ) and R-FM ( fludarabine , mitoxantrone ) .","paragraph":"<h3><u>Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting.</u></h3>Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (<b style='color:Tomato;'><i>rituximab</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>doxorubicin</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>prednisone</i></b>) remains the standard frontline regimen for diffuse Large B -cell lymphoma, the optimal chemotherapy regimen for frontline therapy of advanced IL remains uncertain. FCR (<b style='color:Tomato;'><i>fludarabine</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>rituximab</i></b>) has been shown to be better than <b style='color:Tomato;'><i>fludarabine</i></b> alone and <b style='color:Tomato;'><i>fludarabine</i></b> plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> for IL. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>FOLL05</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>R-CHOP</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>R-CVP</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>R-FM</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>fludarabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>mitoxantrone</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The study showed that R-CHOP appears to have the best risk-benefit ratio for IL. The StiL NHL1 trial showed that BR (<b style='color:Tomato;'><i>bendamustine</i></b>, <b style='color:Tomato;'><i>rituximab</i></b>) has longer progression free survival and is better tolerated than R-CHOP. Long-term complications with secondary malignancies between the two regimens appear to be comparable. In this review, new combination regimens reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"FOLL05","start":3,"end":9,"id":1,"ws":true},{"text":"trial","start":10,"end":15,"id":2,"ws":true},{"text":",","start":16,"end":17,"id":3,"ws":true},{"text":"R-CHOP","start":18,"end":24,"id":4,"ws":true},{"text":"was","start":25,"end":28,"id":5,"ws":true},{"text":"compared","start":29,"end":37,"id":6,"ws":true},{"text":"with","start":38,"end":42,"id":7,"ws":true},{"text":"R-CVP","start":43,"end":48,"id":8,"ws":true},{"text":"(","start":49,"end":50,"id":9,"ws":true},{"text":"cyclophosphamide","start":51,"end":67,"id":10,"ws":true},{"text":",","start":68,"end":69,"id":11,"ws":true},{"text":"vincristine","start":70,"end":81,"id":12,"ws":true},{"text":",","start":82,"end":83,"id":13,"ws":true},{"text":"prednisone","start":84,"end":94,"id":14,"ws":true},{"text":")","start":95,"end":96,"id":15,"ws":true},{"text":"and","start":97,"end":100,"id":16,"ws":true},{"text":"R-FM","start":101,"end":105,"id":17,"ws":true},{"text":"(","start":106,"end":107,"id":18,"ws":true},{"text":"fludarabine","start":108,"end":119,"id":19,"ws":true},{"text":",","start":120,"end":121,"id":20,"ws":true},{"text":"mitoxantrone","start":122,"end":134,"id":21,"ws":true},{"text":")","start":135,"end":136,"id":22,"ws":true},{"text":".","start":137,"end":138,"id":23,"ws":false}],"spans":[{"start":18,"end":24,"token_start":4,"token_end":4,"label":"DRUG"},{"start":51,"end":67,"token_start":10,"token_end":10,"label":"DRUG"},{"start":70,"end":81,"token_start":12,"token_end":12,"label":"DRUG"},{"start":84,"end":94,"token_start":14,"token_end":14,"label":"DRUG"},{"start":108,"end":119,"token_start":19,"token_end":19,"label":"DRUG"},{"start":122,"end":134,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22913602/","_input_hash":1595252911,"_task_hash":989709433,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":10,"child":12,"head_span":{"start":51,"end":67,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":70,"end":81,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":14,"child":12,"head_span":{"start":84,"end":94,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":70,"end":81,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":21,"child":19,"head_span":{"start":122,"end":134,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":108,"end":119,"token_start":19,"token_end":19,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"Posttransplant immunosuppression to prevent graft-versus-host disease ( GVHD ) consisted of cyclosporine and prednisone ( CSA/PSE ) .","paragraph":"<h3><u>A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.</u></h3>Two novel preparatory regimens for conditioning of patients with leukemia for allogeneic bone marrow transplantation (BMT) from histocompatible sibling donors have been tested in a phase III trial under the auspices of the Southwest Oncology Group (SWOG 8612). These two regimens consisted either of fractionated total body irradiation and <b style='color:Tomato;'><i>etoposide</i></b> (FTBI/VP-16) or high-dose <b style='color:Tomato;'><i>busulfan</i></b> with <b style='color:Tomato;'><i>cyclophosphamide</i></b> (BU/CY). Only patients who had failed prior conventional management at least once were study eligible, ie, no patients with acute leukemia in first remission (CR) or in first chronic phase (CP) of chronic myelogenous leukemia (CML) participated. Patients were stratified according to the following risk criteria: \"good-risk\" patients were those who were in second CR of their acute leukemia or in accelerated phase (AP) of CML; \"poor-risk\" patients had further advanced stages of leukemia. During a 52-month period, 131 patients were registered of whom 122 (93%) were study eligible. Sixty-one eligible patients were randomized to the FTBI/VP-16 arm and 61 to the BU/CY regimen. Of these 122 patients, 114 (93%) proceeded to BMT according to protocol. <b style='color:DodgerBlue;'><i>Posttransplant</i></b> <b style='color:DodgerBlue;'><i>immunosuppression</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>graft-versus-host</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>GVHD</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>consisted</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>CSA/PSE</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Neither overall survival nor disease-free survival (DFS) differed significantly between the two treatment groups (P = .89 and .69, respectively). Estimated DFS for \"good-risk\" patients who had been prepared with the FTBI/VP-16 regimen was 55% +/- 11%, as compared with patients treated with BU/CY whose DFS figure was 34% +/- 10% (P = .30). For \"poor-risk\" candidates, the DFS rates at 24 months were 17% +/- 6% (for FTBI/VP-16) and 24% +/- 8% (for BU/CY), respectively (P = .81). These figures do not differ significantly, especially in view of the fact that the \"good-risk\" patients prepared with the FTBI/VP-16 regimen were younger than those treated with BU/CY. Both regimens were well tolerated with no regimen-related deaths encountered during the 6-week period after BMT. This study also confirmed the efficacy of the CSA/PSE combination in the prevention of GVHD with 23 of 113 (20%) of BMT recipients developing moderate to severe acute GVHD. The leading cause for treatment failure was leukemic relapse (45 of the 114 BMT recipients suffered a recurrence of their leukemia), whereas 38 patients died without evidence of relapse. Thirty-one patients are alive and in continued CR after marrow transplantation; four are alive in relapse.(ABSTRACT TRUNCATED AT 400 WORDS)","tokens":[{"text":"Posttransplant","start":0,"end":14,"id":0,"ws":true},{"text":"immunosuppression","start":15,"end":32,"id":1,"ws":true},{"text":"to","start":33,"end":35,"id":2,"ws":true},{"text":"prevent","start":36,"end":43,"id":3,"ws":true},{"text":"graft-versus-host","start":44,"end":61,"id":4,"ws":true},{"text":"disease","start":62,"end":69,"id":5,"ws":true},{"text":"(","start":70,"end":71,"id":6,"ws":true},{"text":"GVHD","start":72,"end":76,"id":7,"ws":true},{"text":")","start":77,"end":78,"id":8,"ws":true},{"text":"consisted","start":79,"end":88,"id":9,"ws":true},{"text":"of","start":89,"end":91,"id":10,"ws":true},{"text":"cyclosporine","start":92,"end":104,"id":11,"ws":true},{"text":"and","start":105,"end":108,"id":12,"ws":true},{"text":"prednisone","start":109,"end":119,"id":13,"ws":true},{"text":"(","start":120,"end":121,"id":14,"ws":true},{"text":"CSA/PSE","start":122,"end":129,"id":15,"ws":true},{"text":")","start":130,"end":131,"id":16,"ws":true},{"text":".","start":132,"end":133,"id":17,"ws":false}],"spans":[{"start":92,"end":104,"token_start":11,"token_end":11,"label":"DRUG"},{"start":109,"end":119,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/8471778/","_input_hash":429142376,"_task_hash":-658872070,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":11,"child":13,"head_span":{"start":92,"end":104,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":109,"end":119,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Tadalafil 20 mg was preferred to sildenafil 50 mg for the initiation of ED therapy in this study population .","paragraph":"<h3><u>A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.</u></h3><b style='color:Tomato;'><i>tadalafil</i></b> is a phosphodiesterase 5 (PDE5) inhibitor approved in >30 countries for the treatment of erectile dysfunction (ED). It has been shown to improve erectile function compared with placebo in Phase III studies, but clinical experience comparing <b style='color:Tomato;'><i>tadalafil</i></b> with the PDE5 inhibitor <b style='color:Tomato;'><i>sildenafil</i></b> citrate is lacking. ### objective This study compared patient preference for <b style='color:Tomato;'><i>tadalafil</i></b> 20 mg or <b style='color:Tomato;'><i>sildenafil</i></b> 50 mg during initial treatment for ED. It also compared the tolerability of the 2 agents at these doses. ### methods This randomized, double-blind, fixed-dose, 2-period crossover trial took place at 13 sites in the United States and Germany. Patients were randomized 1:1 to receive 4 weeks of treatment with <b style='color:Tomato;'><i>tadalafil</i></b> 20 mg or <b style='color:Tomato;'><i>sildenafil</i></b> 50 mg, followed by the alternative treatment, to be taken as needed up to once daily before sexual activity. ### results The study enrolled 215 men with ED, 109 randomized to the <b style='color:Tomato;'><i>tadalafil</i></b>-<b style='color:Tomato;'><i>sildenafil</i></b> sequence and 106 to the <b style='color:Tomato;'><i>sildenafil</i></b>-<b style='color:Tomato;'><i>tadalafil</i></b> sequence. Their mean age was 49.8 years; 84.7% were <b style='color:Tomato;'><i>sildenafil</i></b> naive and 15.3% had undergone a previous inadequate trial of <b style='color:Tomato;'><i>sildenafil</i></b>. Most patients had moderate ED (60.5%) of >or=1 year's duration (74.9%). Of 190 evaluable patients, 126 (66.3%) preferred to initiate treatment with <b style='color:Tomato;'><i>tadalafil</i></b>, compared with 64 (33.7%) with <b style='color:Tomato;'><i>sildenafil</i></b> (P < 0.001). Patients' preference did not differ by age, duration of ED, treatment sequence, or previous <b style='color:Tomato;'><i>sildenafil</i></b> exposure. Both medications were well tolerated, with no significant differences in the incidence of treatment-emergent adverse events. Headache (11.2% <b style='color:Tomato;'><i>tadalafil</i></b>, 8.8% <b style='color:Tomato;'><i>sildenafil</i></b>), dyspepsia (6.0% and 4.2%, respectively), nasopharyngitis (4.7% and 2.8%), and flushing (2.8% and 4.7%) were the most common adverse events. The rate of ocular disturbances was low: 1 patient experienced intermittent bilateral reduction in visual acuity with <b style='color:Tomato;'><i>tadalafil</i></b>, and 2 exhibited conjunctival hyperemia or eyelid edema with <b style='color:Tomato;'><i>sildenafil</i></b>. ### conclusions <b style='color:MediumOrchid;'><i>Tadalafil</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>sildenafil</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>initiation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>ED</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>population</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Both medications were well tolerated.","tokens":[{"text":"Tadalafil","start":0,"end":9,"id":0,"ws":true},{"text":"20","start":10,"end":12,"id":1,"ws":true},{"text":"mg","start":13,"end":15,"id":2,"ws":true},{"text":"was","start":16,"end":19,"id":3,"ws":true},{"text":"preferred","start":20,"end":29,"id":4,"ws":true},{"text":"to","start":30,"end":32,"id":5,"ws":true},{"text":"sildenafil","start":33,"end":43,"id":6,"ws":true},{"text":"50","start":44,"end":46,"id":7,"ws":true},{"text":"mg","start":47,"end":49,"id":8,"ws":true},{"text":"for","start":50,"end":53,"id":9,"ws":true},{"text":"the","start":54,"end":57,"id":10,"ws":true},{"text":"initiation","start":58,"end":68,"id":11,"ws":true},{"text":"of","start":69,"end":71,"id":12,"ws":true},{"text":"ED","start":72,"end":74,"id":13,"ws":true},{"text":"therapy","start":75,"end":82,"id":14,"ws":true},{"text":"in","start":83,"end":85,"id":15,"ws":true},{"text":"this","start":86,"end":90,"id":16,"ws":true},{"text":"study","start":91,"end":96,"id":17,"ws":true},{"text":"population","start":97,"end":107,"id":18,"ws":true},{"text":".","start":108,"end":109,"id":19,"ws":false}],"spans":[{"start":0,"end":9,"token_start":0,"token_end":0,"label":"DRUG"},{"start":33,"end":43,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/14693299/","_input_hash":1795396788,"_task_hash":1898892622,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Reactivity of factor IXa with basic pancreatic trypsin inhibitor is enhanced by low molecular weight heparin ( enoxaparin ) .","paragraph":"<h3><u>Heparin modulates the 99-loop of factor IXa: effects on reactivity with isolated Kunitz-type inhibitor domains.</u></h3> <b style='color:DodgerBlue;'><i>Reactivity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>factor</i></b> <b style='color:DodgerBlue;'><i>IXa</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>basic</i></b> <b style='color:DodgerBlue;'><i>pancreatic</i></b> <b style='color:DodgerBlue;'><i>trypsin</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>enhanced</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>low</i></b> <b style='color:DodgerBlue;'><i>molecular</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:MediumOrchid;'><i>heparin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>enoxaparin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Previous studies by us have suggested that this effect involves allosteric modulation of factor IXa. We examined the reactivity of factor IXa with several isolated Kunitz-type inhibitor domains: basic pancreatic trypsin inhibitor, the Kunitz inhibitor domain of protease Nexin-2, and the first two inhibitor domains of tissue factor pathway inhibitor. We find that enhancement of factor IXa reactivity by <b style='color:Tomato;'><i>enoxaparin</i></b> is greatest for basic pancreatic trypsin inhibitor (>10-fold), followed by the second tissue factor pathway inhibitor domain (1.7-fold) and the Kunitz inhibitor domain of protease Nexin-2 (1.4-fold). Modeling studies of factor IXa with basic pancreatic trypsin inhibitor suggest that binding of this inhibitor is sterically hindered by the 99-loop of factor IXa, specifically residue Lys(98). Slow-binding kinetic studies support the formation of a weak initial enzyme-inhibitor complex between factor IXa and basic pancreatic trypsin inhibitor that is facilitated by <b style='color:Tomato;'><i>enoxaparin</i></b> binding. Mutation of Lys(98) to Ala in factor IXa results in enhanced reactivity with all inhibitors examined, whereas almost completely abrogating the enhancing effects of <b style='color:Tomato;'><i>enoxaparin</i></b>. The results implicate Lys(98) and the 99-loop of factor IXa in defining enzyme inhibitor specificity. More importantly, these results demonstrate the ability of factor IXa to be allosterically modulated by occupation of the <b style='color:Tomato;'><i>heparin</i></b>-binding exosite.","tokens":[{"text":"Reactivity","start":0,"end":10,"id":0,"ws":true},{"text":"of","start":11,"end":13,"id":1,"ws":true},{"text":"factor","start":14,"end":20,"id":2,"ws":true},{"text":"IXa","start":21,"end":24,"id":3,"ws":true},{"text":"with","start":25,"end":29,"id":4,"ws":true},{"text":"basic","start":30,"end":35,"id":5,"ws":true},{"text":"pancreatic","start":36,"end":46,"id":6,"ws":true},{"text":"trypsin","start":47,"end":54,"id":7,"ws":true},{"text":"inhibitor","start":55,"end":64,"id":8,"ws":true},{"text":"is","start":65,"end":67,"id":9,"ws":true},{"text":"enhanced","start":68,"end":76,"id":10,"ws":true},{"text":"by","start":77,"end":79,"id":11,"ws":true},{"text":"low","start":80,"end":83,"id":12,"ws":true},{"text":"molecular","start":84,"end":93,"id":13,"ws":true},{"text":"weight","start":94,"end":100,"id":14,"ws":true},{"text":"heparin","start":101,"end":108,"id":15,"ws":true},{"text":"(","start":109,"end":110,"id":16,"ws":true},{"text":"enoxaparin","start":111,"end":121,"id":17,"ws":true},{"text":")","start":122,"end":123,"id":18,"ws":true},{"text":".","start":124,"end":125,"id":19,"ws":false}],"spans":[{"start":101,"end":108,"token_start":15,"token_end":15,"label":"DRUG"},{"start":111,"end":121,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16766524/","_input_hash":1757287926,"_task_hash":1025618689,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"All patients underwent 3 cycles of neoadjuvant gemcitabine , paclitaxel , and capecitabine .","paragraph":"<h3><u>Direct percutaneous transhepatic portomesenteric venous stenting in management of locally advanced pancreatic cancer.</u></h3>Pancreatectomy with portal and/or superior mesenteric vein resection remains a controversial procedure because of high complexity and morbidity. Neoadjuvant chemotherapy has been shown to increase resectability of these locally advanced lesions. We aimed to assess the utility and efficacy of direct percutaneous transhepatic portomesenteric venous stenting (THVS) with neoadjuvant chemotherapy in increasing surgical resectability of locally advanced pancreatic carcinoma. ### methods Forty pancreatic carcinoma patients with tumor thrombus involving the portal vein and superior mesenteric vein were identified. Patients underwent THVS followed by neoadjuvant chemotherapy. Whipple procedure was offered to responders. ### results THVS was attempted in all. The tumor thrombus could not be crossed in 2 patients (95% technical success rate). <b style='color:DodgerBlue;'><i>All</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>underwent</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>neoadjuvant</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>capecitabine</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Disease progression was noted in 16 patients and surgery was not offered. Twenty-two patients were explored with intent-to-perform a Whipple procedure. In 7 of these (32%), extensive disease precluding surgical resection was identified and the procedure was abandoned. Whipple procedure without vascular resection was performed successfully in 15 patients (68%). There were no perioperative deaths. Negative vascular margins were noted in 3 patients and negative peripancreatic lymph nodes in 5 patients. Median survival was 17 months (range, 5 to 70 mo). In the stented nonoperative group, median survival was 9 months (range, 3 to 19 mo). The stented and resected group achieved a statistically significant (P=0.0422) survival advantage. ### conclusions THVS in combination with neoadjuvant chemotherapy can increase tumor resectability and survival in a select group of locally advanced pancreatic cancer patients.","tokens":[{"text":"All","start":0,"end":3,"id":0,"ws":true},{"text":"patients","start":4,"end":12,"id":1,"ws":true},{"text":"underwent","start":13,"end":22,"id":2,"ws":true},{"text":"3","start":23,"end":24,"id":3,"ws":true},{"text":"cycles","start":25,"end":31,"id":4,"ws":true},{"text":"of","start":32,"end":34,"id":5,"ws":true},{"text":"neoadjuvant","start":35,"end":46,"id":6,"ws":true},{"text":"gemcitabine","start":47,"end":58,"id":7,"ws":true},{"text":",","start":59,"end":60,"id":8,"ws":true},{"text":"paclitaxel","start":61,"end":71,"id":9,"ws":true},{"text":",","start":72,"end":73,"id":10,"ws":true},{"text":"and","start":74,"end":77,"id":11,"ws":true},{"text":"capecitabine","start":78,"end":90,"id":12,"ws":true},{"text":".","start":91,"end":92,"id":13,"ws":false}],"spans":[{"start":47,"end":58,"token_start":7,"token_end":7,"label":"DRUG"},{"start":61,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},{"start":78,"end":90,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23608832/","_input_hash":652974832,"_task_hash":1577574596,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":7,"child":9,"head_span":{"start":47,"end":58,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":61,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":9,"child":12,"head_span":{"start":61,"end":71,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":78,"end":90,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Either 5-fluorouracil ( 5-FU ) and leucovorin for 6 months or 5-FU and levamisole for 12 months are currently considered standard adjuvant treatment for stage III colorectal cancer .","paragraph":"<h3><u>National Cancer Institute Clinical Trials Program in Colorectal Cancer.</u></h3>Colorectal cancer will be diagnosed in approximately 150,000 patients in the USA this year. Chemotherapy has recently been shown to improve survival when given as adjuvant therapy to surgery in patients with stage III colorectal cancer. Demonstration of this benefit required large, randomized controlled trials. <b style='color:DodgerBlue;'><i>Either</i></b> <b style='color:DodgerBlue;'><i>5-fluorouracil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>leucovorin</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>5-FU</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>levamisole</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>currently</i></b> <b style='color:DodgerBlue;'><i>considered</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>colorectal</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, current adjuvant trials are comparing continuous infusion and intravenous bolus 5-FU regimens and oral uracil/Ftorafur with intravenous 5-FU and <b style='color:Tomato;'><i>leucovorin</i></b>, as well as studying the timing of chemotherapy in the adjuvant setting. Subsequent adjuvant trials will examine newer regimens with activity in advanced colorectal cancer, as well as the efficacy of monoclonal antibodies. Other trials will study which type of surgery is optimal and whether adjuvant therapy is helpful in stage II colon cancer. Trials in metastatic disease will focus on combinations of newer agents which may improve survival in this patient group. Studies in rectal cancer will focus on determining which agents are optimal in combination with radiation therapy in the adjuvant setting. Molecular characteristics of tumor cells are being defined, which may guide therapy in the future. Careful, logically designed clinical trials will hopefully provide more efficacious therapy for this common cancer.","tokens":[{"text":"Either","start":0,"end":6,"id":0,"ws":true},{"text":"5-fluorouracil","start":7,"end":21,"id":1,"ws":true},{"text":"(","start":22,"end":23,"id":2,"ws":true},{"text":"5-FU","start":24,"end":28,"id":3,"ws":true},{"text":")","start":29,"end":30,"id":4,"ws":true},{"text":"and","start":31,"end":34,"id":5,"ws":true},{"text":"leucovorin","start":35,"end":45,"id":6,"ws":true},{"text":"for","start":46,"end":49,"id":7,"ws":true},{"text":"6","start":50,"end":51,"id":8,"ws":true},{"text":"months","start":52,"end":58,"id":9,"ws":true},{"text":"or","start":59,"end":61,"id":10,"ws":true},{"text":"5-FU","start":62,"end":66,"id":11,"ws":true},{"text":"and","start":67,"end":70,"id":12,"ws":true},{"text":"levamisole","start":71,"end":81,"id":13,"ws":true},{"text":"for","start":82,"end":85,"id":14,"ws":true},{"text":"12","start":86,"end":88,"id":15,"ws":true},{"text":"months","start":89,"end":95,"id":16,"ws":true},{"text":"are","start":96,"end":99,"id":17,"ws":true},{"text":"currently","start":100,"end":109,"id":18,"ws":true},{"text":"considered","start":110,"end":120,"id":19,"ws":true},{"text":"standard","start":121,"end":129,"id":20,"ws":true},{"text":"adjuvant","start":130,"end":138,"id":21,"ws":true},{"text":"treatment","start":139,"end":148,"id":22,"ws":true},{"text":"for","start":149,"end":152,"id":23,"ws":true},{"text":"stage","start":153,"end":158,"id":24,"ws":true},{"text":"III","start":159,"end":162,"id":25,"ws":true},{"text":"colorectal","start":163,"end":173,"id":26,"ws":true},{"text":"cancer","start":174,"end":180,"id":27,"ws":true},{"text":".","start":181,"end":182,"id":28,"ws":false}],"spans":[{"start":35,"end":45,"token_start":6,"token_end":6,"label":"DRUG"},{"start":71,"end":81,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9750034/","_input_hash":-1591298255,"_task_hash":-348111942,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":3,"child":6,"head_span":{"start":24,"end":28,"token_start":3,"token_end":3,"label":null},"child_span":{"start":35,"end":45,"token_start":6,"token_end":6,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":11,"child":13,"head_span":{"start":62,"end":66,"token_start":11,"token_end":11,"label":null},"child_span":{"start":71,"end":81,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS10","POS20"],"answer":"accept"}
{"text":"The aim of the present investigation was to study and characterize the effect of voriconazole on the fungicidal activity of amphotericin B.","paragraph":"<h3><u>Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>aim</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>investigation</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>characterize</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>voriconazole</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>fungicidal</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amphotericin</i></b> <b style='color:DodgerBlue;'><i>B.</i></b> ### methods Four strains of Candida albicans susceptible to <b style='color:Tomato;'><i>voriconazole</i></b> were exposed to <b style='color:Tomato;'><i>voriconazole</i></b> and <b style='color:Tomato;'><i>amphotericin</i></b> B, either alone, simultaneously or sequentially in an in vitro kinetic model. Bolus doses resulting in <b style='color:Tomato;'><i>voriconazole</i></b> and <b style='color:Tomato;'><i>amphotericin</i></b> B concentrations of 0.005-5 and 2.5 mg/L, respectively, were administered. Antifungal-containing RPMI 1640 was eliminated and replaced by a fresh medium using a peristaltic pump, with a flow rate adjusted to obtain the desired half-lives. With two drugs tested, a computer-controlled dosing pump compensated for differences in the elimination rates. Using static time-kill methodology, one C. albicans strain was exposed to 5 mg/L <b style='color:Tomato;'><i>voriconazole</i></b> for varying durations followed by 2.5 mg/L <b style='color:Tomato;'><i>amphotericin</i></b> B after three repeated washes of <b style='color:Tomato;'><i>voriconazole</i></b>. ### results <b style='color:Tomato;'><i>voriconazole</i></b> and <b style='color:Tomato;'><i>amphotericin</i></b> B treatment alone resulted in fungistatic and fungicidal activities, respectively. Simultaneous administration of <b style='color:Tomato;'><i>voriconazole</i></b> and <b style='color:Tomato;'><i>amphotericin</i></b> B resulted in fungicidal activity, whereas only fungistatic activity was observed when repeated doses of <b style='color:Tomato;'><i>amphotericin</i></b> B were administered sequentially after <b style='color:Tomato;'><i>voriconazole</i></b> at 24-96 h. The inhibition of the fungicidal activity of <b style='color:Tomato;'><i>amphotericin</i></b> B was <b style='color:Tomato;'><i>voriconazole</i></b> dose-dependent, but seemed to be recovered once the <b style='color:Tomato;'><i>voriconazole</i></b> concentration fell below the MIC. The fungicidal activity was quickly regained after the removal of <b style='color:Tomato;'><i>voriconazole</i></b>, irrespective of the duration of <b style='color:Tomato;'><i>voriconazole</i></b> pre-exposure. ### conclusions <b style='color:Tomato;'><i>voriconazole</i></b> inhibited the fungicidal effect of sequentially administered <b style='color:Tomato;'><i>amphotericin</i></b> B in a concentration- and time-dependent manner; the clinical significance of this needs further investigation.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"aim","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"the","start":11,"end":14,"id":3,"ws":true},{"text":"present","start":15,"end":22,"id":4,"ws":true},{"text":"investigation","start":23,"end":36,"id":5,"ws":true},{"text":"was","start":37,"end":40,"id":6,"ws":true},{"text":"to","start":41,"end":43,"id":7,"ws":true},{"text":"study","start":44,"end":49,"id":8,"ws":true},{"text":"and","start":50,"end":53,"id":9,"ws":true},{"text":"characterize","start":54,"end":66,"id":10,"ws":true},{"text":"the","start":67,"end":70,"id":11,"ws":true},{"text":"effect","start":71,"end":77,"id":12,"ws":true},{"text":"of","start":78,"end":80,"id":13,"ws":true},{"text":"voriconazole","start":81,"end":93,"id":14,"ws":true},{"text":"on","start":94,"end":96,"id":15,"ws":true},{"text":"the","start":97,"end":100,"id":16,"ws":true},{"text":"fungicidal","start":101,"end":111,"id":17,"ws":true},{"text":"activity","start":112,"end":120,"id":18,"ws":true},{"text":"of","start":121,"end":123,"id":19,"ws":true},{"text":"amphotericin","start":124,"end":136,"id":20,"ws":true},{"text":"B.","start":137,"end":139,"id":21,"ws":false}],"spans":[{"start":81,"end":93,"token_start":14,"token_end":14,"label":"DRUG"},{"start":124,"end":136,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18408237/","_input_hash":536835514,"_task_hash":1903509668,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Postmenopausal women with stage I-IIIA hormone receptor-positive breast cancer , who were disease-free after about 5 years of treatment with an aromatase inhibitor or tamoxifen followed by an aromatase inhibitor , were randomly assigned ( 1:1 ) to receive 5 years of letrozole ( 2\u00b75 mg orally per day ) or placebo .","paragraph":"<h3><u>Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.</u></h3>The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended <b style='color:Tomato;'><i>letrozole</i></b> treatment improves disease-free survival after 5 years of aromatase inhibitor-based therapy in women with postmenopausal breast cancer. ### methods This randomised, double-blind, placebo-controlled, phase 3 trial was done in 158 centres in the USA, Canada, and Ireland. <b style='color:DodgerBlue;'><i>Postmenopausal</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>I-IIIA</i></b> <b style='color:DodgerBlue;'><i>hormone</i></b> <b style='color:DodgerBlue;'><i>receptor-positive</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>who</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>disease-free</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>about</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>aromatase</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>an</i></b> <b style='color:DodgerBlue;'><i>aromatase</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>1:1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>5</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>2\u00b75</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>orally</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>day</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Randomisation was stratified by pathological node status, previous <b style='color:Tomato;'><i>tamoxifen</i></b> use, and lowest bone mineral density T score in the lumbosacral spine, total hip, or femoral neck. The primary endpoint was disease-free survival, defined as time from randomisation to breast cancer recurrence, second primary malignancy, or death, and was analysed by intention to treat. To adjust for previous interim analyses, the two-sided statistical significance level for disease-free survival was set at 0\u00b70418. This study is registered with ClinicalTrials.gov, number NCT00382070, is active, and is no longer enrolling patients. ### findings Between Sept 28, 2006, and Jan 6, 2010, 3966 patients were randomly assigned to receive <b style='color:Tomato;'><i>letrozole</i></b> (n=1983) or placebo (n=1983). Follow-up information was available for 3903 patients for the analyses of disease-free survival. Median follow-up was 6\u00b79 years (IQR 6\u00b71-7\u00b75). <b style='color:Tomato;'><i>letrozole</i></b> treatment did not significantly improve disease-free survival (339 disease-free survival events were reported in the placebo group and 292 disease-free survival events were reported in the <b style='color:Tomato;'><i>letrozole</i></b> group; hazard ratio 0\u00b785, 95% CI 0\u00b773-0\u00b7999; p=0\u00b7048). 7-year disease-free survival estimate was 81\u00b73% (95% CI 79\u00b73-83\u00b71) in the placebo group and 84\u00b77% (82\u00b79-86\u00b74) in the <b style='color:Tomato;'><i>letrozole</i></b> group. The most common grade 3 adverse events were arthralgia (47 [2%] of 1933 patients in the placebo group vs 50 [3%] of 1941 patients in the <b style='color:Tomato;'><i>letrozole</i></b> group) and back pain (44 [2%] vs 38 [2%]). The most common grade 4 adverse event in the placebo group was thromboembolic event (eight [<1%]) and the most common grade 4 adverse events in the <b style='color:Tomato;'><i>letrozole</i></b> group were urinary tract infection, hypokalaemia, and left ventricular systolic dysfunction (four [<1%] each). ### interpretation After 5 years of aromatase inhibitor-based therapy, 5 years of <b style='color:Tomato;'><i>letrozole</i></b> therapy did not significantly prolong disease-free survival compared with placebo. Careful assessment of potential risks and benefits is required before recommending extended <b style='color:Tomato;'><i>letrozole</i></b> therapy to patients with early-stage breast cancer. ### funding National Cancer Institute, Korea Health Technology R&D Project, Novartis.","tokens":[{"text":"Postmenopausal","start":0,"end":14,"id":0,"ws":true},{"text":"women","start":15,"end":20,"id":1,"ws":true},{"text":"with","start":21,"end":25,"id":2,"ws":true},{"text":"stage","start":26,"end":31,"id":3,"ws":true},{"text":"I-IIIA","start":32,"end":38,"id":4,"ws":true},{"text":"hormone","start":39,"end":46,"id":5,"ws":true},{"text":"receptor-positive","start":47,"end":64,"id":6,"ws":true},{"text":"breast","start":65,"end":71,"id":7,"ws":true},{"text":"cancer","start":72,"end":78,"id":8,"ws":true},{"text":",","start":79,"end":80,"id":9,"ws":true},{"text":"who","start":81,"end":84,"id":10,"ws":true},{"text":"were","start":85,"end":89,"id":11,"ws":true},{"text":"disease-free","start":90,"end":102,"id":12,"ws":true},{"text":"after","start":103,"end":108,"id":13,"ws":true},{"text":"about","start":109,"end":114,"id":14,"ws":true},{"text":"5","start":115,"end":116,"id":15,"ws":true},{"text":"years","start":117,"end":122,"id":16,"ws":true},{"text":"of","start":123,"end":125,"id":17,"ws":true},{"text":"treatment","start":126,"end":135,"id":18,"ws":true},{"text":"with","start":136,"end":140,"id":19,"ws":true},{"text":"an","start":141,"end":143,"id":20,"ws":true},{"text":"aromatase","start":144,"end":153,"id":21,"ws":true},{"text":"inhibitor","start":154,"end":163,"id":22,"ws":true},{"text":"or","start":164,"end":166,"id":23,"ws":true},{"text":"tamoxifen","start":167,"end":176,"id":24,"ws":true},{"text":"followed","start":177,"end":185,"id":25,"ws":true},{"text":"by","start":186,"end":188,"id":26,"ws":true},{"text":"an","start":189,"end":191,"id":27,"ws":true},{"text":"aromatase","start":192,"end":201,"id":28,"ws":true},{"text":"inhibitor","start":202,"end":211,"id":29,"ws":true},{"text":",","start":212,"end":213,"id":30,"ws":true},{"text":"were","start":214,"end":218,"id":31,"ws":true},{"text":"randomly","start":219,"end":227,"id":32,"ws":true},{"text":"assigned","start":228,"end":236,"id":33,"ws":true},{"text":"(","start":237,"end":238,"id":34,"ws":true},{"text":"1:1","start":239,"end":242,"id":35,"ws":true},{"text":")","start":243,"end":244,"id":36,"ws":true},{"text":"to","start":245,"end":247,"id":37,"ws":true},{"text":"receive","start":248,"end":255,"id":38,"ws":true},{"text":"5","start":256,"end":257,"id":39,"ws":true},{"text":"years","start":258,"end":263,"id":40,"ws":true},{"text":"of","start":264,"end":266,"id":41,"ws":true},{"text":"letrozole","start":267,"end":276,"id":42,"ws":true},{"text":"(","start":277,"end":278,"id":43,"ws":true},{"text":"2\u00b75","start":279,"end":282,"id":44,"ws":true},{"text":"mg","start":283,"end":285,"id":45,"ws":true},{"text":"orally","start":286,"end":292,"id":46,"ws":true},{"text":"per","start":293,"end":296,"id":47,"ws":true},{"text":"day","start":297,"end":300,"id":48,"ws":true},{"text":")","start":301,"end":302,"id":49,"ws":true},{"text":"or","start":303,"end":305,"id":50,"ws":true},{"text":"placebo","start":306,"end":313,"id":51,"ws":true},{"text":".","start":314,"end":315,"id":52,"ws":false}],"spans":[{"start":167,"end":176,"token_start":24,"token_end":24,"label":"DRUG"},{"start":267,"end":276,"token_start":42,"token_end":42,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30509771/","_input_hash":-1556521820,"_task_hash":-663735523,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients : A Pilot Study .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Dual</i></b> <b style='color:DodgerBlue;'><i>Therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>Aspirin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Cilostazol</i></b> <b style='color:DodgerBlue;'><i>May</i></b> <b style='color:DodgerBlue;'><i>Improve</i></b> <b style='color:DodgerBlue;'><i>Platelet</i></b> <b style='color:DodgerBlue;'><i>Aggregation</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Noncardioembolic</i></b> <b style='color:DodgerBlue;'><i>Stroke</i></b> <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>Pilot</i></b> <b style='color:DodgerBlue;'><i>Study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Objective Some previous studies have found clinical benefit of dual antiplatelet therapy with <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> for prevention of secondary stroke, but the physiological mechanism involved remains unknown. We aimed to clarify the effects of <b style='color:Tomato;'><i>aspirin</i></b>/<b style='color:Tomato;'><i>cilostazol</i></b> therapy on the platelet and endothelial functions of patients with acute noncardioembolic ischemic stroke, in comparison to patients who were treated with <b style='color:Tomato;'><i>aspirin</i></b> alone. Methods The present randomized prospective pilot study enrolled 24 patients within a week after the onset of noncardioembolic ischemic stroke. The patients were randomly allocated to receive <b style='color:Tomato;'><i>aspirin</i></b> (100 mg/day) (A group; 11 patients) or <b style='color:Tomato;'><i>cilostazol</i></b> (200 mg/day) plus <b style='color:Tomato;'><i>aspirin</i></b> (100 mg/day) (CA group; 13 patients). We measured platelet aggregation, platelet activation, and the thrombomodulin (TM), highly sensitive C-reactive protein (hs-CRP), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and von Willebrand (vWF) antigen levels and vWF activity over a 4-week period after enrollment. Results There was no significant difference in the platelet functions of the A and CA groups. However, the platelet aggregation induced by adenosine diphosphate (ADP) was decreased at 2 and 4 weeks (p<0.05) after treatment in comparison to the pre-treatment values in the CA group, but not in the A group. Platelet activation, and the hs-CRP, TM, ICAM-1, VCAM-1 and vWF values did not significantly decrease after treatment in either group. Conclusion Although there were no significant differences in platelet aggregation, platelet activation or the endothelial biomarker levels of the A and CA groups, dual therapy with <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> inhibited platelet aggregation in comparison to the pre-treatment values, similarly to patients who received <b style='color:Tomato;'><i>aspirin</i></b> alone. This may suggest the clinical usefulness of dual therapy with <b style='color:Tomato;'><i>aspirin</i></b> and <b style='color:Tomato;'><i>cilostazol</i></b> in the treatment of patients with noncardioembolic ischemic stroke.","tokens":[{"text":"Dual","start":0,"end":4,"id":0,"ws":true},{"text":"Therapy","start":5,"end":12,"id":1,"ws":true},{"text":"with","start":13,"end":17,"id":2,"ws":true},{"text":"Aspirin","start":18,"end":25,"id":3,"ws":true},{"text":"and","start":26,"end":29,"id":4,"ws":true},{"text":"Cilostazol","start":30,"end":40,"id":5,"ws":true},{"text":"May","start":41,"end":44,"id":6,"ws":true},{"text":"Improve","start":45,"end":52,"id":7,"ws":true},{"text":"Platelet","start":53,"end":61,"id":8,"ws":true},{"text":"Aggregation","start":62,"end":73,"id":9,"ws":true},{"text":"in","start":74,"end":76,"id":10,"ws":true},{"text":"Noncardioembolic","start":77,"end":93,"id":11,"ws":true},{"text":"Stroke","start":94,"end":100,"id":12,"ws":true},{"text":"Patients","start":101,"end":109,"id":13,"ws":true},{"text":":","start":110,"end":111,"id":14,"ws":true},{"text":"A","start":112,"end":113,"id":15,"ws":true},{"text":"Pilot","start":114,"end":119,"id":16,"ws":true},{"text":"Study","start":120,"end":125,"id":17,"ws":true},{"text":".","start":126,"end":127,"id":18,"ws":false}],"spans":[{"start":18,"end":25,"token_start":3,"token_end":3,"label":"DRUG"},{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/28566591/","_input_hash":-347463043,"_task_hash":830545149,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":18,"end":25,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":30,"end":40,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Efficacy of sorafenib combined with the pan-CDK inhibitor flavopiridol was tested both in vitro and in xenograft experiments .","paragraph":"<h3><u>Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.</u></h3>To clarify the effects of cyclin E1 suppression on antitumor efficacy of <b style='color:Tomato;'><i>sorafenib</i></b> in hepatocellular carcinoma cells and to explore the potential of combining <b style='color:Tomato;'><i>sorafenib</i></b> with cyclin-dependent kinase (CDK) inhibition in therapy. ### Experimental Design The effects of cyclin E1 suppression on <b style='color:Tomato;'><i>sorafenib</i></b>-induced apoptosis were tested in both <b style='color:Tomato;'><i>sorafenib</i></b>-sensitive (Huh-7 and HepG2, IC50 5-6 \u03bcmol/L) and <b style='color:Tomato;'><i>sorafenib</i></b>-resistant (Huh-7R and HepG2R, IC50 14-15 \u03bcmol/L) hepatocellular carcinoma cells. The activity of pertinent signaling pathways and the expression of cell cycle and apoptosis-related proteins were measured using Western blotting. <b style='color:DodgerBlue;'><i>Efficacy</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>pan-CDK</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:MediumOrchid;'><i>flavopiridol</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>tested</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>xenograft</i></b> <b style='color:DodgerBlue;'><i>experiments</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The pertinent downstream mediators of antitumor efficacy were tested in transient transfection and RNA interference experiments. ### results Cyclin E1 mRNA and protein expressions were suppressed after <b style='color:Tomato;'><i>sorafenib</i></b> treatment in <b style='color:Tomato;'><i>sorafenib</i></b>-sensitive but not in <b style='color:Tomato;'><i>sorafenib</i></b>-resistant hepatocellular carcinoma cells. Changes in cyclin E2 or D1 were not correlated with <b style='color:Tomato;'><i>sorafenib</i></b> sensitivity. The knockdown of cyclin E1 expression reversed the resistance of hepatocellular carcinoma cells to <b style='color:Tomato;'><i>sorafenib</i></b> in terms of cell growth and apoptosis induction, whereas the overexpression of cyclin E1 increased the resistance to <b style='color:Tomato;'><i>sorafenib</i></b>. The growth-inhibitory and apoptosis-inducing effects of <b style='color:Tomato;'><i>sorafenib</i></b> were enhanced by <b style='color:Tomato;'><i>flavopiridol</i></b>, and Mcl-1 suppression was determined to play a critical role in mediating this enhancing effect. ### conclusions The cyclin E1 suppression in hepatocellular carcinoma cells may serve as a pharmacodynamic biomarker for predicting <b style='color:Tomato;'><i>sorafenib</i></b> efficacy. The combination of <b style='color:Tomato;'><i>sorafenib</i></b> and CDK inhibitors may improve the efficacy of <b style='color:Tomato;'><i>sorafenib</i></b> in hepatocellular carcinoma. Clin Cancer Res; 22(10); 2555-64. \u00a92015 AACR.","tokens":[{"text":"Efficacy","start":0,"end":8,"id":0,"ws":true},{"text":"of","start":9,"end":11,"id":1,"ws":true},{"text":"sorafenib","start":12,"end":21,"id":2,"ws":true},{"text":"combined","start":22,"end":30,"id":3,"ws":true},{"text":"with","start":31,"end":35,"id":4,"ws":true},{"text":"the","start":36,"end":39,"id":5,"ws":true},{"text":"pan-CDK","start":40,"end":47,"id":6,"ws":true},{"text":"inhibitor","start":48,"end":57,"id":7,"ws":true},{"text":"flavopiridol","start":58,"end":70,"id":8,"ws":true},{"text":"was","start":71,"end":74,"id":9,"ws":true},{"text":"tested","start":75,"end":81,"id":10,"ws":true},{"text":"both","start":82,"end":86,"id":11,"ws":true},{"text":"in","start":87,"end":89,"id":12,"ws":true},{"text":"vitro","start":90,"end":95,"id":13,"ws":true},{"text":"and","start":96,"end":99,"id":14,"ws":true},{"text":"in","start":100,"end":102,"id":15,"ws":true},{"text":"xenograft","start":103,"end":112,"id":16,"ws":true},{"text":"experiments","start":113,"end":124,"id":17,"ws":true},{"text":".","start":125,"end":126,"id":18,"ws":false}],"spans":[{"start":12,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},{"start":58,"end":70,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26603262/","_input_hash":1581641631,"_task_hash":1918393341,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":2,"child":8,"head_span":{"start":12,"end":21,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":58,"end":70,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Gemcitabine and vinorelbine have shown activity in the first-line setting .","paragraph":"<h3><u>Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.</u></h3><b style='color:Tomato;'><i>pemetrexed</i></b>-cisplatin chemotherapy is the standard of care in the first-line treatment of unresectable malignant pleural mesothelioma (MPM). Second-line cytotoxic therapy is considered for a growing group of patients, but the optimal treatment has not been defined to date. <b style='color:MediumOrchid;'><i>Gemcitabine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>first-line</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The objective of this study was to evaluate the activity and toxicity of the <b style='color:Tomato;'><i>gemcitabine</i></b>-<b style='color:Tomato;'><i>vinorelbine</i></b> combination in <b style='color:Tomato;'><i>pemetrexed</i></b>-pretreated patients with MPM. ### methods From January 2004 to September 2006, 30 consecutive patients who were pretreated with <b style='color:Tomato;'><i>pemetrexed</i></b> with or without a platinum-derivative were enrolled. <b style='color:Tomato;'><i>gemcitabine</i></b> 1000 mg/m(2) and <b style='color:Tomato;'><i>vinorelbine</i></b> 25 mg/m(2) were administered intravenously on Days 1 and 8 every 3 weeks. Treatment was repeated for a maximum of 6 cycles or until progression or unacceptable toxicity. ### results A partial response was observed in 3 patients (10%; 95% confidence interval [CI], 2.1-26.5%), and 10 patients (33.3%; 95% CI, 17.3-52.8%) had stable disease after treatment. Overall, 13 patients (43.3%; 95% CI, 25.5-62.6%) achieved disease control. The median time to progression was 2.8 months (range, 0.6-12.1 months), and the median survival was 10.9 months (range, 0.8-25.3 months). Hematologic toxicity was acceptable, with grade 3 or 4 neutropenia occurring in 11% of patients and thrombocytopenia occurring in 4% of patients; no case of febrile neutropenia was observed. Nonhematologic toxicity generally was mild. ### conclusions The <b style='color:Tomato;'><i>gemcitabine</i></b> and <b style='color:Tomato;'><i>vinorelbine</i></b> combination was moderately active and had an acceptable toxicity profile in <b style='color:Tomato;'><i>pemetrexed</i></b>-pretreated patients with MPM. The role of second-line treatment in MPM needs to be evaluated in prospective trials in large series of patients who are stratified according to previous treatment and prognostic factors.","tokens":[{"text":"Gemcitabine","start":0,"end":11,"id":0,"ws":true},{"text":"and","start":12,"end":15,"id":1,"ws":true},{"text":"vinorelbine","start":16,"end":27,"id":2,"ws":true},{"text":"have","start":28,"end":32,"id":3,"ws":true},{"text":"shown","start":33,"end":38,"id":4,"ws":true},{"text":"activity","start":39,"end":47,"id":5,"ws":true},{"text":"in","start":48,"end":50,"id":6,"ws":true},{"text":"the","start":51,"end":54,"id":7,"ws":true},{"text":"first-line","start":55,"end":65,"id":8,"ws":true},{"text":"setting","start":66,"end":73,"id":9,"ws":true},{"text":".","start":74,"end":75,"id":10,"ws":false}],"spans":[{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18286536/","_input_hash":292449858,"_task_hash":-2047803560,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":11,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":16,"end":27,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The combination of tenofovir disoproxil fumarate ( TDF ) plus emtricitabine ( FTC ) is used extensively to treat HIV infection and also has potent activity against hepatitis B virus ( HBV ) infection .","paragraph":"<h3><u>Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tenofovir</i></b> <b style='color:DodgerBlue;'><i>disoproxil</i></b> <b style='color:DodgerBlue;'><i>fumarate</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>TDF</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>emtricitabine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FTC</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>used</i></b> <b style='color:DodgerBlue;'><i>extensively</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>treat</i></b> <b style='color:DodgerBlue;'><i>HIV</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>potent</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>hepatitis</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HBV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The aim of this study was to assess the efficacy and tolerance of TDF + FTC in patients with chronic hepatitis B (CHB). ### methods Seventy eight consecutive CHB patients from five European centers were included. All started a TDF + FTC combination between October 2005 and March 2010. Virological, biochemical, and clinical data were recorded during follow-up. Tolerance was also monitored. Patients were classified into either treatment simplification (TS), where efficacy of the previous treatment was obtained at TDF + FTC initiation, and treatment intensification (TI), where the previous line of therapy had failed. ### results TDF + FTC was given as a TI to 54 patients (69%) and as a TS to 24 (31%). Among patients with TI, 83% were males. The median baseline HBV-DNA was 4.4 log10 IU/mL, and median alanine-transaminase (ALT) was 1.10 \u00d7 ULN. Sixty percent were HBeAg positive, 47% had significant fibrosis (\u2265 F3 Metavir equivalent), and 29% had confirmed cirrhosis. Median treatment duration was 76 weeks (interquartile range 60-116). Kaplan-Meier analysis showed that, 48 weeks after TI, the probability of being HBV-DNA becoming undetectable was 76%, and reached 94% at week 96. No viral breakthrough occurred. Patients with TS (87% males, median baseline HBV-DNA 1.1 log10 IU/mL, median ALT 0.79 \u00d7 ULN, 33% HBeAg positive, 61% with significant fibrosis) were treated for a median duration of 76 weeks. In this subgroup, all patients but one remained HBV-DNA undetectable and no ALT flare-up occurred during follow-up. Creatinine levels did not show kidney-function deterioration in either group of patients. ### conclusions After a median follow-up of > 76 weeks, the TDF + FTC combination showed encouraging antiviral efficacy and a good safety profile in all patients with CHB. TDF + FTC may represent an interesting clinical option to simplify therapy and increase the barrier to resistance, which should be assessed in the long term.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"combination","start":4,"end":15,"id":1,"ws":true},{"text":"of","start":16,"end":18,"id":2,"ws":true},{"text":"tenofovir","start":19,"end":28,"id":3,"ws":true},{"text":"disoproxil","start":29,"end":39,"id":4,"ws":true},{"text":"fumarate","start":40,"end":48,"id":5,"ws":true},{"text":"(","start":49,"end":50,"id":6,"ws":true},{"text":"TDF","start":51,"end":54,"id":7,"ws":true},{"text":")","start":55,"end":56,"id":8,"ws":true},{"text":"plus","start":57,"end":61,"id":9,"ws":true},{"text":"emtricitabine","start":62,"end":75,"id":10,"ws":true},{"text":"(","start":76,"end":77,"id":11,"ws":true},{"text":"FTC","start":78,"end":81,"id":12,"ws":true},{"text":")","start":82,"end":83,"id":13,"ws":true},{"text":"is","start":84,"end":86,"id":14,"ws":true},{"text":"used","start":87,"end":91,"id":15,"ws":true},{"text":"extensively","start":92,"end":103,"id":16,"ws":true},{"text":"to","start":104,"end":106,"id":17,"ws":true},{"text":"treat","start":107,"end":112,"id":18,"ws":true},{"text":"HIV","start":113,"end":116,"id":19,"ws":true},{"text":"infection","start":117,"end":126,"id":20,"ws":true},{"text":"and","start":127,"end":130,"id":21,"ws":true},{"text":"also","start":131,"end":135,"id":22,"ws":true},{"text":"has","start":136,"end":139,"id":23,"ws":true},{"text":"potent","start":140,"end":146,"id":24,"ws":true},{"text":"activity","start":147,"end":155,"id":25,"ws":true},{"text":"against","start":156,"end":163,"id":26,"ws":true},{"text":"hepatitis","start":164,"end":173,"id":27,"ws":true},{"text":"B","start":174,"end":175,"id":28,"ws":true},{"text":"virus","start":176,"end":181,"id":29,"ws":true},{"text":"(","start":182,"end":183,"id":30,"ws":true},{"text":"HBV","start":184,"end":187,"id":31,"ws":true},{"text":")","start":188,"end":189,"id":32,"ws":true},{"text":"infection","start":190,"end":199,"id":33,"ws":true},{"text":".","start":200,"end":201,"id":34,"ws":false}],"spans":[{"start":19,"end":48,"token_start":3,"token_end":5,"label":"DRUG"},{"start":62,"end":75,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21767570/","_input_hash":147048421,"_task_hash":-498901064,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":5,"child":10,"head_span":{"start":19,"end":48,"token_start":3,"token_end":5,"label":"DRUG"},"child_span":{"start":62,"end":75,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Codelivery</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>curcumin</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>directed</i></b> <b style='color:DodgerBlue;'><i>self-assembled</i></b> <b style='color:DodgerBlue;'><i>nanoparticles</i></b> <b style='color:DodgerBlue;'><i>enhances</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>hepatocellular</i></b> <b style='color:DodgerBlue;'><i>carcinoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. Herein, we first reported the codelivery of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>curcumin</i></b> by directed self-assembled nanoparticles (SCN) to enhance the therapeutic effect on HCC. SCN was formed by employing the hydrophobic interactions among the lipophilic structure in <b style='color:Tomato;'><i>sorafenib</i></b>, <b style='color:Tomato;'><i>curcumin</i></b>, and similar hydrophobic segments of polyethylene glycol derivative of vitamin E succinate (PEG-VES), which comprised uniform spherical particles with particle size of 84.97 \u00b1 6.03 nm. SCN presented superior effects over <b style='color:Tomato;'><i>sorafenib</i></b>, <b style='color:Tomato;'><i>curcumin</i></b>, and their physical mixture (Sora + Cur) on enhancing in vitro cytotoxicity and cell apoptosis in BEL-7402 cells and Hep G2 cells, and antiangiogenesis activities in tube formation and microvessel formation from aortic rings. Moreover, the tissue concentration of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>curcumin</i></b> in gastrointestinal tract and major organs were significantly improved after their coassembly into SCN. In particular, in BEL-7402 cells induced tumor xenograft, SCN treatment displayed the obviously enhanced inhibitory effect on tumor progression over free drug monotherapy or their physical mixture, with significantly increased antiproliferation and antiangiogenesis capability. Thereby, the codelivered nanoassemblies of <b style='color:Tomato;'><i>sorafenib</i></b> and <b style='color:Tomato;'><i>curcumin</i></b> provided a promising strategy to enhance the combinational therapy of HCC.","tokens":[{"text":"Codelivery","start":0,"end":10,"id":0,"ws":true},{"text":"of","start":11,"end":13,"id":1,"ws":true},{"text":"sorafenib","start":14,"end":23,"id":2,"ws":true},{"text":"and","start":24,"end":27,"id":3,"ws":true},{"text":"curcumin","start":28,"end":36,"id":4,"ws":true},{"text":"by","start":37,"end":39,"id":5,"ws":true},{"text":"directed","start":40,"end":48,"id":6,"ws":true},{"text":"self-assembled","start":49,"end":63,"id":7,"ws":true},{"text":"nanoparticles","start":64,"end":77,"id":8,"ws":true},{"text":"enhances","start":78,"end":86,"id":9,"ws":true},{"text":"therapeutic","start":87,"end":98,"id":10,"ws":true},{"text":"effect","start":99,"end":105,"id":11,"ws":true},{"text":"on","start":106,"end":108,"id":12,"ws":true},{"text":"hepatocellular","start":109,"end":123,"id":13,"ws":true},{"text":"carcinoma","start":124,"end":133,"id":14,"ws":true},{"text":".","start":134,"end":135,"id":15,"ws":false}],"spans":[{"start":14,"end":23,"token_start":2,"token_end":2,"label":"DRUG"},{"start":28,"end":36,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25622075/","_input_hash":1279427679,"_task_hash":-1203458466,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":14,"end":23,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":28,"end":36,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"HRQOL was better in Japanese postmenopausal women treated with tamoxifen than those treated with exemestane or anastrozole .","paragraph":"<h3><u>Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).</u></h3>Health-related quality of life (HRQOL), symptoms of depression, and adverse events (AEs) were compared between Japanese postmenopausal patients with hormone-sensitive breast cancer (BC) who received adjuvant <b style='color:Tomato;'><i>tamoxifen</i></b>, <b style='color:Tomato;'><i>exemestane</i></b>, or <b style='color:Tomato;'><i>anastrozole</i></b> in an open-labeled, randomized, multicenter trial designated as the National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04 substudy of the <b style='color:Tomato;'><i>tamoxifen</i></b> <b style='color:Tomato;'><i>exemestane</i></b> Adjuvant Multinational (TEAM) trial. During the first year of treatment, HRQOL and symptoms of depression were analyzed using the Functional Assessment of Cancer Therapy-Breast (FACT-B) and its Endocrine Symptom Subscale (ES), and the Center for Epidemiologic Studies Depression Scale (CES-D), respectively. In addition, predefined AEs were analyzed. A total of 166 eligible patients were randomly assigned to receive adjuvant <b style='color:Tomato;'><i>tamoxifen</i></b>, <b style='color:Tomato;'><i>exemestane</i></b>, or <b style='color:Tomato;'><i>anastrozole</i></b>. FACT-B scores increased after treatment began and remained significantly higher in the <b style='color:Tomato;'><i>tamoxifen</i></b> group than in the <b style='color:Tomato;'><i>exemestane</i></b> group or <b style='color:Tomato;'><i>anastrozole</i></b> group during the first year (P\u00a0=\u00a00.045). FACT-B scores were similar in the <b style='color:Tomato;'><i>exemestane</i></b> group and <b style='color:Tomato;'><i>anastrozole</i></b> group. ES scores and CES-D scores were similar in all treatment groups. Arthralgia and fatigue were less frequent, but vaginal discharge was more frequent in the <b style='color:Tomato;'><i>tamoxifen</i></b> group than in the <b style='color:Tomato;'><i>exemestane</i></b> group or <b style='color:Tomato;'><i>anastrozole</i></b> group. <b style='color:DodgerBlue;'><i>HRQOL</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>better</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>Japanese</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>exemestane</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>anastrozole</i></b> <b style='color:DodgerBlue;'><i>.</i></b> HRQOL and AEs were similar with <b style='color:Tomato;'><i>exemestane</i></b> and <b style='color:Tomato;'><i>anastrozole</i></b>. Given the results of the TEAM trial, upfront use of <b style='color:Tomato;'><i>tamoxifen</i></b> followed by an aromatase inhibitor (AI) may be an important option for adjuvant endocrine therapy in Japanese postmenopausal women.","tokens":[{"text":"HRQOL","start":0,"end":5,"id":0,"ws":true},{"text":"was","start":6,"end":9,"id":1,"ws":true},{"text":"better","start":10,"end":16,"id":2,"ws":true},{"text":"in","start":17,"end":19,"id":3,"ws":true},{"text":"Japanese","start":20,"end":28,"id":4,"ws":true},{"text":"postmenopausal","start":29,"end":43,"id":5,"ws":true},{"text":"women","start":44,"end":49,"id":6,"ws":true},{"text":"treated","start":50,"end":57,"id":7,"ws":true},{"text":"with","start":58,"end":62,"id":8,"ws":true},{"text":"tamoxifen","start":63,"end":72,"id":9,"ws":true},{"text":"than","start":73,"end":77,"id":10,"ws":true},{"text":"those","start":78,"end":83,"id":11,"ws":true},{"text":"treated","start":84,"end":91,"id":12,"ws":true},{"text":"with","start":92,"end":96,"id":13,"ws":true},{"text":"exemestane","start":97,"end":107,"id":14,"ws":true},{"text":"or","start":108,"end":110,"id":15,"ws":true},{"text":"anastrozole","start":111,"end":122,"id":16,"ws":true},{"text":".","start":123,"end":124,"id":17,"ws":false}],"spans":[{"start":63,"end":72,"token_start":9,"token_end":9,"label":"DRUG"},{"start":97,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},{"start":111,"end":122,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22234519/","_input_hash":1239761749,"_task_hash":795155084,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"This was driven by the relative advantage of weight loss compared with rosiglitazone , glimepiride , and insulin glargine , and administration frequency compared with exenatide .","paragraph":"<h3><u>Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.</u></h3>The purpose of this study was to investigate the preferences of people with diabetes for <b style='color:Tomato;'><i>liraglutide</i></b> vs other glucose lowering drugs, based on outcomes of clinical trials. ### methods Willingness to pay (WTP) for diabetes drug treatment was assessed by combining results from a recent WTP study with analysis of results from the <b style='color:Tomato;'><i>liraglutide</i></b> Effect and Action in Diabetes (LEAD) programme. The LEAD programme included six randomised clinical trials with 3967 participants analysing efficacy and safety of <b style='color:Tomato;'><i>liraglutide</i></b> 1.2 mg (LEAD 1-6 trials), <b style='color:Tomato;'><i>rosiglitazone</i></b> (LEAD 1 trial), <b style='color:Tomato;'><i>glimepiride</i></b> (LEAD 2-3 trials), insulin glargine (LEAD 5 trial), and exenatide (LEAD 6 trial). The WTP survey used discrete choice experimental (DCE) methodology to evaluate the convenience and clinical effects of glucose lowering treatments. ### results People with type 2 diabetes were prepared to pay an extra \u20ac2.64/day for <b style='color:Tomato;'><i>liraglutide</i></b> compared with <b style='color:Tomato;'><i>rosiglitazone</i></b>, an extra \u20ac1.94/day compared with <b style='color:Tomato;'><i>glimepiride</i></b>, an extra \u20ac3.36/day compared with insulin glargine, and an extra \u20ac0.81/day compared with exenatide. Weight loss was the largest component of WTP for <b style='color:Tomato;'><i>liraglutide</i></b> compared with <b style='color:Tomato;'><i>rosiglitazone</i></b>, <b style='color:Tomato;'><i>glimepiride</i></b>, and insulin glargine. Differences in the administration of the two drugs was the largest component of WTP for <b style='color:Tomato;'><i>liraglutide</i></b> (once daily anytime) compared with exenatide (twice daily with meals). A limitation of the study was that it was based on six clinical trials where <b style='color:Tomato;'><i>liraglutide</i></b> was the test drug, but each trial had a different comparator, therefore the clinical effects of <b style='color:Tomato;'><i>liraglutide</i></b> were much better documented than the comparators. ### conclusions WTP analyses of the clinical results from the LEAD programme suggested that participants with type 2 diabetes were willing to pay appreciably more for <b style='color:Tomato;'><i>liraglutide</i></b> than other glucose lowering treatments. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>driven</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>relative</i></b> <b style='color:DodgerBlue;'><i>advantage</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>weight</i></b> <b style='color:DodgerBlue;'><i>loss</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>rosiglitazone</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>glimepiride</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>insulin</i></b> <b style='color:DodgerBlue;'><i>glargine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>administration</i></b> <b style='color:DodgerBlue;'><i>frequency</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>exenatide</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"was","start":5,"end":8,"id":1,"ws":true},{"text":"driven","start":9,"end":15,"id":2,"ws":true},{"text":"by","start":16,"end":18,"id":3,"ws":true},{"text":"the","start":19,"end":22,"id":4,"ws":true},{"text":"relative","start":23,"end":31,"id":5,"ws":true},{"text":"advantage","start":32,"end":41,"id":6,"ws":true},{"text":"of","start":42,"end":44,"id":7,"ws":true},{"text":"weight","start":45,"end":51,"id":8,"ws":true},{"text":"loss","start":52,"end":56,"id":9,"ws":true},{"text":"compared","start":57,"end":65,"id":10,"ws":true},{"text":"with","start":66,"end":70,"id":11,"ws":true},{"text":"rosiglitazone","start":71,"end":84,"id":12,"ws":true},{"text":",","start":85,"end":86,"id":13,"ws":true},{"text":"glimepiride","start":87,"end":98,"id":14,"ws":true},{"text":",","start":99,"end":100,"id":15,"ws":true},{"text":"and","start":101,"end":104,"id":16,"ws":true},{"text":"insulin","start":105,"end":112,"id":17,"ws":true},{"text":"glargine","start":113,"end":121,"id":18,"ws":true},{"text":",","start":122,"end":123,"id":19,"ws":true},{"text":"and","start":124,"end":127,"id":20,"ws":true},{"text":"administration","start":128,"end":142,"id":21,"ws":true},{"text":"frequency","start":143,"end":152,"id":22,"ws":true},{"text":"compared","start":153,"end":161,"id":23,"ws":true},{"text":"with","start":162,"end":166,"id":24,"ws":true},{"text":"exenatide","start":167,"end":176,"id":25,"ws":true},{"text":".","start":177,"end":178,"id":26,"ws":false}],"spans":[{"start":71,"end":84,"token_start":12,"token_end":12,"label":"DRUG"},{"start":87,"end":98,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/22853443/","_input_hash":1512374233,"_task_hash":-276708399,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Single treatment of closantel plus albendazole mixture reduced egg counts in camels by 100 % , 100 % , 98 % and 77 % for Haemonchus longistipes , Ascaris spp . , Monezia expansa and Fasciola hepatica , respectively .","paragraph":"<h3><u>Efficacy of closantel plus albendazole liquid suspension against natural infection of gastrointestinal parasites in camels.</u></h3>Oral administration of <b style='color:Tomato;'><i>closantel</i></b> in a dose of 10 mg/kg plus <b style='color:Tomato;'><i>albendazole</i></b> in a dose of 5 mg/kg liquid suspension was studied in 75 camels naturally infected with various types of gastrointestinal parasites. The camels involved were 15 pregnant she-camels, 20 non-pregnant she-camels and 40 male camels of various ages. Each camel received a single oral dose of <b style='color:Tomato;'><i>closantel</i></b> (10 mg/kg) plus <b style='color:Tomato;'><i>albendazole</i></b> (5 mg/kg) orally. Two weeks later, 20 camels of this group were re-dosed again with the same dose of the anthelmintic. Fecal samples were collected per rectum from all camels at the time of treatment and again 14 and 42 days post treatment. Fecal egg counts and generic determination of third stage larvae was performed. Results indicated that six different species of gastrointestinal tract parasites were identified in camels. <b style='color:DodgerBlue;'><i>Single</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>closantel</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>albendazole</i></b> <b style='color:DodgerBlue;'><i>mixture</i></b> <b style='color:DodgerBlue;'><i>reduced</i></b> <b style='color:DodgerBlue;'><i>egg</i></b> <b style='color:DodgerBlue;'><i>counts</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>camels</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>100</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>98</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>77</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>Haemonchus</i></b> <b style='color:DodgerBlue;'><i>longistipes</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Ascaris</i></b> <b style='color:DodgerBlue;'><i>spp</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Monezia</i></b> <b style='color:DodgerBlue;'><i>expansa</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Fasciola</i></b> <b style='color:DodgerBlue;'><i>hepatica</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, administration of the drug twice on the base of 2 weeks apart significantly raised the efficacy of the drug for clearance of the parasites from 92.5% to 100% in camels infected with various parasites. Camels were not adversely affected by treatment.","tokens":[{"text":"Single","start":0,"end":6,"id":0,"ws":true},{"text":"treatment","start":7,"end":16,"id":1,"ws":true},{"text":"of","start":17,"end":19,"id":2,"ws":true},{"text":"closantel","start":20,"end":29,"id":3,"ws":true},{"text":"plus","start":30,"end":34,"id":4,"ws":true},{"text":"albendazole","start":35,"end":46,"id":5,"ws":true},{"text":"mixture","start":47,"end":54,"id":6,"ws":true},{"text":"reduced","start":55,"end":62,"id":7,"ws":true},{"text":"egg","start":63,"end":66,"id":8,"ws":true},{"text":"counts","start":67,"end":73,"id":9,"ws":true},{"text":"in","start":74,"end":76,"id":10,"ws":true},{"text":"camels","start":77,"end":83,"id":11,"ws":true},{"text":"by","start":84,"end":86,"id":12,"ws":true},{"text":"100","start":87,"end":90,"id":13,"ws":true},{"text":"%","start":91,"end":92,"id":14,"ws":true},{"text":",","start":93,"end":94,"id":15,"ws":true},{"text":"100","start":95,"end":98,"id":16,"ws":true},{"text":"%","start":99,"end":100,"id":17,"ws":true},{"text":",","start":101,"end":102,"id":18,"ws":true},{"text":"98","start":103,"end":105,"id":19,"ws":true},{"text":"%","start":106,"end":107,"id":20,"ws":true},{"text":"and","start":108,"end":111,"id":21,"ws":true},{"text":"77","start":112,"end":114,"id":22,"ws":true},{"text":"%","start":115,"end":116,"id":23,"ws":true},{"text":"for","start":117,"end":120,"id":24,"ws":true},{"text":"Haemonchus","start":121,"end":131,"id":25,"ws":true},{"text":"longistipes","start":132,"end":143,"id":26,"ws":true},{"text":",","start":144,"end":145,"id":27,"ws":true},{"text":"Ascaris","start":146,"end":153,"id":28,"ws":true},{"text":"spp","start":154,"end":157,"id":29,"ws":true},{"text":".","start":158,"end":159,"id":30,"ws":true},{"text":",","start":160,"end":161,"id":31,"ws":true},{"text":"Monezia","start":162,"end":169,"id":32,"ws":true},{"text":"expansa","start":170,"end":177,"id":33,"ws":true},{"text":"and","start":178,"end":181,"id":34,"ws":true},{"text":"Fasciola","start":182,"end":190,"id":35,"ws":true},{"text":"hepatica","start":191,"end":199,"id":36,"ws":true},{"text":",","start":200,"end":201,"id":37,"ws":true},{"text":"respectively","start":202,"end":214,"id":38,"ws":true},{"text":".","start":215,"end":216,"id":39,"ws":false}],"spans":[{"start":20,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},{"start":35,"end":46,"token_start":5,"token_end":5,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10321589/","_input_hash":265346597,"_task_hash":-1009482935,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":3,"child":5,"head_span":{"start":20,"end":29,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":35,"end":46,"token_start":5,"token_end":5,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"In contrast to patients receiving lidocaine , older patients receiving tetracaine experienced significantly less overall pain and discomfort , unpleasant taste , and dyspnea .","paragraph":"<h3><u>A prospective, randomized, double-blind study comparing the efficacy of topical anesthetics in nasal endoscopy.</u></h3>Transnasal endoscopy is commonly performed in an outpatient otolaryngology setting. Patients are typically administered a topical anesthetic and decongestant prior to this procedure to alleviate discomfort and improve visualization. There is no consensus on which topical anesthetic is most effective in optimizing patient experience during the procedure. ### objective To determine whether there is a difference in the efficacy between atomized 2% <b style='color:Tomato;'><i>tetracaine</i></b> and 4% <b style='color:Tomato;'><i>lidocaine</i></b> as a topical anesthetic prior to transnasal endoscopy. ### Study Design Prospective, randomized, double-blind study. ### methods A total of 99 patients received oxymetazoline and were randomized to receive either 2% <b style='color:Tomato;'><i>tetracaine</i></b> or 4% <b style='color:Tomato;'><i>lidocaine</i></b> prior to transnasal endoscopy. Immediately following the procedure, participants completed a survey assessing level of discomfort and other adverse symptoms pertaining to the procedure using a 10-point visual analog scale (VAS). ### results There were no significant differences in VAS scores between the <b style='color:Tomato;'><i>lidocaine</i></b> and <b style='color:Tomato;'><i>tetracaine</i></b> groups. There were also no significant differences between genders in overall VAS scores and in the <b style='color:Tomato;'><i>lidocaine</i></b> and <b style='color:Tomato;'><i>tetracaine</i></b> subgroups. Older patients demonstrated significantly less discomfort or a sensation of bad taste overall. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>contrast</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>lidocaine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>older</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:MediumOrchid;'><i>tetracaine</i></b> <b style='color:DodgerBlue;'><i>experienced</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>pain</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>discomfort</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>unpleasant</i></b> <b style='color:DodgerBlue;'><i>taste</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>dyspnea</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### conclusion In patients undergoing transnasal endoscopy, use of either 2% <b style='color:Tomato;'><i>tetracaine</i></b> or 4% <b style='color:Tomato;'><i>lidocaine</i></b> has similar effect. <b style='color:Tomato;'><i>tetracaine</i></b> may be a better choice in older patients, however.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"contrast","start":3,"end":11,"id":1,"ws":true},{"text":"to","start":12,"end":14,"id":2,"ws":true},{"text":"patients","start":15,"end":23,"id":3,"ws":true},{"text":"receiving","start":24,"end":33,"id":4,"ws":true},{"text":"lidocaine","start":34,"end":43,"id":5,"ws":true},{"text":",","start":44,"end":45,"id":6,"ws":true},{"text":"older","start":46,"end":51,"id":7,"ws":true},{"text":"patients","start":52,"end":60,"id":8,"ws":true},{"text":"receiving","start":61,"end":70,"id":9,"ws":true},{"text":"tetracaine","start":71,"end":81,"id":10,"ws":true},{"text":"experienced","start":82,"end":93,"id":11,"ws":true},{"text":"significantly","start":94,"end":107,"id":12,"ws":true},{"text":"less","start":108,"end":112,"id":13,"ws":true},{"text":"overall","start":113,"end":120,"id":14,"ws":true},{"text":"pain","start":121,"end":125,"id":15,"ws":true},{"text":"and","start":126,"end":129,"id":16,"ws":true},{"text":"discomfort","start":130,"end":140,"id":17,"ws":true},{"text":",","start":141,"end":142,"id":18,"ws":true},{"text":"unpleasant","start":143,"end":153,"id":19,"ws":true},{"text":"taste","start":154,"end":159,"id":20,"ws":true},{"text":",","start":160,"end":161,"id":21,"ws":true},{"text":"and","start":162,"end":165,"id":22,"ws":true},{"text":"dyspnea","start":166,"end":173,"id":23,"ws":true},{"text":".","start":174,"end":175,"id":24,"ws":false}],"spans":[{"start":34,"end":43,"token_start":5,"token_end":5,"label":"DRUG"},{"start":71,"end":81,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23404424/","_input_hash":290732435,"_task_hash":204247466,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Second-line chemotherapy was also ineffective ; therefore , the bevacizumab and irinotecan were given after a third gross-total resection of the tumor .","paragraph":"<h3><u>Long-term efficacy of bevacizumab and irinotecan in recurrent pediatric glioblastoma.</u></h3>A 5-year-old boy with glioblastoma relapsed soon after postoperative irradiation in combination with <b style='color:Tomato;'><i>temozolomide</i></b>. <b style='color:DodgerBlue;'><i>Second-line</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>also</i></b> <b style='color:DodgerBlue;'><i>ineffective</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>therefore</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>irinotecan</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>third</i></b> <b style='color:DodgerBlue;'><i>gross-total</i></b> <b style='color:DodgerBlue;'><i>resection</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>tumor</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Treatment was interrupted for 1 month due to development of posterior reversible encephalopathy syndrome, but was re-initiated at a lower dose of <b style='color:Tomato;'><i>bevacizumab</i></b> with prolonged intervals between treatments. The patient was alive and disease free 2 years after initial diagnosis. <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>irinotecan</i></b> are a promising regimen for pediatric cases of recurrent glioblastoma after gross-total resection, although the optimal treatment schedule must be determined on a patient-by-patient basis.","tokens":[{"text":"Second-line","start":0,"end":11,"id":0,"ws":true},{"text":"chemotherapy","start":12,"end":24,"id":1,"ws":true},{"text":"was","start":25,"end":28,"id":2,"ws":true},{"text":"also","start":29,"end":33,"id":3,"ws":true},{"text":"ineffective","start":34,"end":45,"id":4,"ws":true},{"text":";","start":46,"end":47,"id":5,"ws":true},{"text":"therefore","start":48,"end":57,"id":6,"ws":true},{"text":",","start":58,"end":59,"id":7,"ws":true},{"text":"the","start":60,"end":63,"id":8,"ws":true},{"text":"bevacizumab","start":64,"end":75,"id":9,"ws":true},{"text":"and","start":76,"end":79,"id":10,"ws":true},{"text":"irinotecan","start":80,"end":90,"id":11,"ws":true},{"text":"were","start":91,"end":95,"id":12,"ws":true},{"text":"given","start":96,"end":101,"id":13,"ws":true},{"text":"after","start":102,"end":107,"id":14,"ws":true},{"text":"a","start":108,"end":109,"id":15,"ws":true},{"text":"third","start":110,"end":115,"id":16,"ws":true},{"text":"gross-total","start":116,"end":127,"id":17,"ws":true},{"text":"resection","start":128,"end":137,"id":18,"ws":true},{"text":"of","start":138,"end":140,"id":19,"ws":true},{"text":"the","start":141,"end":144,"id":20,"ws":true},{"text":"tumor","start":145,"end":150,"id":21,"ws":true},{"text":".","start":151,"end":152,"id":22,"ws":false}],"spans":[{"start":64,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},{"start":80,"end":90,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25711258/","_input_hash":-1340233831,"_task_hash":-1917079631,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":64,"end":75,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":80,"end":90,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer : results of the phase II CAPRICE study .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Pegylated</i></b> <b style='color:DodgerBlue;'><i>liposomal</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>elderly</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>cardiotoxicity-prone</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>high-risk</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>results</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>CAPRICE</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>Anthracycline and taxane-based primary chemotherapy (PCT) is the standard treatment for high-risk breast cancer (HRBC). However, conventional anthracyclines are not commonly used in elderly patients or those prone to cardiotoxicity. Pegylated liposomal <b style='color:Tomato;'><i>doxorubicin</i></b>, (PLD) has comparable efficacy, but less cardiotoxicity than conventional anthracyclines. We conducted a phase II single-arm trial to assess the efficacy and safety of PCT based on PLD followed by <b style='color:Tomato;'><i>paclitaxel</i></b> (PTX) in a HRBC population usually undertreated. Fifty patients with stage II-IIIB breast cancer and at least one risk factor for developing cardiotoxicity initiated PLD 35\u00a0mg/m(2) plus <b style='color:Tomato;'><i>cyclophosphamide</i></b> 600\u00a0mg/m(2) every 4\u00a0weeks for four cycles, followed by 80\u00a0mg/m(2) weekly PTX for 12. Close cardiac monitoring was performed. Primary endpoint was the pathological complete response rate (pCR) in the breast. Treatment delivery and toxicities were assessed. Eighty-four per cent of patients were older than 65\u00a0years, 64\u00a0% suffered from hypertension, and 10\u00a0% had prior cardiac disease. In an intention-to-treat analysis, breast pCR was 32\u00a0% (95\u00a0% CI 19.5-46.7\u00a0%) and pCR in breast and axilla was 24\u00a0% (95\u00a0% CI 12.1-35.8\u00a0%). At diagnosis only, 26\u00a0% of patients were candidates for breast conservative surgery, which increased to 58.7\u00a0% after PCT. No significant decrease in left ventricular ejection fraction was seen. PLD followed by PTX was feasible in a fragile population of patients who were not candidates for conventional <b style='color:Tomato;'><i>doxorubicin</i></b>. Moreover, it achieved a pCR similar to standard therapy and could therefore be an option for elderly patients or cardiotoxicity-prone who present HRBC.","tokens":[{"text":"Pegylated","start":0,"end":9,"id":0,"ws":true},{"text":"liposomal","start":10,"end":19,"id":1,"ws":true},{"text":"doxorubicin","start":20,"end":31,"id":2,"ws":true},{"text":"plus","start":32,"end":36,"id":3,"ws":true},{"text":"cyclophosphamide","start":37,"end":53,"id":4,"ws":true},{"text":"followed","start":54,"end":62,"id":5,"ws":true},{"text":"by","start":63,"end":65,"id":6,"ws":true},{"text":"paclitaxel","start":66,"end":76,"id":7,"ws":true},{"text":"as","start":77,"end":79,"id":8,"ws":true},{"text":"primary","start":80,"end":87,"id":9,"ws":true},{"text":"chemotherapy","start":88,"end":100,"id":10,"ws":true},{"text":"in","start":101,"end":103,"id":11,"ws":true},{"text":"elderly","start":104,"end":111,"id":12,"ws":true},{"text":"or","start":112,"end":114,"id":13,"ws":true},{"text":"cardiotoxicity-prone","start":115,"end":135,"id":14,"ws":true},{"text":"patients","start":136,"end":144,"id":15,"ws":true},{"text":"with","start":145,"end":149,"id":16,"ws":true},{"text":"high-risk","start":150,"end":159,"id":17,"ws":true},{"text":"breast","start":160,"end":166,"id":18,"ws":true},{"text":"cancer","start":167,"end":173,"id":19,"ws":true},{"text":":","start":174,"end":175,"id":20,"ws":true},{"text":"results","start":176,"end":183,"id":21,"ws":true},{"text":"of","start":184,"end":186,"id":22,"ws":true},{"text":"the","start":187,"end":190,"id":23,"ws":true},{"text":"phase","start":191,"end":196,"id":24,"ws":true},{"text":"II","start":197,"end":199,"id":25,"ws":true},{"text":"CAPRICE","start":200,"end":207,"id":26,"ws":true},{"text":"study","start":208,"end":213,"id":27,"ws":true},{"text":".","start":214,"end":215,"id":28,"ws":false}],"spans":[{"start":20,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},{"start":37,"end":53,"token_start":4,"token_end":4,"label":"DRUG"},{"start":66,"end":76,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25981896/","_input_hash":-1383242339,"_task_hash":259977807,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":20,"end":31,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":37,"end":53,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":4,"child":7,"head_span":{"start":37,"end":53,"token_start":4,"token_end":4,"label":"DRUG"},"child_span":{"start":66,"end":76,"token_start":7,"token_end":7,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"In unselected patients with advanced HCC immunotherapeutics , namely the programmed cell death-1 ( PD-1 ) antibodies , nivolumab and pembrolizumab have shown promising efficacy in therapy-na\u00efve , as well as pre-treated patients with advanced HCC .","paragraph":"<h3><u>Recent developments with immunotherapy for hepatocellular carcinoma.</u></h3>Immunotherapy is on the way to become the new standard of care for advanced hepatocellular carcinoma (HCC) worldwide. With higher rates of objective responses, and overall less side effects compared to tyrosine-kinase inhibitors (TKIs) immunotherapeutics will probably replace <b style='color:Tomato;'><i>sorafenib</i></b> from standard first-line treatment. ### Areas Covered This review covers recent clinical data on systemic agents and ongoing trials in patients with advanced HCC focusing on immunotherapy. ### Expert Opinion <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>unselected</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>HCC</i></b> <b style='color:DodgerBlue;'><i>immunotherapeutics</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>namely</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>programmed</i></b> <b style='color:DodgerBlue;'><i>cell</i></b> <b style='color:DodgerBlue;'><i>death-1</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PD-1</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>antibodies</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>nivolumab</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>pembrolizumab</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>promising</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>therapy-na\u00efve</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>as</i></b> <b style='color:DodgerBlue;'><i>pre-treated</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>HCC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> However, only 10-20 percent of treated patients show an objective and durable response to the indicated therapeutics. Therefore, combination therapies including different immunotherapeutics, e.g. PD-1/programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies, or combinations of immunotherapeutics and small molecules, or bifunctional antibodies will be needed to improve response rates. ### abbreviations HCC: hepatocellular carcinoma; TKI: tyrosine-kinase inhibitors; PD-1: programmed death receptor-1; PD-L1: programmed cell death 1 ligand 1; CTLA-4: cytotoxic T-lymphocyte-associated Protein 4; CAR-T: chimeric T cell receptors; TACE: transarterial chemoembolization; SIRT: selective internal radiation therapy; SBRT: stereotactic body radiation therapy; VEGF: vascular endothelial growth factor; MEK: mitogen-activated protein kinase kinase; NK cell: natural killer cell; TGF\u03b2: transforming growth factor-\u03b2; OV: Oncolytic viruses; PFU: plaque-forming unit.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"unselected","start":3,"end":13,"id":1,"ws":true},{"text":"patients","start":14,"end":22,"id":2,"ws":true},{"text":"with","start":23,"end":27,"id":3,"ws":true},{"text":"advanced","start":28,"end":36,"id":4,"ws":true},{"text":"HCC","start":37,"end":40,"id":5,"ws":true},{"text":"immunotherapeutics","start":41,"end":59,"id":6,"ws":true},{"text":",","start":60,"end":61,"id":7,"ws":true},{"text":"namely","start":62,"end":68,"id":8,"ws":true},{"text":"the","start":69,"end":72,"id":9,"ws":true},{"text":"programmed","start":73,"end":83,"id":10,"ws":true},{"text":"cell","start":84,"end":88,"id":11,"ws":true},{"text":"death-1","start":89,"end":96,"id":12,"ws":true},{"text":"(","start":97,"end":98,"id":13,"ws":true},{"text":"PD-1","start":99,"end":103,"id":14,"ws":true},{"text":")","start":104,"end":105,"id":15,"ws":true},{"text":"antibodies","start":106,"end":116,"id":16,"ws":true},{"text":",","start":117,"end":118,"id":17,"ws":true},{"text":"nivolumab","start":119,"end":128,"id":18,"ws":true},{"text":"and","start":129,"end":132,"id":19,"ws":true},{"text":"pembrolizumab","start":133,"end":146,"id":20,"ws":true},{"text":"have","start":147,"end":151,"id":21,"ws":true},{"text":"shown","start":152,"end":157,"id":22,"ws":true},{"text":"promising","start":158,"end":167,"id":23,"ws":true},{"text":"efficacy","start":168,"end":176,"id":24,"ws":true},{"text":"in","start":177,"end":179,"id":25,"ws":true},{"text":"therapy-na\u00efve","start":180,"end":193,"id":26,"ws":true},{"text":",","start":194,"end":195,"id":27,"ws":true},{"text":"as","start":196,"end":198,"id":28,"ws":true},{"text":"well","start":199,"end":203,"id":29,"ws":true},{"text":"as","start":204,"end":206,"id":30,"ws":true},{"text":"pre-treated","start":207,"end":218,"id":31,"ws":true},{"text":"patients","start":219,"end":227,"id":32,"ws":true},{"text":"with","start":228,"end":232,"id":33,"ws":true},{"text":"advanced","start":233,"end":241,"id":34,"ws":true},{"text":"HCC","start":242,"end":245,"id":35,"ws":true},{"text":".","start":246,"end":247,"id":36,"ws":false}],"spans":[{"start":119,"end":128,"token_start":18,"token_end":18,"label":"DRUG"},{"start":133,"end":146,"token_start":20,"token_end":20,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29995439/","_input_hash":1975216327,"_task_hash":1461705986,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We randomly assigned 410 women with advanced ovarian cancer and residual masses larger than 1 cm after initial surgery to receive cisplatin ( 75 mg per square meter of body-surface area ) with either cyclophosphamide ( 750 mg per square meter ) or paclitaxel ( 135 mg per square meter over 24 hours ) .","paragraph":"<h3><u>Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.</u></h3>Chemotherapy combinations that include an alkylating agent and a platinum coordination complex have high response rates in women with advanced ovarian cancer. Such combinations provide long-term control of disease in few patients, however. We compared two combinations, cisplatin and <b style='color:Tomato;'><i>cyclophosphamide</i></b> and cisplatin and <b style='color:Tomato;'><i>paclitaxel</i></b>, in women with ovarian cancer. ### methods <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>randomly</i></b> <b style='color:DodgerBlue;'><i>assigned</i></b> <b style='color:DodgerBlue;'><i>410</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>advanced</i></b> <b style='color:DodgerBlue;'><i>ovarian</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>residual</i></b> <b style='color:DodgerBlue;'><i>masses</i></b> <b style='color:DodgerBlue;'><i>larger</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>1</i></b> <b style='color:DodgerBlue;'><i>cm</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>initial</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>receive</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>75</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>square</i></b> <b style='color:DodgerBlue;'><i>meter</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>body-surface</i></b> <b style='color:DodgerBlue;'><i>area</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>either</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>750</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>square</i></b> <b style='color:DodgerBlue;'><i>meter</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>135</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>per</i></b> <b style='color:DodgerBlue;'><i>square</i></b> <b style='color:DodgerBlue;'><i>meter</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### results Three hundred eighty-six women met all the eligibility criteria. Known prognostic factors were similar in the two treatment groups. Alopecia, neutropenia, fever, and allergic reactions were reported more frequently in the cisplatin-<b style='color:Tomato;'><i>paclitaxel</i></b> group. Among 216 women with measurable disease, 73 percent in the cisplatin-<b style='color:Tomato;'><i>paclitaxel</i></b> group responded to therapy, as compared with 60 percent in the cisplatin-<b style='color:Tomato;'><i>cyclophosphamide</i></b> group (P = 0.01). The frequency of surgically verified complete response was similar in the two groups. Progression-free survival was significantly longer (P < 0.001) in the cisplatin-<b style='color:Tomato;'><i>paclitaxel</i></b> group than in the cisplatin-<b style='color:Tomato;'><i>cyclophosphamide</i></b> group (median, 18 vs. 13 months). Survival was also significantly longer (P < 0.001) in the cisplatin-<b style='color:Tomato;'><i>paclitaxel</i></b> group (median, 38 vs. 24 months). ### conclusions Incorporating <b style='color:Tomato;'><i>paclitaxel</i></b> into first-line therapy improves the duration of progression-free survival and of overall survival in women with incompletely resected stage III and stage IV ovarian cancer.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"randomly","start":3,"end":11,"id":1,"ws":true},{"text":"assigned","start":12,"end":20,"id":2,"ws":true},{"text":"410","start":21,"end":24,"id":3,"ws":true},{"text":"women","start":25,"end":30,"id":4,"ws":true},{"text":"with","start":31,"end":35,"id":5,"ws":true},{"text":"advanced","start":36,"end":44,"id":6,"ws":true},{"text":"ovarian","start":45,"end":52,"id":7,"ws":true},{"text":"cancer","start":53,"end":59,"id":8,"ws":true},{"text":"and","start":60,"end":63,"id":9,"ws":true},{"text":"residual","start":64,"end":72,"id":10,"ws":true},{"text":"masses","start":73,"end":79,"id":11,"ws":true},{"text":"larger","start":80,"end":86,"id":12,"ws":true},{"text":"than","start":87,"end":91,"id":13,"ws":true},{"text":"1","start":92,"end":93,"id":14,"ws":true},{"text":"cm","start":94,"end":96,"id":15,"ws":true},{"text":"after","start":97,"end":102,"id":16,"ws":true},{"text":"initial","start":103,"end":110,"id":17,"ws":true},{"text":"surgery","start":111,"end":118,"id":18,"ws":true},{"text":"to","start":119,"end":121,"id":19,"ws":true},{"text":"receive","start":122,"end":129,"id":20,"ws":true},{"text":"cisplatin","start":130,"end":139,"id":21,"ws":true},{"text":"(","start":140,"end":141,"id":22,"ws":true},{"text":"75","start":142,"end":144,"id":23,"ws":true},{"text":"mg","start":145,"end":147,"id":24,"ws":true},{"text":"per","start":148,"end":151,"id":25,"ws":true},{"text":"square","start":152,"end":158,"id":26,"ws":true},{"text":"meter","start":159,"end":164,"id":27,"ws":true},{"text":"of","start":165,"end":167,"id":28,"ws":true},{"text":"body-surface","start":168,"end":180,"id":29,"ws":true},{"text":"area","start":181,"end":185,"id":30,"ws":true},{"text":")","start":186,"end":187,"id":31,"ws":true},{"text":"with","start":188,"end":192,"id":32,"ws":true},{"text":"either","start":193,"end":199,"id":33,"ws":true},{"text":"cyclophosphamide","start":200,"end":216,"id":34,"ws":true},{"text":"(","start":217,"end":218,"id":35,"ws":true},{"text":"750","start":219,"end":222,"id":36,"ws":true},{"text":"mg","start":223,"end":225,"id":37,"ws":true},{"text":"per","start":226,"end":229,"id":38,"ws":true},{"text":"square","start":230,"end":236,"id":39,"ws":true},{"text":"meter","start":237,"end":242,"id":40,"ws":true},{"text":")","start":243,"end":244,"id":41,"ws":true},{"text":"or","start":245,"end":247,"id":42,"ws":true},{"text":"paclitaxel","start":248,"end":258,"id":43,"ws":true},{"text":"(","start":259,"end":260,"id":44,"ws":true},{"text":"135","start":261,"end":264,"id":45,"ws":true},{"text":"mg","start":265,"end":267,"id":46,"ws":true},{"text":"per","start":268,"end":271,"id":47,"ws":true},{"text":"square","start":272,"end":278,"id":48,"ws":true},{"text":"meter","start":279,"end":284,"id":49,"ws":true},{"text":"over","start":285,"end":289,"id":50,"ws":true},{"text":"24","start":290,"end":292,"id":51,"ws":true},{"text":"hours","start":293,"end":298,"id":52,"ws":true},{"text":")","start":299,"end":300,"id":53,"ws":true},{"text":".","start":301,"end":302,"id":54,"ws":false}],"spans":[{"start":130,"end":139,"token_start":21,"token_end":21,"label":"DRUG"},{"start":200,"end":216,"token_start":34,"token_end":34,"label":"DRUG"},{"start":248,"end":258,"token_start":43,"token_end":43,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/7494563/","_input_hash":-574521188,"_task_hash":1260243567,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":21,"child":43,"head_span":{"start":130,"end":139,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":248,"end":258,"token_start":43,"token_end":43,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":21,"child":34,"head_span":{"start":130,"end":139,"token_start":21,"token_end":21,"label":"DRUG"},"child_span":{"start":200,"end":216,"token_start":34,"token_end":34,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Treatment with rapamycin and paclitaxel resulted in decreased phosphorylation of S6 and 4E-BP1 , two critical downstream targets of the mTOR pathway .","paragraph":"<h3><u>Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.</u></h3>Mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) inhibitors modulate signaling pathways involved in cell cycle progression, and recent phase II trials demonstrate activity in patients with endometrial cancer. Our objective was to examine the effects of combination therapy with <b style='color:Tomato;'><i>rapamycin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> in endometrial cancer cell lines. <b style='color:Tomato;'><i>paclitaxel</i></b> inhibited proliferation in a dose-dependent manner in both cell lines with IC(50) values of 0.1-0.5 nM and 1-5 nM for Ishikawa and ECC-1 cells, respectively. To assess synergy of <b style='color:Tomato;'><i>paclitaxel</i></b> and <b style='color:Tomato;'><i>rapamycin</i></b>, the combination index (CI) was calculated by the method of Chou and Talalay. Simultaneous exposure of cells to various doses of <b style='color:Tomato;'><i>paclitaxel</i></b> in combination with <b style='color:Tomato;'><i>rapamycin</i></b> (1 nM) resulted in a significant synergistic anti-proliferative effect (CI <1, range 0.131-0.920). <b style='color:Tomato;'><i>rapamycin</i></b> alone did not induce apoptosis, but combined treatment with <b style='color:Tomato;'><i>paclitaxel</i></b> increased apoptosis over that of <b style='color:Tomato;'><i>paclitaxel</i></b> alone. <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>rapamycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>decreased</i></b> <b style='color:DodgerBlue;'><i>phosphorylation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>S6</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>4E-BP1</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>critical</i></b> <b style='color:DodgerBlue;'><i>downstream</i></b> <b style='color:DodgerBlue;'><i>targets</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>mTOR</i></b> <b style='color:DodgerBlue;'><i>pathway</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>rapamycin</i></b> decreased hTERT mRNA expression by real-time RT-PCR while <b style='color:Tomato;'><i>paclitaxel</i></b> alone had no effect on telomerase activity. <b style='color:Tomato;'><i>paclitaxel</i></b> increased polymerization and acetylation of tubulin, and <b style='color:Tomato;'><i>rapamycin</i></b> appeared to enhance this effect. Thus, in conclusion, we demonstrate that <b style='color:Tomato;'><i>rapamycin</i></b> potentiates the effects of <b style='color:Tomato;'><i>paclitaxel</i></b> in endometrial cancer cells through inhibition of cell proliferation, induction of apoptosis and potentially increased polymerization and acetylation of tubulin. This suggests that the combination of <b style='color:Tomato;'><i>rapamycin</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> may be a promising effective targeted therapy for endometrial cancer.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"with","start":10,"end":14,"id":1,"ws":true},{"text":"rapamycin","start":15,"end":24,"id":2,"ws":true},{"text":"and","start":25,"end":28,"id":3,"ws":true},{"text":"paclitaxel","start":29,"end":39,"id":4,"ws":true},{"text":"resulted","start":40,"end":48,"id":5,"ws":true},{"text":"in","start":49,"end":51,"id":6,"ws":true},{"text":"decreased","start":52,"end":61,"id":7,"ws":true},{"text":"phosphorylation","start":62,"end":77,"id":8,"ws":true},{"text":"of","start":78,"end":80,"id":9,"ws":true},{"text":"S6","start":81,"end":83,"id":10,"ws":true},{"text":"and","start":84,"end":87,"id":11,"ws":true},{"text":"4E-BP1","start":88,"end":94,"id":12,"ws":true},{"text":",","start":95,"end":96,"id":13,"ws":true},{"text":"two","start":97,"end":100,"id":14,"ws":true},{"text":"critical","start":101,"end":109,"id":15,"ws":true},{"text":"downstream","start":110,"end":120,"id":16,"ws":true},{"text":"targets","start":121,"end":128,"id":17,"ws":true},{"text":"of","start":129,"end":131,"id":18,"ws":true},{"text":"the","start":132,"end":135,"id":19,"ws":true},{"text":"mTOR","start":136,"end":140,"id":20,"ws":true},{"text":"pathway","start":141,"end":148,"id":21,"ws":true},{"text":".","start":149,"end":150,"id":22,"ws":false}],"spans":[{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},{"start":29,"end":39,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19688827/","_input_hash":-1539248830,"_task_hash":-2048830506,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":15,"end":24,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":29,"end":39,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Conversely , the IMbrave150 trial recently showed that , among patients with previously untreated unresectable HCC , treatment with atezolizumab plus bevacizumab resulted in significantly longer overall survival and progression-free survival compared to sorafenib monotherapy .","paragraph":"<h3><u>Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.</u></h3>Hepatocellular carcinoma (HCC) represents the most commonly diagnosed liver cancer worldwide, and the overall survival of patients with unresectable disease is poor. In the last five years, immune checkpoint inhibitors (ICIs) have revolutionized the treatment scenario of several hematological and solid tumors, and these agents have been actively explored in unresectable HCC. Firstly, promising findings of phase I and II clinical studies reporting durable responses and a tolerable safety profile have led to the assessment of ICIs as single agents in phase III clinical studies; however, the latter have provided controversial results, and the activity of ICI monotherapy seems limited to a small subgroup of patients. <b style='color:DodgerBlue;'><i>Conversely</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>IMbrave150</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>recently</i></b> <b style='color:DodgerBlue;'><i>showed</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>among</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>previously</i></b> <b style='color:DodgerBlue;'><i>untreated</i></b> <b style='color:DodgerBlue;'><i>unresectable</i></b> <b style='color:DodgerBlue;'><i>HCC</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>atezolizumab</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>resulted</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>significantly</i></b> <b style='color:DodgerBlue;'><i>longer</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>progression-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>compared</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>sorafenib</i></b> <b style='color:DodgerBlue;'><i>monotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In addition, the activity of several other ICIs is under investigation, as combination immunotherapy as well as combinations of immunotherapy with antiangiogenic agents. Nonetheless, there are currently no validated predictive biomarkers able to guide treatment choice in this setting, where the identification of specific predictors of response to ICIs represents a major challenge. In this review, we aim to provide a critical overview of recent evidence on biochemical predictors of response to ICIs in patients with unresectable HCC, especially focusing on PD-L1, TMB, MSI, and other emerging biomarkers.","tokens":[{"text":"Conversely","start":0,"end":10,"id":0,"ws":true},{"text":",","start":11,"end":12,"id":1,"ws":true},{"text":"the","start":13,"end":16,"id":2,"ws":true},{"text":"IMbrave150","start":17,"end":27,"id":3,"ws":true},{"text":"trial","start":28,"end":33,"id":4,"ws":true},{"text":"recently","start":34,"end":42,"id":5,"ws":true},{"text":"showed","start":43,"end":49,"id":6,"ws":true},{"text":"that","start":50,"end":54,"id":7,"ws":true},{"text":",","start":55,"end":56,"id":8,"ws":true},{"text":"among","start":57,"end":62,"id":9,"ws":true},{"text":"patients","start":63,"end":71,"id":10,"ws":true},{"text":"with","start":72,"end":76,"id":11,"ws":true},{"text":"previously","start":77,"end":87,"id":12,"ws":true},{"text":"untreated","start":88,"end":97,"id":13,"ws":true},{"text":"unresectable","start":98,"end":110,"id":14,"ws":true},{"text":"HCC","start":111,"end":114,"id":15,"ws":true},{"text":",","start":115,"end":116,"id":16,"ws":true},{"text":"treatment","start":117,"end":126,"id":17,"ws":true},{"text":"with","start":127,"end":131,"id":18,"ws":true},{"text":"atezolizumab","start":132,"end":144,"id":19,"ws":true},{"text":"plus","start":145,"end":149,"id":20,"ws":true},{"text":"bevacizumab","start":150,"end":161,"id":21,"ws":true},{"text":"resulted","start":162,"end":170,"id":22,"ws":true},{"text":"in","start":171,"end":173,"id":23,"ws":true},{"text":"significantly","start":174,"end":187,"id":24,"ws":true},{"text":"longer","start":188,"end":194,"id":25,"ws":true},{"text":"overall","start":195,"end":202,"id":26,"ws":true},{"text":"survival","start":203,"end":211,"id":27,"ws":true},{"text":"and","start":212,"end":215,"id":28,"ws":true},{"text":"progression-free","start":216,"end":232,"id":29,"ws":true},{"text":"survival","start":233,"end":241,"id":30,"ws":true},{"text":"compared","start":242,"end":250,"id":31,"ws":true},{"text":"to","start":251,"end":253,"id":32,"ws":true},{"text":"sorafenib","start":254,"end":263,"id":33,"ws":true},{"text":"monotherapy","start":264,"end":275,"id":34,"ws":true},{"text":".","start":276,"end":277,"id":35,"ws":false}],"spans":[{"start":132,"end":144,"token_start":19,"token_end":19,"label":"DRUG"},{"start":150,"end":161,"token_start":21,"token_end":21,"label":"DRUG"},{"start":254,"end":263,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33549983/","_input_hash":1227576386,"_task_hash":92750848,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":19,"child":21,"head_span":{"start":132,"end":144,"token_start":19,"token_end":19,"label":"DRUG"},"child_span":{"start":150,"end":161,"token_start":21,"token_end":21,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Evaluation</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>tamoxifen</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>letrozole</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>assessment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>pharmacokinetic</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>postmenopausal</i></b> <b style='color:DodgerBlue;'><i>women</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>metastatic</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The goals of this clinical trial involving postmenopausal women with metastatic breast cancer were to: (a) examine the effects of <b style='color:Tomato;'><i>letrozole</i></b> on <b style='color:Tomato;'><i>tamoxifen</i></b> (TAM) pharmacokinetics; (b) examine estrogen suppression in patients receiving TAM plus <b style='color:Tomato;'><i>letrozole</i></b>; and (c) evaluate tolerability, toxicity, objective response, and time to progression for the combination. Postmenopausal women with measurable or evaluable metastatic breast cancer received TAM (20 mg daily) for 6 weeks, and then <b style='color:Tomato;'><i>letrozole</i></b> (2.5 mg daily) was added. To examine for any effect of <b style='color:Tomato;'><i>letrozole</i></b> on the levels of TAM and two metabolites [N-desmethyl-TAM and 4-hydroxy-TAM], serum samples were obtained at 6, 12, 18, and 24 weeks. To examine for aromatase inhibition, serum samples were obtained before treatment and at 6, 12, 18, and 24 weeks for estradiol, <b style='color:Tomato;'><i>estrone</i></b> (E1) E1 sulfate, and sex hormone-binding globulin. A total of 34 patients were entered on this trial, and 23 patients were still on study at week 24, 18 of whom had blood samples available at both week 6 and week 24. The 95% confidence interval for the mean difference between levels at week 24 and levels at week 6 was -34 to 15 ng/ml for TAM, -35 to 45 ng/ml for N-desmethyl-TAM, and -1 to 2 for 4-hydroxy-TAM. For estradiol, a significant decrease (median, 88.5%; range, 73.7-95.2%) was identified after 6 weeks of <b style='color:Tomato;'><i>letrozole</i></b>, which was maintained for an additional 12 weeks. Similar significant reductions were identified for E1. E1 sulfate levels increased after 6 weeks of TAM alone but then decreased significantly after the addition of <b style='color:Tomato;'><i>letrozole</i></b>. Sex hormone-binding globulin levels were significantly elevated after 6 weeks of TAM alone and remained elevated after the addition of <b style='color:Tomato;'><i>letrozole</i></b>. Six of the 34 patients (17.6%) achieved an objective response (95% confidence interval, 6.8-34.5%), with a median time to disease progression of 7.6 months. There was no indication of a systematic decrease in TAM, N-desmethyl-TAM, or 4-hydroxy-TAM after the additional of <b style='color:Tomato;'><i>letrozole</i></b>. Estrogen suppression induced by <b style='color:Tomato;'><i>letrozole</i></b> was substantial despite the concomitant administration of TAM. The antitumor effect of TAM plus <b style='color:Tomato;'><i>letrozole</i></b> was less than expected.","tokens":[{"text":"Evaluation","start":0,"end":10,"id":0,"ws":true},{"text":"of","start":11,"end":13,"id":1,"ws":true},{"text":"tamoxifen","start":14,"end":23,"id":2,"ws":true},{"text":"plus","start":24,"end":28,"id":3,"ws":true},{"text":"letrozole","start":29,"end":38,"id":4,"ws":true},{"text":"with","start":39,"end":43,"id":5,"ws":true},{"text":"assessment","start":44,"end":54,"id":6,"ws":true},{"text":"of","start":55,"end":57,"id":7,"ws":true},{"text":"pharmacokinetic","start":58,"end":73,"id":8,"ws":true},{"text":"interaction","start":74,"end":85,"id":9,"ws":true},{"text":"in","start":86,"end":88,"id":10,"ws":true},{"text":"postmenopausal","start":89,"end":103,"id":11,"ws":true},{"text":"women","start":104,"end":109,"id":12,"ws":true},{"text":"with","start":110,"end":114,"id":13,"ws":true},{"text":"metastatic","start":115,"end":125,"id":14,"ws":true},{"text":"breast","start":126,"end":132,"id":15,"ws":true},{"text":"cancer","start":133,"end":139,"id":16,"ws":true},{"text":".","start":140,"end":141,"id":17,"ws":false}],"spans":[{"start":14,"end":23,"token_start":2,"token_end":2,"label":"DRUG"},{"start":29,"end":38,"token_start":4,"token_end":4,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10430063/","_input_hash":-750578039,"_task_hash":-1911141189,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":14,"end":23,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":29,"end":38,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Moreover , the BCR/ABL1 inhibitors nilotinib and ponatinib were found to decrease STAT5 activity and CD25 expression in KU812 cells and primary CML LSCs .","paragraph":"<h3><u>Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.</u></h3>In chronic myelogenous leukemia (CML), leukemic stem cells (LSC) represent a critical target of therapy. However, little is known about markers and targets expressed by LSCs. The aim of this project was to identify novel relevant markers of CML LSCs. ### Experimental Design CML LSCs were examined by flow cytometry, qPCR, and various bioassays. In addition, we examined the multipotent CD25(+)CML cell line KU812. ### results In contrast to normal hematopoietic stem cells, CD34(+)/CD38(-)CML LSCs expressed the IL-2 receptor alpha chain, IL-2RA (CD25). STAT5 was found to induce expression of CD25 in Lin(-)/Sca-1(+)/Kit(+)stem cells in C57Bl/6 mice. Correspondingly, shRNA-induced STAT5 depletion resulted in decreased CD25 expression in KU812 cells. <b style='color:DodgerBlue;'><i>Moreover</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>BCR/ABL1</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:MediumOrchid;'><i>nilotinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>ponatinib</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>found</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>decrease</i></b> <b style='color:DodgerBlue;'><i>STAT5</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>CD25</i></b> <b style='color:DodgerBlue;'><i>expression</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>KU812</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>primary</i></b> <b style='color:DodgerBlue;'><i>CML</i></b> <b style='color:DodgerBlue;'><i>LSCs</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A CD25-targeting shRNA was found to augment proliferation of KU812 cellsin vitroand their engraftmentin vivoin NOD/SCID-IL-2R\u03b3(-/-)mice. In drug-screening experiments, the PI3K/mTOR blocker BEZ235 promoted the expression of STAT5 and CD25 in CML cells. Finally, we found that BEZ235 produces synergistic antineoplastic effects on CML cells when applied in combination with <b style='color:Tomato;'><i>nilotinib</i></b> or <b style='color:Tomato;'><i>ponatinib</i></b>. ### conclusions CD25 is a novel STAT5-dependent marker of CML LSCs and may be useful for LSC detection and LSC isolation in clinical practice and basic science. Moreover, CD25 serves as a growth regulator of CML LSCs, which may have biologic and clinical implications and may pave the way for the development of new more effective LSC-eradicating treatment strategies in CML.","tokens":[{"text":"Moreover","start":0,"end":8,"id":0,"ws":true},{"text":",","start":9,"end":10,"id":1,"ws":true},{"text":"the","start":11,"end":14,"id":2,"ws":true},{"text":"BCR/ABL1","start":15,"end":23,"id":3,"ws":true},{"text":"inhibitors","start":24,"end":34,"id":4,"ws":true},{"text":"nilotinib","start":35,"end":44,"id":5,"ws":true},{"text":"and","start":45,"end":48,"id":6,"ws":true},{"text":"ponatinib","start":49,"end":58,"id":7,"ws":true},{"text":"were","start":59,"end":63,"id":8,"ws":true},{"text":"found","start":64,"end":69,"id":9,"ws":true},{"text":"to","start":70,"end":72,"id":10,"ws":true},{"text":"decrease","start":73,"end":81,"id":11,"ws":true},{"text":"STAT5","start":82,"end":87,"id":12,"ws":true},{"text":"activity","start":88,"end":96,"id":13,"ws":true},{"text":"and","start":97,"end":100,"id":14,"ws":true},{"text":"CD25","start":101,"end":105,"id":15,"ws":true},{"text":"expression","start":106,"end":116,"id":16,"ws":true},{"text":"in","start":117,"end":119,"id":17,"ws":true},{"text":"KU812","start":120,"end":125,"id":18,"ws":true},{"text":"cells","start":126,"end":131,"id":19,"ws":true},{"text":"and","start":132,"end":135,"id":20,"ws":true},{"text":"primary","start":136,"end":143,"id":21,"ws":true},{"text":"CML","start":144,"end":147,"id":22,"ws":true},{"text":"LSCs","start":148,"end":152,"id":23,"ws":true},{"text":".","start":153,"end":154,"id":24,"ws":false}],"spans":[{"start":35,"end":44,"token_start":5,"token_end":5,"label":"DRUG"},{"start":49,"end":58,"token_start":7,"token_end":7,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/26607600/","_input_hash":-1776148781,"_task_hash":-538181250,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The EVERLAR study reports prospective data of somatostatin analogue in combination with everolimus in nonfunctioning gastrointestinal neuroendocrine tumors suggesting meaningful activity and favorable toxicity profile that supports drug combination in this setting .","paragraph":"<h3><u>Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.</u></h3>Antitumor activity of the combination of <b style='color:Tomato;'><i>somatostatin</i></b> analogues (SSAs) and the mammalian target of <b style='color:Tomato;'><i>rapamycin</i></b> (mTOR) inhibitor <b style='color:Tomato;'><i>everolimus</i></b> in patients with neuroendocrine tumors (NETs) has been reported but not confirmed in prospective trials. ### Materials And Methods This prospective, multicenter, single-arm phase II EVERLAR study evaluated <b style='color:Tomato;'><i>everolimus</i></b> 10 mg/day and the SSA <b style='color:Tomato;'><i>octreotide</i></b> 30 mg every 28 days in patients with advanced nonfunctioning well-differentiated gastrointestinal NETs (GI-NETs) that progressed in the last 12 months (ClinicalTrials.gov NCT01567488). Prior treatment with SSAs and any systemic or locoregional therapy was allowed except for mTOR inhibitors. Patients continued treatment until disease progression or unacceptable adverse events (AEs). The primary endpoint was progression-free survival (PFS) at 12 months; secondary endpoints included early biochemical response, objective response rate (ORR) by RECIST v1.0, overall survival (OS), AEs, activation of mTOR pathway (insulin-like growth factor 1 receptor [IGF1R] and phosphoS6 [pS6] expression). ### results Forty-three patients were included in the intent-to-treat analyses. After 12 months of treatment, 62.3% (95% confidence interval [CI] 48%-77%) of patients had not progressed or died. The 24-month PFS rate was 43.6% (95% CI 29%-58%). The confirmed ORR was 2.3%, and stable disease was 58.1%. Median OS was not reached after 24 months of median follow-up. Dose reductions and temporary interruptions due to AEs were required in 14 (33%) and 33 (77%) patients, respectively. The most frequent AEs were diarrhea, asthenia, mucositis, rash, and hyperglycemia. No correlation was observed between IGFR1 and pS6 expression and PFS/OS. ### conclusion The <b style='color:Tomato;'><i>everolimus</i></b>-<b style='color:Tomato;'><i>octreotide</i></b> combination provided clinically relevant efficacy in nonfunctioning GI-NETs, similar to the results of RADIANT-2 in functioning setting. ### Implications For Practice <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>EVERLAR</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>reports</i></b> <b style='color:DodgerBlue;'><i>prospective</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>somatostatin</i></b> <b style='color:DodgerBlue;'><i>analogue</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>everolimus</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>nonfunctioning</i></b> <b style='color:DodgerBlue;'><i>gastrointestinal</i></b> <b style='color:DodgerBlue;'><i>neuroendocrine</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>suggesting</i></b> <b style='color:DodgerBlue;'><i>meaningful</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>favorable</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>profile</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>supports</i></b> <b style='color:DodgerBlue;'><i>drug</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>this</i></b> <b style='color:DodgerBlue;'><i>setting</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"EVERLAR","start":4,"end":11,"id":1,"ws":true},{"text":"study","start":12,"end":17,"id":2,"ws":true},{"text":"reports","start":18,"end":25,"id":3,"ws":true},{"text":"prospective","start":26,"end":37,"id":4,"ws":true},{"text":"data","start":38,"end":42,"id":5,"ws":true},{"text":"of","start":43,"end":45,"id":6,"ws":true},{"text":"somatostatin","start":46,"end":58,"id":7,"ws":true},{"text":"analogue","start":59,"end":67,"id":8,"ws":true},{"text":"in","start":68,"end":70,"id":9,"ws":true},{"text":"combination","start":71,"end":82,"id":10,"ws":true},{"text":"with","start":83,"end":87,"id":11,"ws":true},{"text":"everolimus","start":88,"end":98,"id":12,"ws":true},{"text":"in","start":99,"end":101,"id":13,"ws":true},{"text":"nonfunctioning","start":102,"end":116,"id":14,"ws":true},{"text":"gastrointestinal","start":117,"end":133,"id":15,"ws":true},{"text":"neuroendocrine","start":134,"end":148,"id":16,"ws":true},{"text":"tumors","start":149,"end":155,"id":17,"ws":true},{"text":"suggesting","start":156,"end":166,"id":18,"ws":true},{"text":"meaningful","start":167,"end":177,"id":19,"ws":true},{"text":"activity","start":178,"end":186,"id":20,"ws":true},{"text":"and","start":187,"end":190,"id":21,"ws":true},{"text":"favorable","start":191,"end":200,"id":22,"ws":true},{"text":"toxicity","start":201,"end":209,"id":23,"ws":true},{"text":"profile","start":210,"end":217,"id":24,"ws":true},{"text":"that","start":218,"end":222,"id":25,"ws":true},{"text":"supports","start":223,"end":231,"id":26,"ws":true},{"text":"drug","start":232,"end":236,"id":27,"ws":true},{"text":"combination","start":237,"end":248,"id":28,"ws":true},{"text":"in","start":249,"end":251,"id":29,"ws":true},{"text":"this","start":252,"end":256,"id":30,"ws":true},{"text":"setting","start":257,"end":264,"id":31,"ws":true},{"text":".","start":265,"end":266,"id":32,"ws":false}],"spans":[{"start":46,"end":58,"token_start":7,"token_end":7,"label":"DRUG"},{"start":88,"end":98,"token_start":12,"token_end":12,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29794066/","_input_hash":-793143143,"_task_hash":-208776702,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":7,"child":12,"head_span":{"start":46,"end":58,"token_start":7,"token_end":7,"label":"DRUG"},"child_span":{"start":88,"end":98,"token_start":12,"token_end":12,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Synergism between anti-HER2 monoclonal antibody ( trastuzumab ) and paclitaxel has been shown in vitro and in vivo .","paragraph":"<h3><u>Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.</u></h3> <b style='color:DodgerBlue;'><i>Synergism</i></b> <b style='color:DodgerBlue;'><i>between</i></b> <b style='color:DodgerBlue;'><i>anti-HER2</i></b> <b style='color:DodgerBlue;'><i>monoclonal</i></b> <b style='color:DodgerBlue;'><i>antibody</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>been</i></b> <b style='color:DodgerBlue;'><i>shown</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vitro</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>vivo</i></b> <b style='color:DodgerBlue;'><i>.</i></b> In previous experiences, weekly administration of <b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> has shown significant activity in metastatic breast cancer. In this phase II study, we evaluated the activity and the toxicity of this weekly regimen in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Between November 1999 and July 2001, 25 patients were treated with <b style='color:Tomato;'><i>trastuzumab</i></b> (4 mg kg(-1) i.v. loading dose followed by 2 mg kg(-1) i.v. week(-1)) and <b style='color:Tomato;'><i>paclitaxel</i></b> (60-90 mg m(-2) h(-1) i.v. infusion week(-1)). The treatment was planned to continue until disease progression or prohibitive toxicity; in patients with responsive or stable disease, after 6 months of therapy, the decision to stop <b style='color:Tomato;'><i>paclitaxel</i></b> while continuing weekly <b style='color:Tomato;'><i>trastuzumab</i></b> was left to the physicians' judgement. At the median follow-up of 19.6 months (range 9.2-38.1), all patients are evaluable for response and toxicity. We obtained four (16%) complete responses (CR), 10 (40%) partial responses (PR), four (16%) stable diseases and seven (28%) disease progressions. The response rate (CR+PR) was 56% (95% CI, 36.5-75.5%). The median duration of response was 10.4 months (range 4.1-24.2+). Median time to progression was 8.6 months (range 2.5-24.2+). The toxicity was mild; five patients experienced fever and chills during the first infusion of <b style='color:Tomato;'><i>trastuzumab</i></b> (20%); leukopenia grade 2 was recorded in one patient (4%). Two patients (8%) came off study for grade 3 cardiotoxicity (after 9 and 17 weeks of treatment, respectively): both had already received anthracyclines and taxanes. Onycholysis grade 2 was observed in five patients (20%). These results confirm that weekly administration of <b style='color:Tomato;'><i>trastuzumab</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> is active in anthracycline- and taxane-pretreated metastatic breast cancer patients HER2-overexpressing. Since cardiac disfunctions grade 3 were observed (8%), we recommend that cardiac function should be monitored in these patients.","tokens":[{"text":"Synergism","start":0,"end":9,"id":0,"ws":true},{"text":"between","start":10,"end":17,"id":1,"ws":true},{"text":"anti-HER2","start":18,"end":27,"id":2,"ws":true},{"text":"monoclonal","start":28,"end":38,"id":3,"ws":true},{"text":"antibody","start":39,"end":47,"id":4,"ws":true},{"text":"(","start":48,"end":49,"id":5,"ws":true},{"text":"trastuzumab","start":50,"end":61,"id":6,"ws":true},{"text":")","start":62,"end":63,"id":7,"ws":true},{"text":"and","start":64,"end":67,"id":8,"ws":true},{"text":"paclitaxel","start":68,"end":78,"id":9,"ws":true},{"text":"has","start":79,"end":82,"id":10,"ws":true},{"text":"been","start":83,"end":87,"id":11,"ws":true},{"text":"shown","start":88,"end":93,"id":12,"ws":true},{"text":"in","start":94,"end":96,"id":13,"ws":true},{"text":"vitro","start":97,"end":102,"id":14,"ws":true},{"text":"and","start":103,"end":106,"id":15,"ws":true},{"text":"in","start":107,"end":109,"id":16,"ws":true},{"text":"vivo","start":110,"end":114,"id":17,"ws":true},{"text":".","start":115,"end":116,"id":18,"ws":false}],"spans":[{"start":50,"end":61,"token_start":6,"token_end":6,"label":"DRUG"},{"start":68,"end":78,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/14710203/","_input_hash":-1410452084,"_task_hash":-440081934,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[{"head":6,"child":9,"head_span":{"start":50,"end":61,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":68,"end":78,"token_start":9,"token_end":9,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Between September 1998 and December 1999 , we treated 25 patients at risk for post-operative renal dysfunction ( high-risk basiliximab group ) with the new induction regimen and another 33 patients not at risk ( low-risk CsA group ) for renal dysfunction with our standard cyclosporine protocol .","paragraph":"<h3><u>Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation.</u></h3><b style='color:Tomato;'><i>cyclosporin</i></b>e (CsA) is frequently initiated as induction therapy in patients undergoing orthotopic heart transplantation, but our experience has identified a significant rate of post-operative renal dysfunction. We therefore devised a renal-sparing <b style='color:Tomato;'><i>cyclosporin</i></b>e-free induction regimen consisting of the early administration <b style='color:Tomato;'><i>basiliximab</i></b>, an interleukin-2 receptor monoclonal antibody, followed by the late initiation of <b style='color:Tomato;'><i>cyclosporin</i></b>e on post-operative Day 4. ### methods <b style='color:DodgerBlue;'><i>Between</i></b> <b style='color:DodgerBlue;'><i>September</i></b> <b style='color:DodgerBlue;'><i>1998</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>December</i></b> <b style='color:DodgerBlue;'><i>1999</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>we</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>25</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>post-operative</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>dysfunction</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>high-risk</i></b> <b style='color:MediumOrchid;'><i>basiliximab</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>another</i></b> <b style='color:DodgerBlue;'><i>33</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>risk</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>low-risk</i></b> <b style='color:DodgerBlue;'><i>CsA</i></b> <b style='color:DodgerBlue;'><i>group</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>dysfunction</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>our</i></b> <b style='color:DodgerBlue;'><i>standard</i></b> <b style='color:MediumOrchid;'><i>cyclosporine</i></b> <b style='color:DodgerBlue;'><i>protocol</i></b> <b style='color:DodgerBlue;'><i>.</i></b> We identified a historical control group (1996 through 1998) of 32 patients at risk for renal dysfunction (high-risk CsA group) who had received our standard <b style='color:Tomato;'><i>cyclosporin</i></b>e protocol. ### results The increase in serum creatinine levels after transplantation was less in the high-risk <b style='color:Tomato;'><i>basiliximab</i></b> group (-0.1 +/- 0.7) than in the high-risk CsA group (0.5 +/- 1.0, p < 0.02) and comparable to the low-risk CsA group (0.03 +/- 0.6). The <b style='color:Tomato;'><i>basiliximab</i></b> protocol did not increase rejection; the percentage of rejection episodes was high-risk <b style='color:Tomato;'><i>basiliximab</i></b>, 0; high-risk CsA, 13; and low-risk CsA, 3 (p = .13). ### conclusion <b style='color:Tomato;'><i>basiliximab</i></b> induction therapy allows delayed initiation of <b style='color:Tomato;'><i>cyclosporin</i></b>e after cardiac transplantation without an increase in rejection and reduces the risk of post-operative renal dysfunction.","tokens":[{"text":"Between","start":0,"end":7,"id":0,"ws":true},{"text":"September","start":8,"end":17,"id":1,"ws":true},{"text":"1998","start":18,"end":22,"id":2,"ws":true},{"text":"and","start":23,"end":26,"id":3,"ws":true},{"text":"December","start":27,"end":35,"id":4,"ws":true},{"text":"1999","start":36,"end":40,"id":5,"ws":true},{"text":",","start":41,"end":42,"id":6,"ws":true},{"text":"we","start":43,"end":45,"id":7,"ws":true},{"text":"treated","start":46,"end":53,"id":8,"ws":true},{"text":"25","start":54,"end":56,"id":9,"ws":true},{"text":"patients","start":57,"end":65,"id":10,"ws":true},{"text":"at","start":66,"end":68,"id":11,"ws":true},{"text":"risk","start":69,"end":73,"id":12,"ws":true},{"text":"for","start":74,"end":77,"id":13,"ws":true},{"text":"post-operative","start":78,"end":92,"id":14,"ws":true},{"text":"renal","start":93,"end":98,"id":15,"ws":true},{"text":"dysfunction","start":99,"end":110,"id":16,"ws":true},{"text":"(","start":111,"end":112,"id":17,"ws":true},{"text":"high-risk","start":113,"end":122,"id":18,"ws":true},{"text":"basiliximab","start":123,"end":134,"id":19,"ws":true},{"text":"group","start":135,"end":140,"id":20,"ws":true},{"text":")","start":141,"end":142,"id":21,"ws":true},{"text":"with","start":143,"end":147,"id":22,"ws":true},{"text":"the","start":148,"end":151,"id":23,"ws":true},{"text":"new","start":152,"end":155,"id":24,"ws":true},{"text":"induction","start":156,"end":165,"id":25,"ws":true},{"text":"regimen","start":166,"end":173,"id":26,"ws":true},{"text":"and","start":174,"end":177,"id":27,"ws":true},{"text":"another","start":178,"end":185,"id":28,"ws":true},{"text":"33","start":186,"end":188,"id":29,"ws":true},{"text":"patients","start":189,"end":197,"id":30,"ws":true},{"text":"not","start":198,"end":201,"id":31,"ws":true},{"text":"at","start":202,"end":204,"id":32,"ws":true},{"text":"risk","start":205,"end":209,"id":33,"ws":true},{"text":"(","start":210,"end":211,"id":34,"ws":true},{"text":"low-risk","start":212,"end":220,"id":35,"ws":true},{"text":"CsA","start":221,"end":224,"id":36,"ws":true},{"text":"group","start":225,"end":230,"id":37,"ws":true},{"text":")","start":231,"end":232,"id":38,"ws":true},{"text":"for","start":233,"end":236,"id":39,"ws":true},{"text":"renal","start":237,"end":242,"id":40,"ws":true},{"text":"dysfunction","start":243,"end":254,"id":41,"ws":true},{"text":"with","start":255,"end":259,"id":42,"ws":true},{"text":"our","start":260,"end":263,"id":43,"ws":true},{"text":"standard","start":264,"end":272,"id":44,"ws":true},{"text":"cyclosporine","start":273,"end":285,"id":45,"ws":true},{"text":"protocol","start":286,"end":294,"id":46,"ws":true},{"text":".","start":295,"end":296,"id":47,"ws":false}],"spans":[{"start":123,"end":134,"token_start":19,"token_end":19,"label":"DRUG"},{"start":273,"end":285,"token_start":45,"token_end":45,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16143252/","_input_hash":-842226561,"_task_hash":-651892887,"_session_id":"drug_drug_pilot_split2c-maytal","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Changes</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>absorption</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cholesterol</i></b> <b style='color:DodgerBlue;'><i>synthesis</i></b> <b style='color:DodgerBlue;'><i>caused</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:MediumOrchid;'><i>ezetimibe</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:MediumOrchid;'><i>simvastatin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>men</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>This study evaluates changes in cholesterol balance in hypercholesterolemic subjects following treatment with an inhibitor of cholesterol absorption or cholesterol synthesis or coadministration of both agents. This was a randomized, double blind, placebo-controlled, four-period crossover study to evaluate the effects of coadministering 10 mg <b style='color:Tomato;'><i>ezetimibe</i></b> with 20 mg <b style='color:Tomato;'><i>simvastatin</i></b> (<b style='color:Tomato;'><i>ezetimibe</i></b>/<b style='color:Tomato;'><i>simvastatin</i></b>) on cholesterol absorption and synthesis relative to either drug alone or placebo in 41 subjects. Each treatment period lasted 7 weeks. <b style='color:Tomato;'><i>ezetimibe</i></b> and <b style='color:Tomato;'><i>ezetimibe</i></b>/<b style='color:Tomato;'><i>simvastatin</i></b> decreased fractional cholesterol absorption by 65% and 59%, respectively (P < 0.001 for both relative to placebo). <b style='color:Tomato;'><i>simvastatin</i></b> did not significantly affect cholesterol absorption. <b style='color:Tomato;'><i>ezetimibe</i></b> and <b style='color:Tomato;'><i>ezetimibe</i></b>/<b style='color:Tomato;'><i>simvastatin</i></b> increased fecal sterol excretion (corrected for dietary cholesterol), which also represents net steady state cholesterol synthesis, by 109% and 79%, respectively (P < 0.001). <b style='color:Tomato;'><i>ezetimibe</i></b>, <b style='color:Tomato;'><i>simvastatin</i></b>, and <b style='color:Tomato;'><i>ezetimibe</i></b>/<b style='color:Tomato;'><i>simvastatin</i></b> decreased plasma LDL-cholesterol by 20, 38, and 55%, respectively. The coadministered therapy was well tolerated. The decreases in net cholesterol synthesis and increased fecal sterol excretion yielded nearly additive reductions in LDL-cholesterol for the coadministration of <b style='color:Tomato;'><i>ezetimibe</i></b> and <b style='color:Tomato;'><i>simvastatin</i></b>.","tokens":[{"text":"Changes","start":0,"end":7,"id":0,"ws":true},{"text":"in","start":8,"end":10,"id":1,"ws":true},{"text":"cholesterol","start":11,"end":22,"id":2,"ws":true},{"text":"absorption","start":23,"end":33,"id":3,"ws":true},{"text":"and","start":34,"end":37,"id":4,"ws":true},{"text":"cholesterol","start":38,"end":49,"id":5,"ws":true},{"text":"synthesis","start":50,"end":59,"id":6,"ws":true},{"text":"caused","start":60,"end":66,"id":7,"ws":true},{"text":"by","start":67,"end":69,"id":8,"ws":true},{"text":"ezetimibe","start":70,"end":79,"id":9,"ws":true},{"text":"and/or","start":80,"end":86,"id":10,"ws":true},{"text":"simvastatin","start":87,"end":98,"id":11,"ws":true},{"text":"in","start":99,"end":101,"id":12,"ws":true},{"text":"men","start":102,"end":105,"id":13,"ws":true},{"text":".","start":106,"end":107,"id":14,"ws":false}],"spans":[{"start":70,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},{"start":87,"end":98,"token_start":11,"token_end":11,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19380898/","_input_hash":2060678417,"_task_hash":-580376587,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":9,"child":11,"head_span":{"start":70,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},"child_span":{"start":87,"end":98,"token_start":11,"token_end":11,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The US government regulated precursor chemicals , ephedrine and pseudoephedrine , multiple times to limit methamphetamine production/availability and thus methamphetamine problems .","paragraph":"<h3><u>Impacts of federal precursor chemical regulations on methamphetamine arrests.</u></h3> <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>US</i></b> <b style='color:DodgerBlue;'><i>government</i></b> <b style='color:DodgerBlue;'><i>regulated</i></b> <b style='color:DodgerBlue;'><i>precursor</i></b> <b style='color:DodgerBlue;'><i>chemicals</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ephedrine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>pseudoephedrine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>times</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>limit</i></b> <b style='color:MediumOrchid;'><i>methamphetamine</i></b> <b style='color:DodgerBlue;'><i>production/availability</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>thus</i></b> <b style='color:MediumOrchid;'><i>methamphetamine</i></b> <b style='color:DodgerBlue;'><i>problems</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Research has found that the regulations reduced <b style='color:Tomato;'><i>methamphetamine</i></b> hospital admissions, but authors have argued that other problems were unaffected. This study examines whether the regulations impacted <b style='color:Tomato;'><i>methamphetamine</i></b> arrests. ### design ARIMA-intervention time-series analysis with control series. ### setting California (1982-2001). ### measurements Dependent variable series: monthly <b style='color:Tomato;'><i>methamphetamine</i></b> arrests. Control series: monthly marijuana arrests and cocaine/heroin arrests. ### interventions Bulk powder ephedrine and <b style='color:Tomato;'><i>pseudoephedrine</i></b>: regulated November 1989. Products containing ephedrine as the single active medicinal ingredient: regulated August 1995. <b style='color:Tomato;'><i>pseudoephedrine</i></b> products: regulated October 1997. Large-scale producers used ephedrine and <b style='color:Tomato;'><i>pseudoephedrine</i></b> in these forms. Ephedrine combined with other active medicinal ingredients (e.g. various cold medicines)-used mainly by small-scale producers: regulated October 1996. ### findings The regulation targeting small-scale producers (1996) had no significant impact. In contrast, <b style='color:Tomato;'><i>methamphetamine</i></b> arrests stopped rising and dropped 31% to 45% each of the three times precursor chemicals used by large-scale producers were regulated. Within 3 years of the bulk powder regulation (1989) and again within 2 years of the ephedrine single ingredient regulation (1995), arrests fully rebounded. During the 4 years following the last regulation (<b style='color:Tomato;'><i>pseudoephedrine</i></b> products, 1997) arrests only partially rebounded. These effects parallel those reported on hospital admissions. The control series were generally unaffected. ### conclusions Precursor regulations targeting large-scale producers impacted <b style='color:Tomato;'><i>methamphetamine</i></b> arrests, a criminal justice problem, much as they impacted the public health problem of <b style='color:Tomato;'><i>methamphetamine</i></b> hospital admissions. Ongoing research is needed to determine whether these problems eventually fully rebound from the last regulation.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"US","start":4,"end":6,"id":1,"ws":true},{"text":"government","start":7,"end":17,"id":2,"ws":true},{"text":"regulated","start":18,"end":27,"id":3,"ws":true},{"text":"precursor","start":28,"end":37,"id":4,"ws":true},{"text":"chemicals","start":38,"end":47,"id":5,"ws":true},{"text":",","start":48,"end":49,"id":6,"ws":true},{"text":"ephedrine","start":50,"end":59,"id":7,"ws":true},{"text":"and","start":60,"end":63,"id":8,"ws":true},{"text":"pseudoephedrine","start":64,"end":79,"id":9,"ws":true},{"text":",","start":80,"end":81,"id":10,"ws":true},{"text":"multiple","start":82,"end":90,"id":11,"ws":true},{"text":"times","start":91,"end":96,"id":12,"ws":true},{"text":"to","start":97,"end":99,"id":13,"ws":true},{"text":"limit","start":100,"end":105,"id":14,"ws":true},{"text":"methamphetamine","start":106,"end":121,"id":15,"ws":true},{"text":"production/availability","start":122,"end":145,"id":16,"ws":true},{"text":"and","start":146,"end":149,"id":17,"ws":true},{"text":"thus","start":150,"end":154,"id":18,"ws":true},{"text":"methamphetamine","start":155,"end":170,"id":19,"ws":true},{"text":"problems","start":171,"end":179,"id":20,"ws":true},{"text":".","start":180,"end":181,"id":21,"ws":false}],"spans":[{"start":64,"end":79,"token_start":9,"token_end":9,"label":"DRUG"},{"start":106,"end":121,"token_start":15,"token_end":15,"label":"DRUG"},{"start":155,"end":170,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15784062/","_input_hash":-629534182,"_task_hash":-1189202745,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We now present the long-term follow-up findings of a randomized phase III study on the addition of six cycles of procarbazine , lomustine , and vincristine ( PCV ) chemotherapy to radiotherapy ( RT ) .","paragraph":"<h3><u>Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.</u></h3>Anaplastic oligodendroglioma are chemotherapy-sensitive tumors. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>now</i></b> <b style='color:DodgerBlue;'><i>present</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>long-term</i></b> <b style='color:DodgerBlue;'><i>follow-up</i></b> <b style='color:DodgerBlue;'><i>findings</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>six</i></b> <b style='color:DodgerBlue;'><i>cycles</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>procarbazine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>lomustine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PCV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>RT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### Patients And Methods Adult patients with newly diagnosed anaplastic oligodendroglial tumors were randomly assigned to either 59.4 Gy of RT or the same RT followed by six cycles of adjuvant PCV. An exploratory analysis of the correlation between 1p/19q status and survival was part of the study. Retrospectively, the methylation status of the methyl-guanine methyl transferase gene promoter and the mutational status of the isocitrate dehydrogenase (IDH) gene were determined. The primary end points were overall survival (OS) and progression-free survival based on intent-to-treat analysis. ### results A total of 368 patients were enrolled. With a median follow-up of 140 months, OS in the RT/PCV arm was significantly longer (42.3 v 30.6 months in the RT arm, hazard ratio [HR], 0.75; 95% CI, 0.60 to 0.95). In the 80 patients with a 1p/19q codeletion, OS was increased, with a trend toward more benefit from adjuvant PCV (OS not reached in the RT/PCV group v 112 months in the RT group; HR, 0.56; 95% CI, 0.31 to 1.03). IDH mutational status was also of prognostic significance. ### conclusion The addition of six cycles of PCV after 59.4 Gy of RT increases both OS and PFS in anaplastic oligodendroglial tumors. 1p/19q-codeleted tumors derive more benefit from adjuvant PCV compared with non-1p/19q-deleted tumors.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"now","start":3,"end":6,"id":1,"ws":true},{"text":"present","start":7,"end":14,"id":2,"ws":true},{"text":"the","start":15,"end":18,"id":3,"ws":true},{"text":"long-term","start":19,"end":28,"id":4,"ws":true},{"text":"follow-up","start":29,"end":38,"id":5,"ws":true},{"text":"findings","start":39,"end":47,"id":6,"ws":true},{"text":"of","start":48,"end":50,"id":7,"ws":true},{"text":"a","start":51,"end":52,"id":8,"ws":true},{"text":"randomized","start":53,"end":63,"id":9,"ws":true},{"text":"phase","start":64,"end":69,"id":10,"ws":true},{"text":"III","start":70,"end":73,"id":11,"ws":true},{"text":"study","start":74,"end":79,"id":12,"ws":true},{"text":"on","start":80,"end":82,"id":13,"ws":true},{"text":"the","start":83,"end":86,"id":14,"ws":true},{"text":"addition","start":87,"end":95,"id":15,"ws":true},{"text":"of","start":96,"end":98,"id":16,"ws":true},{"text":"six","start":99,"end":102,"id":17,"ws":true},{"text":"cycles","start":103,"end":109,"id":18,"ws":true},{"text":"of","start":110,"end":112,"id":19,"ws":true},{"text":"procarbazine","start":113,"end":125,"id":20,"ws":true},{"text":",","start":126,"end":127,"id":21,"ws":true},{"text":"lomustine","start":128,"end":137,"id":22,"ws":true},{"text":",","start":138,"end":139,"id":23,"ws":true},{"text":"and","start":140,"end":143,"id":24,"ws":true},{"text":"vincristine","start":144,"end":155,"id":25,"ws":true},{"text":"(","start":156,"end":157,"id":26,"ws":true},{"text":"PCV","start":158,"end":161,"id":27,"ws":true},{"text":")","start":162,"end":163,"id":28,"ws":true},{"text":"chemotherapy","start":164,"end":176,"id":29,"ws":true},{"text":"to","start":177,"end":179,"id":30,"ws":true},{"text":"radiotherapy","start":180,"end":192,"id":31,"ws":true},{"text":"(","start":193,"end":194,"id":32,"ws":true},{"text":"RT","start":195,"end":197,"id":33,"ws":true},{"text":")","start":198,"end":199,"id":34,"ws":true},{"text":".","start":200,"end":201,"id":35,"ws":false}],"spans":[{"start":113,"end":125,"token_start":20,"token_end":20,"label":"DRUG"},{"start":128,"end":137,"token_start":22,"token_end":22,"label":"DRUG"},{"start":144,"end":155,"token_start":25,"token_end":25,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/23071237/","_input_hash":1994652939,"_task_hash":-432329763,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":113,"end":125,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":128,"end":137,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":25,"child":22,"head_span":{"start":144,"end":155,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":128,"end":137,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":25,"child":31,"head_span":{"start":144,"end":155,"token_start":25,"token_end":25,"label":"DRUG"},"child_span":{"start":180,"end":192,"token_start":31,"token_end":31,"label":null},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"A phase II clinical trial was conducted to evaluate the efficacy and toxicity of vinorelbine plus gemcitabine in very old patients with inoperable ( stage IIIb or IV ) NSCLC .","paragraph":"<h3><u>A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older.</u></h3><b style='color:Tomato;'><i>vinorelbine</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> are two active single agents with mild toxicity profiles that are used in the treatment of non-small-cell lung cancer (NSCLC). Whether or not very old NSCLC patients, such as those aged 80 years or older, should still be considered for chemotherapy is unknown, since their response to the treatment is also unknown. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>conducted</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>evaluate</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>efficacy</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>toxicity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>vinorelbine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>very</i></b> <b style='color:DodgerBlue;'><i>old</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>inoperable</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>stage</i></b> <b style='color:DodgerBlue;'><i>IIIb</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>IV</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>NSCLC</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:Tomato;'><i>vinorelbine</i></b> 20 mg/m(2) was given as a 10-min intravenous infusion, followed by a 30-min intravenous infusion of <b style='color:Tomato;'><i>gemcitabine</i></b> 800 mg/m(2) on days 1, 8, and 15 of each 28-day cycle. From March 1998 to December 2001, 20 patients (16 males, four females) were enrolled in the study. The median age was 83 years, within the range 80-88 years. The median number of treatment cycles per patient was four. With the exception of one, all patients received at least two cycles of treatment. Thirteen patients achieved a partial response, with an overall response rate of 65% (95% confidence interval, 44.1-85.9%). Median survival was 10 months. The significant (WHO grade 3/4) toxicities were myelosuppression, including leukopenia in five (25%) patients, neutropenia in eight (40%), anaemia in six (30%), and thrombocytopenia in three (15%) patients. Febrile neutropenia occurred in two patients and accounted for one treatment-related death. Non-haematological toxicity was generally mild, except one patient who suffered from grade 3 interstitial pneumonitis. Another patient suffered from a cerebral infarction after three cycles of treatment. In conclusion, the combination of <b style='color:Tomato;'><i>vinorelbine</i></b> and <b style='color:Tomato;'><i>gemcitabine</i></b> in very old patients with advanced NSCLC is a highly active regimen with an acceptable toxicity profile.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"phase","start":2,"end":7,"id":1,"ws":true},{"text":"II","start":8,"end":10,"id":2,"ws":true},{"text":"clinical","start":11,"end":19,"id":3,"ws":true},{"text":"trial","start":20,"end":25,"id":4,"ws":true},{"text":"was","start":26,"end":29,"id":5,"ws":true},{"text":"conducted","start":30,"end":39,"id":6,"ws":true},{"text":"to","start":40,"end":42,"id":7,"ws":true},{"text":"evaluate","start":43,"end":51,"id":8,"ws":true},{"text":"the","start":52,"end":55,"id":9,"ws":true},{"text":"efficacy","start":56,"end":64,"id":10,"ws":true},{"text":"and","start":65,"end":68,"id":11,"ws":true},{"text":"toxicity","start":69,"end":77,"id":12,"ws":true},{"text":"of","start":78,"end":80,"id":13,"ws":true},{"text":"vinorelbine","start":81,"end":92,"id":14,"ws":true},{"text":"plus","start":93,"end":97,"id":15,"ws":true},{"text":"gemcitabine","start":98,"end":109,"id":16,"ws":true},{"text":"in","start":110,"end":112,"id":17,"ws":true},{"text":"very","start":113,"end":117,"id":18,"ws":true},{"text":"old","start":118,"end":121,"id":19,"ws":true},{"text":"patients","start":122,"end":130,"id":20,"ws":true},{"text":"with","start":131,"end":135,"id":21,"ws":true},{"text":"inoperable","start":136,"end":146,"id":22,"ws":true},{"text":"(","start":147,"end":148,"id":23,"ws":true},{"text":"stage","start":149,"end":154,"id":24,"ws":true},{"text":"IIIb","start":155,"end":159,"id":25,"ws":true},{"text":"or","start":160,"end":162,"id":26,"ws":true},{"text":"IV","start":163,"end":165,"id":27,"ws":true},{"text":")","start":166,"end":167,"id":28,"ws":true},{"text":"NSCLC","start":168,"end":173,"id":29,"ws":true},{"text":".","start":174,"end":175,"id":30,"ws":false}],"spans":[{"start":81,"end":92,"token_start":14,"token_end":14,"label":"DRUG"},{"start":98,"end":109,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/12711125/","_input_hash":2080813707,"_task_hash":-1542936782,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":81,"end":92,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":98,"end":109,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Tobramycin was probably less effective than gentamicin in combination with the penicillinase-resistant penicillins against enterococci .","paragraph":"<h3><u>Comparative in vitro activity of nafcillin, oxacillin, and methicillin in combination with gentamicin and tobramycin against enterococci.</u></h3>The in vitro activity of <b style='color:Tomato;'><i>nafcillin</i></b>, <b style='color:Tomato;'><i>oxacillin</i></b>, and methicillin alone and in combination with <b style='color:Tomato;'><i>gentamicin</i></b> and <b style='color:Tomato;'><i>tobramycin</i></b> against 30 strains of enterococci was investigated. The penicillinase-resistant penicillins were less active than penicillin and <b style='color:Tomato;'><i>ampicillin</i></b> against the enterococci. <b style='color:Tomato;'><i>nafcillin</i></b> was more active than <b style='color:Tomato;'><i>oxacillin</i></b> and methicillin. Sixty-six percent of strains were inhibited by <b style='color:Tomato;'><i>nafcillin</i></b> at 6.25 mug/ml, but none was inhibited by <b style='color:Tomato;'><i>oxacillin</i></b> and methicillin at the same concentration. At 12.5 mug/ml, 83, 16, and 0% were inhibited by <b style='color:Tomato;'><i>nafcillin</i></b>, <b style='color:Tomato;'><i>oxacillin</i></b>, and methicillin, respectively. By using a variety of criteria and analyses, it was shown that none of the antibiotic combinations studied demonstrated enhanced killing of all strains of enterococci. <b style='color:Tomato;'><i>nafcillin</i></b>-<b style='color:Tomato;'><i>gentamicin</i></b> was the best combination, and enhanced killing was demonstrated against most strains. <b style='color:Tomato;'><i>oxacillin</i></b> was more effective than methicillin when combined with <b style='color:Tomato;'><i>gentamicin</i></b>. <b style='color:MediumOrchid;'><i>Tobramycin</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>probably</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>effective</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>gentamicin</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>penicillinase-resistant</i></b> <b style='color:DodgerBlue;'><i>penicillins</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>enterococci</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"Tobramycin","start":0,"end":10,"id":0,"ws":true},{"text":"was","start":11,"end":14,"id":1,"ws":true},{"text":"probably","start":15,"end":23,"id":2,"ws":true},{"text":"less","start":24,"end":28,"id":3,"ws":true},{"text":"effective","start":29,"end":38,"id":4,"ws":true},{"text":"than","start":39,"end":43,"id":5,"ws":true},{"text":"gentamicin","start":44,"end":54,"id":6,"ws":true},{"text":"in","start":55,"end":57,"id":7,"ws":true},{"text":"combination","start":58,"end":69,"id":8,"ws":true},{"text":"with","start":70,"end":74,"id":9,"ws":true},{"text":"the","start":75,"end":78,"id":10,"ws":true},{"text":"penicillinase-resistant","start":79,"end":102,"id":11,"ws":true},{"text":"penicillins","start":103,"end":114,"id":12,"ws":true},{"text":"against","start":115,"end":122,"id":13,"ws":true},{"text":"enterococci","start":123,"end":134,"id":14,"ws":true},{"text":".","start":135,"end":136,"id":15,"ws":false}],"spans":[{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},{"start":44,"end":54,"token_start":6,"token_end":6,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/836017/","_input_hash":611981779,"_task_hash":1981686877,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[{"head":6,"child":12,"head_span":{"start":44,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":103,"end":114,"token_start":12,"token_end":12,"label":null},"color":"#c5bdf4","label":"POS1"},{"head":0,"child":12,"head_span":{"start":0,"end":10,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":103,"end":114,"token_start":12,"token_end":12,"label":null},"color":"#96e8ce","label":"COMB1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Despite the absence of strong data , entecavir and telbivudine seem to be the preferred options for nucleoside analogue-naive CHB patients with chronic kidney disease , depending on viraemia and severity of renal dysfunction .","paragraph":"<h3><u>Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.</u></h3>The treatment of chronic hepatitis B (CHB) in patients with chronic kidney disease (CKD) is based on nucleoside (<b style='color:Tomato;'><i>lamivudine</i></b>, <b style='color:Tomato;'><i>telbivudine</i></b>, <b style='color:Tomato;'><i>entecavir</i></b>) or nucleotide (<b style='color:Tomato;'><i>adefovir</i></b>, <b style='color:Tomato;'><i>tenofovir</i></b>) analogues (NAs), but it may be complex and the information is scarce. <b style='color:Tomato;'><i>entecavir</i></b> and <b style='color:Tomato;'><i>tenofovir</i></b> represent the currently recommended first-line NAs for NA-naive CHB patients, while <b style='color:Tomato;'><i>tenofovir</i></b> is the NA of choice for CHB patients with resistance to nucleosides. ### aim To review the efficacy and safety of NAs in adult CHB patients with CKD and to provide reasonable recommendations for their optimal management. ### methods Literature search in PubMed/Medline and manual search of relevant articles, reviews and book chapters. ### results NAs are cleared by kidneys and their dosage should be adjusted in patients with creatinine clearance <50\u00a0mL/min. There are concerns about nephrotoxic potential of the nucleotides, particularly <b style='color:Tomato;'><i>adefovir</i></b>, while improvements of creatinine clearance have been reported under <b style='color:Tomato;'><i>telbivudine</i></b>. Most existing data in CHB patients with CKD are for <b style='color:Tomato;'><i>lamivudine</i></b> and, less frequently, for other NAs, mostly <b style='color:Tomato;'><i>entecavir</i></b>. Besides CHB, NA should be used in case of immunosuppressive therapy in any HBsAg-positive patient with CKD including renal transplant (RT) recipients and in anti-HBs-positive recipients of kidney grafts from HBsAg-positive donors. ### conclusions Chronic hepatitis B patients with chronic kidney disease receiving nucleoside analogues should be followed carefully for treatment efficacy and renal safety. <b style='color:DodgerBlue;'><i>Despite</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>absence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>strong</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>entecavir</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>telbivudine</i></b> <b style='color:DodgerBlue;'><i>seem</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>preferred</i></b> <b style='color:DodgerBlue;'><i>options</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>nucleoside</i></b> <b style='color:DodgerBlue;'><i>analogue-naive</i></b> <b style='color:DodgerBlue;'><i>CHB</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>chronic</i></b> <b style='color:DodgerBlue;'><i>kidney</i></b> <b style='color:DodgerBlue;'><i>disease</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>depending</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>viraemia</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>severity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>renal</i></b> <b style='color:DodgerBlue;'><i>dysfunction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> More studies are certainly needed in this setting.","tokens":[{"text":"Despite","start":0,"end":7,"id":0,"ws":true},{"text":"the","start":8,"end":11,"id":1,"ws":true},{"text":"absence","start":12,"end":19,"id":2,"ws":true},{"text":"of","start":20,"end":22,"id":3,"ws":true},{"text":"strong","start":23,"end":29,"id":4,"ws":true},{"text":"data","start":30,"end":34,"id":5,"ws":true},{"text":",","start":35,"end":36,"id":6,"ws":true},{"text":"entecavir","start":37,"end":46,"id":7,"ws":true},{"text":"and","start":47,"end":50,"id":8,"ws":true},{"text":"telbivudine","start":51,"end":62,"id":9,"ws":true},{"text":"seem","start":63,"end":67,"id":10,"ws":true},{"text":"to","start":68,"end":70,"id":11,"ws":true},{"text":"be","start":71,"end":73,"id":12,"ws":true},{"text":"the","start":74,"end":77,"id":13,"ws":true},{"text":"preferred","start":78,"end":87,"id":14,"ws":true},{"text":"options","start":88,"end":95,"id":15,"ws":true},{"text":"for","start":96,"end":99,"id":16,"ws":true},{"text":"nucleoside","start":100,"end":110,"id":17,"ws":true},{"text":"analogue-naive","start":111,"end":125,"id":18,"ws":true},{"text":"CHB","start":126,"end":129,"id":19,"ws":true},{"text":"patients","start":130,"end":138,"id":20,"ws":true},{"text":"with","start":139,"end":143,"id":21,"ws":true},{"text":"chronic","start":144,"end":151,"id":22,"ws":true},{"text":"kidney","start":152,"end":158,"id":23,"ws":true},{"text":"disease","start":159,"end":166,"id":24,"ws":true},{"text":",","start":167,"end":168,"id":25,"ws":true},{"text":"depending","start":169,"end":178,"id":26,"ws":true},{"text":"on","start":179,"end":181,"id":27,"ws":true},{"text":"viraemia","start":182,"end":190,"id":28,"ws":true},{"text":"and","start":191,"end":194,"id":29,"ws":true},{"text":"severity","start":195,"end":203,"id":30,"ws":true},{"text":"of","start":204,"end":206,"id":31,"ws":true},{"text":"renal","start":207,"end":212,"id":32,"ws":true},{"text":"dysfunction","start":213,"end":224,"id":33,"ws":true},{"text":".","start":225,"end":226,"id":34,"ws":false}],"spans":[{"start":37,"end":46,"token_start":7,"token_end":7,"label":"DRUG"},{"start":51,"end":62,"token_start":9,"token_end":9,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/24299322/","_input_hash":1590525858,"_task_hash":1765201580,"_session_id":"drug_drug_pilot_split2c-yuval","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"A randomized Phase III trial demonstrated noninferiority of APF530 500 mg SC ( granisetron 10 mg ) to intravenous palonosetron 0.25 mg in preventing CINV in patients receiving MEC or HEC in acute ( 0 - 24 hours ) and delayed ( 24 - 120 hours ) settings , with activity over 120 hours .","paragraph":"<h3><u>Biochronomer\u2122 technology and the development of APF530, a sustained release formulation of granisetron.</u></h3><b style='color:Tomato;'><i>granisetron</i></b> and other 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are first-line agents for preventing chemotherapy-induced nausea and vomiting (CINV). Current treatment guidelines prefer the longer-acting agent, <b style='color:Tomato;'><i>palonosetron</i></b>, for CINV prevention in some chemotherapy regimens. A new <b style='color:Tomato;'><i>granisetron</i></b> formulation, APF530, has been developed as an alternative long-acting agent. APF530 utilizes Biochronomer(\u2122) technology to formulate a viscous tri(ethylene glycol) poly(orthoester)-based formulation that delivers - by single subcutaneous (SC) injection - therapeutic <b style='color:Tomato;'><i>granisetron</i></b> concentrations over 5 days. The poly(orthoester) polymer family contain an orthoester linkage; these bioerodible polymer systems are specifically designed for controlled, sustained drug delivery. Pharmacokinetics and pharmacodynamics of APF530 250, 500, or 750 mg SC (<b style='color:Tomato;'><i>granisetron</i></b> 5, 10, or 15 mg, respectively) administered 30-60 minutes before chemotherapy were evaluated in two Phase II trials in cancer patients receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy. Pharmacokinetics were dose proportional, with slow <b style='color:Tomato;'><i>granisetron</i></b> absorption and elimination. Both trials demonstrated similar results for median half-life, time to maximum concentration, and exposure for APF530 250 and 500 mg, with no differences between patients receiving MEC or HEC. <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>Phase</i></b> <b style='color:DodgerBlue;'><i>III</i></b> <b style='color:DodgerBlue;'><i>trial</i></b> <b style='color:DodgerBlue;'><i>demonstrated</i></b> <b style='color:DodgerBlue;'><i>noninferiority</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>APF530</i></b> <b style='color:DodgerBlue;'><i>500</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>SC</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>granisetron</i></b> <b style='color:DodgerBlue;'><i>10</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>palonosetron</i></b> <b style='color:DodgerBlue;'><i>0.25</i></b> <b style='color:DodgerBlue;'><i>mg</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>preventing</i></b> <b style='color:DodgerBlue;'><i>CINV</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>receiving</i></b> <b style='color:DodgerBlue;'><i>MEC</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>HEC</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>acute</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>0</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>delayed</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>24</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>settings</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>over</i></b> <b style='color:DodgerBlue;'><i>120</i></b> <b style='color:DodgerBlue;'><i>hours</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Mean maximum <b style='color:Tomato;'><i>granisetron</i></b> plasma concentrations were 10.8 and 17.8 ng/mL, and mean half-lives were 30.8 and 35.9 hours after SC administration of APF530 250 and 500 mg, respectively. Therapeutic <b style='color:Tomato;'><i>granisetron</i></b> concentrations were maintained for greater than 120 hours (5 days) in both APF530 dose groups. These data suggest that APF530 - an SC-administered formulation of <b style='color:Tomato;'><i>granisetron</i></b> delivered via Biochronomer technology - represents an effective treatment option for the prevention of both acute and delayed CINV in patients receiving either MEC or HEC.","tokens":[{"text":"A","start":0,"end":1,"id":0,"ws":true},{"text":"randomized","start":2,"end":12,"id":1,"ws":true},{"text":"Phase","start":13,"end":18,"id":2,"ws":true},{"text":"III","start":19,"end":22,"id":3,"ws":true},{"text":"trial","start":23,"end":28,"id":4,"ws":true},{"text":"demonstrated","start":29,"end":41,"id":5,"ws":true},{"text":"noninferiority","start":42,"end":56,"id":6,"ws":true},{"text":"of","start":57,"end":59,"id":7,"ws":true},{"text":"APF530","start":60,"end":66,"id":8,"ws":true},{"text":"500","start":67,"end":70,"id":9,"ws":true},{"text":"mg","start":71,"end":73,"id":10,"ws":true},{"text":"SC","start":74,"end":76,"id":11,"ws":true},{"text":"(","start":77,"end":78,"id":12,"ws":true},{"text":"granisetron","start":79,"end":90,"id":13,"ws":true},{"text":"10","start":91,"end":93,"id":14,"ws":true},{"text":"mg","start":94,"end":96,"id":15,"ws":true},{"text":")","start":97,"end":98,"id":16,"ws":true},{"text":"to","start":99,"end":101,"id":17,"ws":true},{"text":"intravenous","start":102,"end":113,"id":18,"ws":true},{"text":"palonosetron","start":114,"end":126,"id":19,"ws":true},{"text":"0.25","start":127,"end":131,"id":20,"ws":true},{"text":"mg","start":132,"end":134,"id":21,"ws":true},{"text":"in","start":135,"end":137,"id":22,"ws":true},{"text":"preventing","start":138,"end":148,"id":23,"ws":true},{"text":"CINV","start":149,"end":153,"id":24,"ws":true},{"text":"in","start":154,"end":156,"id":25,"ws":true},{"text":"patients","start":157,"end":165,"id":26,"ws":true},{"text":"receiving","start":166,"end":175,"id":27,"ws":true},{"text":"MEC","start":176,"end":179,"id":28,"ws":true},{"text":"or","start":180,"end":182,"id":29,"ws":true},{"text":"HEC","start":183,"end":186,"id":30,"ws":true},{"text":"in","start":187,"end":189,"id":31,"ws":true},{"text":"acute","start":190,"end":195,"id":32,"ws":true},{"text":"(","start":196,"end":197,"id":33,"ws":true},{"text":"0","start":198,"end":199,"id":34,"ws":true},{"text":"-","start":200,"end":201,"id":35,"ws":true},{"text":"24","start":202,"end":204,"id":36,"ws":true},{"text":"hours","start":205,"end":210,"id":37,"ws":true},{"text":")","start":211,"end":212,"id":38,"ws":true},{"text":"and","start":213,"end":216,"id":39,"ws":true},{"text":"delayed","start":217,"end":224,"id":40,"ws":true},{"text":"(","start":225,"end":226,"id":41,"ws":true},{"text":"24","start":227,"end":229,"id":42,"ws":true},{"text":"-","start":230,"end":231,"id":43,"ws":true},{"text":"120","start":232,"end":235,"id":44,"ws":true},{"text":"hours","start":236,"end":241,"id":45,"ws":true},{"text":")","start":242,"end":243,"id":46,"ws":true},{"text":"settings","start":244,"end":252,"id":47,"ws":true},{"text":",","start":253,"end":254,"id":48,"ws":true},{"text":"with","start":255,"end":259,"id":49,"ws":true},{"text":"activity","start":260,"end":268,"id":50,"ws":true},{"text":"over","start":269,"end":273,"id":51,"ws":true},{"text":"120","start":274,"end":277,"id":52,"ws":true},{"text":"hours","start":278,"end":283,"id":53,"ws":true},{"text":".","start":284,"end":285,"id":54,"ws":false}],"spans":[{"start":79,"end":90,"token_start":13,"token_end":13,"label":"DRUG"},{"start":114,"end":126,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27186139/","_input_hash":710174417,"_task_hash":-2112930405,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Classical NSAIDs are still the most logical choice for agents that will slow the progression or delay the onset of AD and other neurodegenerative diseases despite failures of naproxen , celecoxib and rofecoxib in AD clinical trials .","paragraph":"<h3><u>Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease.</u></h3>Inflammation is characteristic of a broad spectrum of neurodegenerative diseases. These include Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases, amyotrophic lateral sclerosis, all of the tauopathies, multiple sclerosis and many other less common conditions. Morphologically, the level of inflammation is determined by the concentration and degree of activation of microglial cells. Biochemically, it is judged by the presence of a spectrum of inflammatory mediators. Epidemiological evidence indicates that anti-inflammatory agents such as non-steroidal anti-inflammatory drugs (NSAIDs) have a sparing effect on AD and PD indicating that inflammation exacerbates the pathology in these diseases. NSAIDs are protective in transgenic animal models of AD, providing further evidence of the negative consequences of inflammation. Here we describe an in vitro model, which was used to study the protective effects of NSAIDs in AD. This model is based on neuronal cell killing by stimulated microglia or microglia-like cells. In this model NSAIDs show protective effects at a therapeutically relevant level, which is in the low micromolar range. There are reports suggesting that NSAIDs act independently of cyclooxygenase (COX) inhibition, but only at higher doses. <b style='color:DodgerBlue;'><i>Classical</i></b> <b style='color:DodgerBlue;'><i>NSAIDs</i></b> <b style='color:DodgerBlue;'><i>are</i></b> <b style='color:DodgerBlue;'><i>still</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>most</i></b> <b style='color:DodgerBlue;'><i>logical</i></b> <b style='color:DodgerBlue;'><i>choice</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>will</i></b> <b style='color:DodgerBlue;'><i>slow</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>delay</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>onset</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>AD</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>neurodegenerative</i></b> <b style='color:DodgerBlue;'><i>diseases</i></b> <b style='color:DodgerBlue;'><i>despite</i></b> <b style='color:DodgerBlue;'><i>failures</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>naproxen</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>celecoxib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rofecoxib</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>AD</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>trials</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Several other classes of anti-inflammatory drugs have been identified as potentially beneficial in this and similar assay systems. Therefore combination therapy with other anti-inflammatory agents that work through different mechanisms of action might prove to be a superior therapeutic strategy.","tokens":[{"text":"Classical","start":0,"end":9,"id":0,"ws":true},{"text":"NSAIDs","start":10,"end":16,"id":1,"ws":true},{"text":"are","start":17,"end":20,"id":2,"ws":true},{"text":"still","start":21,"end":26,"id":3,"ws":true},{"text":"the","start":27,"end":30,"id":4,"ws":true},{"text":"most","start":31,"end":35,"id":5,"ws":true},{"text":"logical","start":36,"end":43,"id":6,"ws":true},{"text":"choice","start":44,"end":50,"id":7,"ws":true},{"text":"for","start":51,"end":54,"id":8,"ws":true},{"text":"agents","start":55,"end":61,"id":9,"ws":true},{"text":"that","start":62,"end":66,"id":10,"ws":true},{"text":"will","start":67,"end":71,"id":11,"ws":true},{"text":"slow","start":72,"end":76,"id":12,"ws":true},{"text":"the","start":77,"end":80,"id":13,"ws":true},{"text":"progression","start":81,"end":92,"id":14,"ws":true},{"text":"or","start":93,"end":95,"id":15,"ws":true},{"text":"delay","start":96,"end":101,"id":16,"ws":true},{"text":"the","start":102,"end":105,"id":17,"ws":true},{"text":"onset","start":106,"end":111,"id":18,"ws":true},{"text":"of","start":112,"end":114,"id":19,"ws":true},{"text":"AD","start":115,"end":117,"id":20,"ws":true},{"text":"and","start":118,"end":121,"id":21,"ws":true},{"text":"other","start":122,"end":127,"id":22,"ws":true},{"text":"neurodegenerative","start":128,"end":145,"id":23,"ws":true},{"text":"diseases","start":146,"end":154,"id":24,"ws":true},{"text":"despite","start":155,"end":162,"id":25,"ws":true},{"text":"failures","start":163,"end":171,"id":26,"ws":true},{"text":"of","start":172,"end":174,"id":27,"ws":true},{"text":"naproxen","start":175,"end":183,"id":28,"ws":true},{"text":",","start":184,"end":185,"id":29,"ws":true},{"text":"celecoxib","start":186,"end":195,"id":30,"ws":true},{"text":"and","start":196,"end":199,"id":31,"ws":true},{"text":"rofecoxib","start":200,"end":209,"id":32,"ws":true},{"text":"in","start":210,"end":212,"id":33,"ws":true},{"text":"AD","start":213,"end":215,"id":34,"ws":true},{"text":"clinical","start":216,"end":224,"id":35,"ws":true},{"text":"trials","start":225,"end":231,"id":36,"ws":true},{"text":".","start":232,"end":233,"id":37,"ws":false}],"spans":[{"start":175,"end":183,"token_start":28,"token_end":28,"label":"DRUG"},{"start":186,"end":195,"token_start":30,"token_end":30,"label":"DRUG"},{"start":200,"end":209,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15974901/","_input_hash":-796826148,"_task_hash":-107330078,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Between 1987 and 2003 , patients 18 years old were given adjuvant chemotherapy consisting of one of two ' paediatric ' regimens ( depending on the time of presentation ) and craniospinal local-boost radiotherapy : regimen A ( n = 12 ) , vincristine ( VCR ) , intrathecal and/or intravenous methotrexate and conventional radiotherapy ; or regimen B ( n = 11 ) sequencing intensive doses of multiple agents followed by hyperfractionated accelerated radiotherapy ( HART ) .","paragraph":"<h3><u>Survival of adults treated for medulloblastoma using paediatric protocols.</u></h3>We retrospectively studied 26 consecutive adults treated for medulloblastoma using paediatric protocols. <b style='color:DodgerBlue;'><i>Between</i></b> <b style='color:DodgerBlue;'><i>1987</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>2003</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>18</i></b> <b style='color:DodgerBlue;'><i>years</i></b> <b style='color:DodgerBlue;'><i>old</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>adjuvant</i></b> <b style='color:DodgerBlue;'><i>chemotherapy</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>one</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>two</i></b> <b style='color:DodgerBlue;'><i>'</i></b> <b style='color:DodgerBlue;'><i>paediatric</i></b> <b style='color:DodgerBlue;'><i>'</i></b> <b style='color:DodgerBlue;'><i>regimens</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>depending</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>presentation</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>craniospinal</i></b> <b style='color:DodgerBlue;'><i>local-boost</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>VCR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>intrathecal</i></b> <b style='color:DodgerBlue;'><i>and/or</i></b> <b style='color:DodgerBlue;'><i>intravenous</i></b> <b style='color:MediumOrchid;'><i>methotrexate</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>conventional</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>;</i></b> <b style='color:DodgerBlue;'><i>or</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>11</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>sequencing</i></b> <b style='color:DodgerBlue;'><i>intensive</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>multiple</i></b> <b style='color:DodgerBlue;'><i>agents</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>hyperfractionated</i></b> <b style='color:DodgerBlue;'><i>accelerated</i></b> <b style='color:DodgerBlue;'><i>radiotherapy</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>HART</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A VCR-<b style='color:Tomato;'><i>lomustine</i></b>-based maintenance followed both regimens. Three additional patients received a tailored treatment due to their impaired neurological status after surgery. The median age at diagnosis was 26 years (range 18-41 years). With a median follow-up of 46 months, 5-year disease-free and overall survival rates were 65+/-11% and 73+/-10%, respectively, for the series as a whole. All patients who received regimen B (5 of whom had metastatic Chang M2-M3 disease) are alive with no evidence of disease at 39 months. Although the number of patients is limited, our data suggest that the sandwich sequential, moderately intensive chemotherapy in combination with HART is an effective treatment for medulloblastoma in adults, and this approach seems to overcome previously-recognised risk factors.","tokens":[{"text":"Between","start":0,"end":7,"id":0,"ws":true},{"text":"1987","start":8,"end":12,"id":1,"ws":true},{"text":"and","start":13,"end":16,"id":2,"ws":true},{"text":"2003","start":17,"end":21,"id":3,"ws":true},{"text":",","start":22,"end":23,"id":4,"ws":true},{"text":"patients","start":24,"end":32,"id":5,"ws":true},{"text":"18","start":33,"end":35,"id":6,"ws":true},{"text":"years","start":36,"end":41,"id":7,"ws":true},{"text":"old","start":42,"end":45,"id":8,"ws":true},{"text":"were","start":46,"end":50,"id":9,"ws":true},{"text":"given","start":51,"end":56,"id":10,"ws":true},{"text":"adjuvant","start":57,"end":65,"id":11,"ws":true},{"text":"chemotherapy","start":66,"end":78,"id":12,"ws":true},{"text":"consisting","start":79,"end":89,"id":13,"ws":true},{"text":"of","start":90,"end":92,"id":14,"ws":true},{"text":"one","start":93,"end":96,"id":15,"ws":true},{"text":"of","start":97,"end":99,"id":16,"ws":true},{"text":"two","start":100,"end":103,"id":17,"ws":true},{"text":"'","start":104,"end":105,"id":18,"ws":true},{"text":"paediatric","start":106,"end":116,"id":19,"ws":true},{"text":"'","start":117,"end":118,"id":20,"ws":true},{"text":"regimens","start":119,"end":127,"id":21,"ws":true},{"text":"(","start":128,"end":129,"id":22,"ws":true},{"text":"depending","start":130,"end":139,"id":23,"ws":true},{"text":"on","start":140,"end":142,"id":24,"ws":true},{"text":"the","start":143,"end":146,"id":25,"ws":true},{"text":"time","start":147,"end":151,"id":26,"ws":true},{"text":"of","start":152,"end":154,"id":27,"ws":true},{"text":"presentation","start":155,"end":167,"id":28,"ws":true},{"text":")","start":168,"end":169,"id":29,"ws":true},{"text":"and","start":170,"end":173,"id":30,"ws":true},{"text":"craniospinal","start":174,"end":186,"id":31,"ws":true},{"text":"local-boost","start":187,"end":198,"id":32,"ws":true},{"text":"radiotherapy","start":199,"end":211,"id":33,"ws":true},{"text":":","start":212,"end":213,"id":34,"ws":true},{"text":"regimen","start":214,"end":221,"id":35,"ws":true},{"text":"A","start":222,"end":223,"id":36,"ws":true},{"text":"(","start":224,"end":225,"id":37,"ws":true},{"text":"n","start":226,"end":227,"id":38,"ws":true},{"text":"=","start":228,"end":229,"id":39,"ws":true},{"text":"12","start":230,"end":232,"id":40,"ws":true},{"text":")","start":233,"end":234,"id":41,"ws":true},{"text":",","start":235,"end":236,"id":42,"ws":true},{"text":"vincristine","start":237,"end":248,"id":43,"ws":true},{"text":"(","start":249,"end":250,"id":44,"ws":true},{"text":"VCR","start":251,"end":254,"id":45,"ws":true},{"text":")","start":255,"end":256,"id":46,"ws":true},{"text":",","start":257,"end":258,"id":47,"ws":true},{"text":"intrathecal","start":259,"end":270,"id":48,"ws":true},{"text":"and/or","start":271,"end":277,"id":49,"ws":true},{"text":"intravenous","start":278,"end":289,"id":50,"ws":true},{"text":"methotrexate","start":290,"end":302,"id":51,"ws":true},{"text":"and","start":303,"end":306,"id":52,"ws":true},{"text":"conventional","start":307,"end":319,"id":53,"ws":true},{"text":"radiotherapy","start":320,"end":332,"id":54,"ws":true},{"text":";","start":333,"end":334,"id":55,"ws":true},{"text":"or","start":335,"end":337,"id":56,"ws":true},{"text":"regimen","start":338,"end":345,"id":57,"ws":true},{"text":"B","start":346,"end":347,"id":58,"ws":true},{"text":"(","start":348,"end":349,"id":59,"ws":true},{"text":"n","start":350,"end":351,"id":60,"ws":true},{"text":"=","start":352,"end":353,"id":61,"ws":true},{"text":"11","start":354,"end":356,"id":62,"ws":true},{"text":")","start":357,"end":358,"id":63,"ws":true},{"text":"sequencing","start":359,"end":369,"id":64,"ws":true},{"text":"intensive","start":370,"end":379,"id":65,"ws":true},{"text":"doses","start":380,"end":385,"id":66,"ws":true},{"text":"of","start":386,"end":388,"id":67,"ws":true},{"text":"multiple","start":389,"end":397,"id":68,"ws":true},{"text":"agents","start":398,"end":404,"id":69,"ws":true},{"text":"followed","start":405,"end":413,"id":70,"ws":true},{"text":"by","start":414,"end":416,"id":71,"ws":true},{"text":"hyperfractionated","start":417,"end":434,"id":72,"ws":true},{"text":"accelerated","start":435,"end":446,"id":73,"ws":true},{"text":"radiotherapy","start":447,"end":459,"id":74,"ws":true},{"text":"(","start":460,"end":461,"id":75,"ws":true},{"text":"HART","start":462,"end":466,"id":76,"ws":true},{"text":")","start":467,"end":468,"id":77,"ws":true},{"text":".","start":469,"end":470,"id":78,"ws":false}],"spans":[{"start":237,"end":248,"token_start":43,"token_end":43,"label":"DRUG"},{"start":290,"end":302,"token_start":51,"token_end":51,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/15869875/","_input_hash":-1431707466,"_task_hash":104155681,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":43,"child":51,"head_span":{"start":237,"end":248,"token_start":43,"token_end":43,"label":"DRUG"},"child_span":{"start":290,"end":302,"token_start":51,"token_end":51,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"The US Food and Drug Administration ( FDA ) recommends that \" concomitant use of drugs that inhibit CYP2C19 ( e.g. , omeprazole ) should be discouraged . \" As the presence of PPIs and clopidogrel in plasma is short lived , separation by 12 - 20 h should in theory prevent competitive inhibition of CYP metabolism and minimize any potential , though unproven , clinical interaction .","paragraph":"<h3><u>Proton pump inhibitor and clopidogrel interaction: fact or fiction?</u></h3>Current consensus recommendations state that patients prescribed <b style='color:Tomato;'><i>clopidogrel</i></b> plus <b style='color:Tomato;'><i>aspirin</i></b> should receive a proton pump inhibitor (PPI) to reduce gastrointestinal bleeding. <b style='color:Tomato;'><i>clopidogrel</i></b> is converted to its active metabolite by cytochrome P450 (CYP) enzymes. <b style='color:Tomato;'><i>clopidogrel</i></b> users with decreased CYP2C19 function have less inhibition of platelet aggregation and increased cardiovascular (CV) events. As PPI metabolism also involves CYP2C19, it was hypothesized that competition by PPIs might interfere with <b style='color:Tomato;'><i>clopidogrel</i></b>'s action. <b style='color:Tomato;'><i>omeprazole</i></b>, but not other PPIs, worsens surrogate markers of <b style='color:Tomato;'><i>clopidogrel</i></b> efficacy. Some (but not all) observational studies show that <b style='color:Tomato;'><i>clopidogrel</i></b> users prescribed PPIs have increased risks of CV events (hazard/odds ratios=1.25-1.5). When effect sizes are small to moderate (relative risks<1.5-2.0), however, it is only possible to conclude whether statistical associations are valid in randomized trials. A randomized trial of <b style='color:Tomato;'><i>omeprazole</i></b> vs. placebo in <b style='color:Tomato;'><i>clopidogrel</i></b> users showed no difference in CV events (hazard ratio=1.02,0.70-1.51). Thus, current evidence does not justify a conclusion that PPIs are associated with CV events among <b style='color:Tomato;'><i>clopidogrel</i></b> users, let alone a judgment of causality. Nonetheless, positive results from some observational studies and biological plausibility have led some health-care providers to accept that PPIs reduce <b style='color:Tomato;'><i>clopidogrel</i></b>'s efficacy. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>US</i></b> <b style='color:DodgerBlue;'><i>Food</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>Drug</i></b> <b style='color:DodgerBlue;'><i>Administration</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>FDA</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>recommends</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>\"</i></b> <b style='color:DodgerBlue;'><i>concomitant</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>inhibit</i></b> <b style='color:DodgerBlue;'><i>CYP2C19</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>e.g.</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>omeprazole</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>should</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>discouraged</i></b> <b style='color:DodgerBlue;'><i>.</i></b> <b style='color:DodgerBlue;'><i>\"</i></b> <b style='color:DodgerBlue;'><i>As</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>presence</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>PPIs</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>clopidogrel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>plasma</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>short</i></b> <b style='color:DodgerBlue;'><i>lived</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>separation</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>12</i></b> <b style='color:DodgerBlue;'><i>-</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>should</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>theory</i></b> <b style='color:DodgerBlue;'><i>prevent</i></b> <b style='color:DodgerBlue;'><i>competitive</i></b> <b style='color:DodgerBlue;'><i>inhibition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>CYP</i></b> <b style='color:DodgerBlue;'><i>metabolism</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>minimize</i></b> <b style='color:DodgerBlue;'><i>any</i></b> <b style='color:DodgerBlue;'><i>potential</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>though</i></b> <b style='color:DodgerBlue;'><i>unproven</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>interaction</i></b> <b style='color:DodgerBlue;'><i>.</i></b> PPI may be given before breakfast and <b style='color:Tomato;'><i>clopidogrel</i></b> at bedtime, or PPI may be taken before dinner and <b style='color:Tomato;'><i>clopidogrel</i></b> at lunchtime.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"US","start":4,"end":6,"id":1,"ws":true},{"text":"Food","start":7,"end":11,"id":2,"ws":true},{"text":"and","start":12,"end":15,"id":3,"ws":true},{"text":"Drug","start":16,"end":20,"id":4,"ws":true},{"text":"Administration","start":21,"end":35,"id":5,"ws":true},{"text":"(","start":36,"end":37,"id":6,"ws":true},{"text":"FDA","start":38,"end":41,"id":7,"ws":true},{"text":")","start":42,"end":43,"id":8,"ws":true},{"text":"recommends","start":44,"end":54,"id":9,"ws":true},{"text":"that","start":55,"end":59,"id":10,"ws":true},{"text":"\"","start":60,"end":61,"id":11,"ws":true},{"text":"concomitant","start":62,"end":73,"id":12,"ws":true},{"text":"use","start":74,"end":77,"id":13,"ws":true},{"text":"of","start":78,"end":80,"id":14,"ws":true},{"text":"drugs","start":81,"end":86,"id":15,"ws":true},{"text":"that","start":87,"end":91,"id":16,"ws":true},{"text":"inhibit","start":92,"end":99,"id":17,"ws":true},{"text":"CYP2C19","start":100,"end":107,"id":18,"ws":true},{"text":"(","start":108,"end":109,"id":19,"ws":true},{"text":"e.g.","start":110,"end":114,"id":20,"ws":true},{"text":",","start":115,"end":116,"id":21,"ws":true},{"text":"omeprazole","start":117,"end":127,"id":22,"ws":true},{"text":")","start":128,"end":129,"id":23,"ws":true},{"text":"should","start":130,"end":136,"id":24,"ws":true},{"text":"be","start":137,"end":139,"id":25,"ws":true},{"text":"discouraged","start":140,"end":151,"id":26,"ws":true},{"text":".","start":152,"end":153,"id":27,"ws":true},{"text":"\"","start":154,"end":155,"id":28,"ws":true},{"text":"As","start":156,"end":158,"id":29,"ws":true},{"text":"the","start":159,"end":162,"id":30,"ws":true},{"text":"presence","start":163,"end":171,"id":31,"ws":true},{"text":"of","start":172,"end":174,"id":32,"ws":true},{"text":"PPIs","start":175,"end":179,"id":33,"ws":true},{"text":"and","start":180,"end":183,"id":34,"ws":true},{"text":"clopidogrel","start":184,"end":195,"id":35,"ws":true},{"text":"in","start":196,"end":198,"id":36,"ws":true},{"text":"plasma","start":199,"end":205,"id":37,"ws":true},{"text":"is","start":206,"end":208,"id":38,"ws":true},{"text":"short","start":209,"end":214,"id":39,"ws":true},{"text":"lived","start":215,"end":220,"id":40,"ws":true},{"text":",","start":221,"end":222,"id":41,"ws":true},{"text":"separation","start":223,"end":233,"id":42,"ws":true},{"text":"by","start":234,"end":236,"id":43,"ws":true},{"text":"12","start":237,"end":239,"id":44,"ws":true},{"text":"-","start":240,"end":241,"id":45,"ws":true},{"text":"20","start":242,"end":244,"id":46,"ws":true},{"text":"h","start":245,"end":246,"id":47,"ws":true},{"text":"should","start":247,"end":253,"id":48,"ws":true},{"text":"in","start":254,"end":256,"id":49,"ws":true},{"text":"theory","start":257,"end":263,"id":50,"ws":true},{"text":"prevent","start":264,"end":271,"id":51,"ws":true},{"text":"competitive","start":272,"end":283,"id":52,"ws":true},{"text":"inhibition","start":284,"end":294,"id":53,"ws":true},{"text":"of","start":295,"end":297,"id":54,"ws":true},{"text":"CYP","start":298,"end":301,"id":55,"ws":true},{"text":"metabolism","start":302,"end":312,"id":56,"ws":true},{"text":"and","start":313,"end":316,"id":57,"ws":true},{"text":"minimize","start":317,"end":325,"id":58,"ws":true},{"text":"any","start":326,"end":329,"id":59,"ws":true},{"text":"potential","start":330,"end":339,"id":60,"ws":true},{"text":",","start":340,"end":341,"id":61,"ws":true},{"text":"though","start":342,"end":348,"id":62,"ws":true},{"text":"unproven","start":349,"end":357,"id":63,"ws":true},{"text":",","start":358,"end":359,"id":64,"ws":true},{"text":"clinical","start":360,"end":368,"id":65,"ws":true},{"text":"interaction","start":369,"end":380,"id":66,"ws":true},{"text":".","start":381,"end":382,"id":67,"ws":false}],"spans":[{"start":117,"end":127,"token_start":22,"token_end":22,"label":"DRUG"},{"start":184,"end":195,"token_start":35,"token_end":35,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/19904241/","_input_hash":-388572547,"_task_hash":1928480581,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":22,"child":35,"head_span":{"start":117,"end":127,"token_start":22,"token_end":22,"label":"DRUG"},"child_span":{"start":184,"end":195,"token_start":35,"token_end":35,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Long-term overall- and progression-free survival after pentostatin , cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Long-term</i></b> <b style='color:DodgerBlue;'><i>overall-</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>progression-free</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>pentostatin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rituximab</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>indolent</i></b> <b style='color:DodgerBlue;'><i>non-Hodgkin</i></b> <b style='color:DodgerBlue;'><i>lymphoma</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>In a prospective phase II trial, pentostatin combined with <b style='color:Tomato;'><i>cyclophosphamide</i></b> and <b style='color:Tomato;'><i>rituximab</i></b> (PCR) induced strong responses and was well-tolerated in previously untreated patients with advanced-stage, indolent non-Hodgkin lymphoma (iNHL). After a median patient follow-up of more than 108\u00a0months, we performed an intent-to-treat analysis of our 83 participants. Progression-free survival (PFS) rates at 108\u00a0months for follicular lymphoma (FL), marginal zone lymphoma (MZL) and small lymphocytic lymphoma (SLL) were 71%, 67% and 15%, respectively, and were affected by clinicopathological characteristics. Ten-year PFS rates for those with beta-2-microglobulin levels <2\u00b72 and \u22652\u00b72\u00a0mg/l prior to treatment were 71% and 21%, respectively. Patients without bone marrow involvement had 10-year PFS rates of 72% vs. 29% for those with involvement. At time of analysis, the median overall survival (OS) had not been reached. The OS rate was 64% at 10\u00a0years and differed significantly based on histology: 94% for FL, 66% for MZL and 39% for SLL. Long-term toxicities included 18 (21\u00b77%) patients with second malignancies and 2 (2\u00b74%) who developed myelodysplastic syndrome after receiving additional lines of chemotherapy. Our 10-year follow-up analysis confirms that PCR is an effective, robust and tolerable treatment regimen for patients with iNHL.","tokens":[{"text":"Long-term","start":0,"end":9,"id":0,"ws":true},{"text":"overall-","start":10,"end":18,"id":1,"ws":true},{"text":"and","start":19,"end":22,"id":2,"ws":true},{"text":"progression-free","start":23,"end":39,"id":3,"ws":true},{"text":"survival","start":40,"end":48,"id":4,"ws":true},{"text":"after","start":49,"end":54,"id":5,"ws":true},{"text":"pentostatin","start":55,"end":66,"id":6,"ws":true},{"text":",","start":67,"end":68,"id":7,"ws":true},{"text":"cyclophosphamide","start":69,"end":85,"id":8,"ws":true},{"text":"and","start":86,"end":89,"id":9,"ws":true},{"text":"rituximab","start":90,"end":99,"id":10,"ws":true},{"text":"therapy","start":100,"end":107,"id":11,"ws":true},{"text":"for","start":108,"end":111,"id":12,"ws":true},{"text":"indolent","start":112,"end":120,"id":13,"ws":true},{"text":"non-Hodgkin","start":121,"end":132,"id":14,"ws":true},{"text":"lymphoma","start":133,"end":141,"id":15,"ws":true},{"text":".","start":142,"end":143,"id":16,"ws":false}],"spans":[{"start":69,"end":85,"token_start":8,"token_end":8,"label":"DRUG"},{"start":90,"end":99,"token_start":10,"token_end":10,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/30820940/","_input_hash":541687394,"_task_hash":-382835800,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":55,"end":66,"token_start":6,"token_end":6,"label":null},"child_span":{"start":69,"end":85,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":8,"child":10,"head_span":{"start":69,"end":85,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":90,"end":99,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"Once-weekly isoniazid and rifapentine for 3 months is a treatment option in persons with human immunodeficiency virus and latent tuberculosis infection .","paragraph":"<h3><u>Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.</u></h3> <b style='color:DodgerBlue;'><i>Once-weekly</i></b> <b style='color:MediumOrchid;'><i>isoniazid</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>rifapentine</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>3</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>option</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>persons</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>human</i></b> <b style='color:DodgerBlue;'><i>immunodeficiency</i></b> <b style='color:DodgerBlue;'><i>virus</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>latent</i></b> <b style='color:DodgerBlue;'><i>tuberculosis</i></b> <b style='color:DodgerBlue;'><i>infection</i></b> <b style='color:DodgerBlue;'><i>.</i></b> This study aimed to examine pharmacokinetic drug-drug interactions between this regimen and <b style='color:Tomato;'><i>dolutegravir</i></b>, a first-line antiretroviral medication. ### methods This was a single-center, open-label, fixed-sequence, drug-drug interaction study in healthy volunteers. Subjects received oral <b style='color:Tomato;'><i>dolutegravir</i></b> 50 mg once daily alone (days 1-4) and concomitantly with once-weekly <b style='color:Tomato;'><i>isoniazid</i></b> 900 mg, <b style='color:Tomato;'><i>rifapentine</i></b> 900 mg, and <b style='color:Tomato;'><i>pyridoxine</i></b> 50 mg (days 5-19). <b style='color:Tomato;'><i>dolutegravir</i></b> concentrations were measured on days 4, 14, and 19, and <b style='color:Tomato;'><i>rifapentine</i></b>, 25-desacetyl-<b style='color:Tomato;'><i>rifapentine</i></b>, and <b style='color:Tomato;'><i>isoniazid</i></b> concentrations were measured on day 19. Cytokines and antidrug antibodies to <b style='color:Tomato;'><i>isoniazid</i></b> and <b style='color:Tomato;'><i>rifapentine</i></b> were examined at select time points. ### results The study was terminated following the development of flu-like syndrome and elevated aminotransferase levels in 2 of 4 subjects after the third <b style='color:Tomato;'><i>isoniazid</i></b>-<b style='color:Tomato;'><i>rifapentine</i></b> dose. Markedly elevated levels of interferon-\u03b3, CXCL10, C-reactive protein, and other cytokines were temporally associated with symptoms. Antidrug antibodies were infrequently detected. <b style='color:Tomato;'><i>dolutegravir</i></b> area under the curve (AUC) was decreased by 46% (90% confidence interval, 27-110%; P = .13) on day 14. <b style='color:Tomato;'><i>rifapentine</i></b> and 25-desacetyl <b style='color:Tomato;'><i>rifapentine</i></b> levels on day 19 were comparable to reference data, whereas <b style='color:Tomato;'><i>isoniazid</i></b> AUCs were approximately 67%-92% higher in the subjects who developed toxicities. ### conclusions The combined use of <b style='color:Tomato;'><i>dolutegravir</i></b> with once-weekly <b style='color:Tomato;'><i>isoniazid</i></b>-<b style='color:Tomato;'><i>rifapentine</i></b> resulted in unexpected and serious toxicities that were mediated by endogenous cytokine release. Additional investigations are necessary to examine the safety and efficacy of coadministering these medications. ### Clinical Trials Registration NCT02771249.","tokens":[{"text":"Once-weekly","start":0,"end":11,"id":0,"ws":true},{"text":"isoniazid","start":12,"end":21,"id":1,"ws":true},{"text":"and","start":22,"end":25,"id":2,"ws":true},{"text":"rifapentine","start":26,"end":37,"id":3,"ws":true},{"text":"for","start":38,"end":41,"id":4,"ws":true},{"text":"3","start":42,"end":43,"id":5,"ws":true},{"text":"months","start":44,"end":50,"id":6,"ws":true},{"text":"is","start":51,"end":53,"id":7,"ws":true},{"text":"a","start":54,"end":55,"id":8,"ws":true},{"text":"treatment","start":56,"end":65,"id":9,"ws":true},{"text":"option","start":66,"end":72,"id":10,"ws":true},{"text":"in","start":73,"end":75,"id":11,"ws":true},{"text":"persons","start":76,"end":83,"id":12,"ws":true},{"text":"with","start":84,"end":88,"id":13,"ws":true},{"text":"human","start":89,"end":94,"id":14,"ws":true},{"text":"immunodeficiency","start":95,"end":111,"id":15,"ws":true},{"text":"virus","start":112,"end":117,"id":16,"ws":true},{"text":"and","start":118,"end":121,"id":17,"ws":true},{"text":"latent","start":122,"end":128,"id":18,"ws":true},{"text":"tuberculosis","start":129,"end":141,"id":19,"ws":true},{"text":"infection","start":142,"end":151,"id":20,"ws":true},{"text":".","start":152,"end":153,"id":21,"ws":false}],"spans":[{"start":12,"end":21,"token_start":1,"token_end":1,"label":"DRUG"},{"start":26,"end":37,"token_start":3,"token_end":3,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29415190/","_input_hash":-655714867,"_task_hash":645335847,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":1,"child":3,"head_span":{"start":12,"end":21,"token_start":1,"token_end":1,"label":"DRUG"},"child_span":{"start":26,"end":37,"token_start":3,"token_end":3,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"We investigated the effects of these inhibitors on other anticancer drugs including docetaxel , vinblastine , doxorubicin , 10-Hydroxycamptothecin ( 10-HCPT ) and cisplatin and find that both inhibitors induces DU145-TxR cells to be more sensitive only to the microtubule-targeting drugs ( paclitaxel , docetaxel and vinblastine ) .","paragraph":"<h3><u>The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.</u></h3>Resistance is a significant limitation to the effectiveness of cancer therapies. The PI3K/Akt and MAP kinase pathways play important roles in a variety of normal cellular processes and tumorigenesis. This study is designed to explore the relationship of these signaling pathways with multidrug resistance in prostate cancer (PCa). The PI3K/Akt and MAP kinase pathways were investigated utilizing <b style='color:Tomato;'><i>paclitaxel</i></b> resistant DU145-TxR PCa cells and their parental non-resistant DU145 cells to determine their relationship with resistance to <b style='color:Tomato;'><i>paclitaxel</i></b> and other anticancer drugs. Our results demonstrate that the PI3K/Akt and MAP kinase pathways are upregulated in DU145-TxR cells compared to the DU145 cells. Inactivating these pathways using the PI3K/Akt pathway inhibitor LY294002 or the MAP kinase pathway inhibitor PD98059 renders the DU145-TxR cells more sensitive to <b style='color:Tomato;'><i>paclitaxel</i></b>. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>investigated</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>other</i></b> <b style='color:DodgerBlue;'><i>anticancer</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>including</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>10-Hydroxycamptothecin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>10-HCPT</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>cisplatin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>find</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>both</i></b> <b style='color:DodgerBlue;'><i>inhibitors</i></b> <b style='color:DodgerBlue;'><i>induces</i></b> <b style='color:DodgerBlue;'><i>DU145-TxR</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>sensitive</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>microtubule-targeting</i></b> <b style='color:DodgerBlue;'><i>drugs</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>vinblastine</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Furthermore, the treatment with these inhibitors induces cleaved-PARP production in DU145-TxR cells, suggesting that apoptosis induction might be one of the mechanisms for the reversal of drug resistance. In conclusion, the PI3K/Akt and MAP kinase pathways are associated with resistance to multiple chemotherapeutic drugs. Inactivating these pathways renders these PCa cells more sensitive to microtubule-targeting drugs such as <b style='color:Tomato;'><i>paclitaxel</i></b>, <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>vinblastine</i></b>. Combination therapies with novel inhibitors of these two signaling pathways potentially represents a more effective treatment for drug resistant PCa.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"investigated","start":3,"end":15,"id":1,"ws":true},{"text":"the","start":16,"end":19,"id":2,"ws":true},{"text":"effects","start":20,"end":27,"id":3,"ws":true},{"text":"of","start":28,"end":30,"id":4,"ws":true},{"text":"these","start":31,"end":36,"id":5,"ws":true},{"text":"inhibitors","start":37,"end":47,"id":6,"ws":true},{"text":"on","start":48,"end":50,"id":7,"ws":true},{"text":"other","start":51,"end":56,"id":8,"ws":true},{"text":"anticancer","start":57,"end":67,"id":9,"ws":true},{"text":"drugs","start":68,"end":73,"id":10,"ws":true},{"text":"including","start":74,"end":83,"id":11,"ws":true},{"text":"docetaxel","start":84,"end":93,"id":12,"ws":true},{"text":",","start":94,"end":95,"id":13,"ws":true},{"text":"vinblastine","start":96,"end":107,"id":14,"ws":true},{"text":",","start":108,"end":109,"id":15,"ws":true},{"text":"doxorubicin","start":110,"end":121,"id":16,"ws":true},{"text":",","start":122,"end":123,"id":17,"ws":true},{"text":"10-Hydroxycamptothecin","start":124,"end":146,"id":18,"ws":true},{"text":"(","start":147,"end":148,"id":19,"ws":true},{"text":"10-HCPT","start":149,"end":156,"id":20,"ws":true},{"text":")","start":157,"end":158,"id":21,"ws":true},{"text":"and","start":159,"end":162,"id":22,"ws":true},{"text":"cisplatin","start":163,"end":172,"id":23,"ws":true},{"text":"and","start":173,"end":176,"id":24,"ws":true},{"text":"find","start":177,"end":181,"id":25,"ws":true},{"text":"that","start":182,"end":186,"id":26,"ws":true},{"text":"both","start":187,"end":191,"id":27,"ws":true},{"text":"inhibitors","start":192,"end":202,"id":28,"ws":true},{"text":"induces","start":203,"end":210,"id":29,"ws":true},{"text":"DU145-TxR","start":211,"end":220,"id":30,"ws":true},{"text":"cells","start":221,"end":226,"id":31,"ws":true},{"text":"to","start":227,"end":229,"id":32,"ws":true},{"text":"be","start":230,"end":232,"id":33,"ws":true},{"text":"more","start":233,"end":237,"id":34,"ws":true},{"text":"sensitive","start":238,"end":247,"id":35,"ws":true},{"text":"only","start":248,"end":252,"id":36,"ws":true},{"text":"to","start":253,"end":255,"id":37,"ws":true},{"text":"the","start":256,"end":259,"id":38,"ws":true},{"text":"microtubule-targeting","start":260,"end":281,"id":39,"ws":true},{"text":"drugs","start":282,"end":287,"id":40,"ws":true},{"text":"(","start":288,"end":289,"id":41,"ws":true},{"text":"paclitaxel","start":290,"end":300,"id":42,"ws":true},{"text":",","start":301,"end":302,"id":43,"ws":true},{"text":"docetaxel","start":303,"end":312,"id":44,"ws":true},{"text":"and","start":313,"end":316,"id":45,"ws":true},{"text":"vinblastine","start":317,"end":328,"id":46,"ws":true},{"text":")","start":329,"end":330,"id":47,"ws":true},{"text":".","start":331,"end":332,"id":48,"ws":false}],"spans":[{"start":84,"end":93,"token_start":12,"token_end":12,"label":"DRUG"},{"start":96,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},{"start":110,"end":121,"token_start":16,"token_end":16,"label":"DRUG"},{"start":290,"end":300,"token_start":42,"token_end":42,"label":"DRUG"},{"start":303,"end":312,"token_start":44,"token_end":44,"label":"DRUG"},{"start":317,"end":328,"token_start":46,"token_end":46,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25640606/","_input_hash":1870680176,"_task_hash":1850379618,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Group B : From January , 1976 to December , 1980 , 55 evaluable patients participated in a consecutive study that added Adriamycin ( doxorubicin ) and cyclophosphamide to the former induction regimen .","paragraph":"<h3><u>Comparison of two consecutive trials for treatment of childhood non-Hodgkin's lymphoma.</u></h3>Two consecutive trials for the treatment of childhood non-Hodgkin's lymphoma were evaluated, carried out by the same cooperative groups. Group A: From June, 1973 to December, 1975, 50 evaluable patients under 16 years of age participated in a study that included <b style='color:Tomato;'><i>vincristine</i></b> and <b style='color:Tomato;'><i>prednisone</i></b> plus surgery and/or radiotherapy as induction. This was followed by 2400 rad of cranial radiotherapy plus 5 doses of intrathecal <b style='color:Tomato;'><i>methotrexate</i></b>-<b style='color:Tomato;'><i>dexamethasone</i></b> and anti-leukemia (6-<b style='color:Tomato;'><i>mercaptopurine</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, <b style='color:Tomato;'><i>cyclophosphamide</i></b>) or anti-lymphoma (<b style='color:Tomato;'><i>cyclophosphamide</i></b>, <b style='color:Tomato;'><i>vincristine</i></b>, <b style='color:Tomato;'><i>procarbazine</i></b>, and <b style='color:Tomato;'><i>prednisone</i></b>) maintenance treatment. <b style='color:DodgerBlue;'><i>Group</i></b> <b style='color:DodgerBlue;'><i>B</i></b> <b style='color:DodgerBlue;'><i>:</i></b> <b style='color:DodgerBlue;'><i>From</i></b> <b style='color:DodgerBlue;'><i>January</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1976</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>December</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>1980</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>55</i></b> <b style='color:DodgerBlue;'><i>evaluable</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>participated</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>consecutive</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>added</i></b> <b style='color:DodgerBlue;'><i>Adriamycin</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>former</i></b> <b style='color:DodgerBlue;'><i>induction</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Central nervous system (CNS) prevention was performed with 5 doses of intrathecal <b style='color:Tomato;'><i>methotrexate</i></b>-<b style='color:Tomato;'><i>dexamethasone</i></b>. Maintenance treatment was the same. Prognostic factors as stage and primary site were comparable in both groups. A total of 33 (66%) of 50 children of Group A and 48 (87%) of 55 children of Group B achieved complete remission (P less than 0.005). Disease-free survival at 60 months was 27% in Group A and 49% in Group B; for Stage I-II, 30% in Group A and 85% in Group B (P less than 0.025); for Stage III-IV 28% in Group A and 36% in Group B (not significant). In Group A, 9.1% and in Group B, 8.3% had primary CNS relapse. Both maintenance schedules had the same relapse rate. It was concluded that: (1) the addition of Adriamycin and <b style='color:Tomato;'><i>cyclophosphamide</i></b> to <b style='color:Tomato;'><i>vincristine</i></b>-<b style='color:Tomato;'><i>prednisone</i></b> in Group B produces a higher rate of complete remission in Stage III-IV, a higher rate of disease-free survival in Stage I-II, and a higher survival rate in all stages; (2) CNS prevention with intrathecal <b style='color:Tomato;'><i>methotrexate</i></b>-<b style='color:Tomato;'><i>dexamethasone</i></b> is equally effective as cranial radiation plus intrathecal <b style='color:Tomato;'><i>methotrexate</i></b>-<b style='color:Tomato;'><i>dexamethasone</i></b>; and (3) anti-leukemia and anti-lymphoma maintenance are equally effective in the context of this study.","tokens":[{"text":"Group","start":0,"end":5,"id":0,"ws":true},{"text":"B","start":6,"end":7,"id":1,"ws":true},{"text":":","start":8,"end":9,"id":2,"ws":true},{"text":"From","start":10,"end":14,"id":3,"ws":true},{"text":"January","start":15,"end":22,"id":4,"ws":true},{"text":",","start":23,"end":24,"id":5,"ws":true},{"text":"1976","start":25,"end":29,"id":6,"ws":true},{"text":"to","start":30,"end":32,"id":7,"ws":true},{"text":"December","start":33,"end":41,"id":8,"ws":true},{"text":",","start":42,"end":43,"id":9,"ws":true},{"text":"1980","start":44,"end":48,"id":10,"ws":true},{"text":",","start":49,"end":50,"id":11,"ws":true},{"text":"55","start":51,"end":53,"id":12,"ws":true},{"text":"evaluable","start":54,"end":63,"id":13,"ws":true},{"text":"patients","start":64,"end":72,"id":14,"ws":true},{"text":"participated","start":73,"end":85,"id":15,"ws":true},{"text":"in","start":86,"end":88,"id":16,"ws":true},{"text":"a","start":89,"end":90,"id":17,"ws":true},{"text":"consecutive","start":91,"end":102,"id":18,"ws":true},{"text":"study","start":103,"end":108,"id":19,"ws":true},{"text":"that","start":109,"end":113,"id":20,"ws":true},{"text":"added","start":114,"end":119,"id":21,"ws":true},{"text":"Adriamycin","start":120,"end":130,"id":22,"ws":true},{"text":"(","start":131,"end":132,"id":23,"ws":true},{"text":"doxorubicin","start":133,"end":144,"id":24,"ws":true},{"text":")","start":145,"end":146,"id":25,"ws":true},{"text":"and","start":147,"end":150,"id":26,"ws":true},{"text":"cyclophosphamide","start":151,"end":167,"id":27,"ws":true},{"text":"to","start":168,"end":170,"id":28,"ws":true},{"text":"the","start":171,"end":174,"id":29,"ws":true},{"text":"former","start":175,"end":181,"id":30,"ws":true},{"text":"induction","start":182,"end":191,"id":31,"ws":true},{"text":"regimen","start":192,"end":199,"id":32,"ws":true},{"text":".","start":200,"end":201,"id":33,"ws":false}],"spans":[{"start":133,"end":144,"token_start":24,"token_end":24,"label":"DRUG"},{"start":151,"end":167,"token_start":27,"token_end":27,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/6388820/","_input_hash":2014933255,"_task_hash":1016909622,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"When given in repeated doses from 6 h on , 50 g followed by 12.5 g at 6-h intervals , charcoal shortened the serum half-life of amitriptyline by 20 % and that of nortriptyline by 35 % ( p less than 0.05 ) .","paragraph":"<h3><u>Pharmacokinetics of amitriptyline influenced by oral charcoal and urine pH.</u></h3>The effects of orally given <b style='color:Tomato;'><i>activated charcoal</i></b>, sodium bicarbonate and ammonium chloride on the pharmacokinetics of <b style='color:Tomato;'><i>amitriptyline</i></b> were studied in 6 volunteers in a randomized, cross-over study. The serum and urine concentrations of <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b> were determined by HPLC for up to 72 h. <b style='color:Tomato;'><i>activated charcoal</i></b> (50 g), given within 5 min of the <b style='color:Tomato;'><i>amitriptyline</i></b> hydrochloride dose (75 mg), reduced its absorption by 99%. <b style='color:DodgerBlue;'><i>When</i></b> <b style='color:DodgerBlue;'><i>given</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>repeated</i></b> <b style='color:DodgerBlue;'><i>doses</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>6</i></b> <b style='color:DodgerBlue;'><i>h</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>50</i></b> <b style='color:DodgerBlue;'><i>g</i></b> <b style='color:DodgerBlue;'><i>followed</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>12.5</i></b> <b style='color:DodgerBlue;'><i>g</i></b> <b style='color:DodgerBlue;'><i>at</i></b> <b style='color:DodgerBlue;'><i>6-h</i></b> <b style='color:DodgerBlue;'><i>intervals</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>charcoal</i></b> <b style='color:DodgerBlue;'><i>shortened</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>serum</i></b> <b style='color:DodgerBlue;'><i>half-life</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>amitriptyline</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>20</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>nortriptyline</i></b> <b style='color:DodgerBlue;'><i>by</i></b> <b style='color:DodgerBlue;'><i>35</i></b> <b style='color:DodgerBlue;'><i>%</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>p</i></b> <b style='color:DodgerBlue;'><i>less</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>0.05</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The renal excretions of <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b> increased 1000-fold by the acidification of urine pH to 4. However, the cumulative excretion of <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b> even into acidic urine only accounted for up to 5% of the dose during 72 h. Since urinary pH has a great influence on the ratio of urinary versus serum <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b> concentrations, pH should be taken into consideration, when the clinical significance of their concentrations in urine is evaluated. <b style='color:Tomato;'><i>activated charcoal</i></b> in adequate doses very effectively prevents the absorption of that fraction of <b style='color:Tomato;'><i>amitriptyline</i></b> which is in the stomach at the time of charcoal administration. Furthermore, given in repeated oral doses, charcoal increases, to some extent, the rate of elimination of <b style='color:Tomato;'><i>amitriptyline</i></b> and <b style='color:Tomato;'><i>nortriptyline</i></b>, probably by interrupting their enterohepatic or enteroenteric circulation.","tokens":[{"text":"When","start":0,"end":4,"id":0,"ws":true},{"text":"given","start":5,"end":10,"id":1,"ws":true},{"text":"in","start":11,"end":13,"id":2,"ws":true},{"text":"repeated","start":14,"end":22,"id":3,"ws":true},{"text":"doses","start":23,"end":28,"id":4,"ws":true},{"text":"from","start":29,"end":33,"id":5,"ws":true},{"text":"6","start":34,"end":35,"id":6,"ws":true},{"text":"h","start":36,"end":37,"id":7,"ws":true},{"text":"on","start":38,"end":40,"id":8,"ws":true},{"text":",","start":41,"end":42,"id":9,"ws":true},{"text":"50","start":43,"end":45,"id":10,"ws":true},{"text":"g","start":46,"end":47,"id":11,"ws":true},{"text":"followed","start":48,"end":56,"id":12,"ws":true},{"text":"by","start":57,"end":59,"id":13,"ws":true},{"text":"12.5","start":60,"end":64,"id":14,"ws":true},{"text":"g","start":65,"end":66,"id":15,"ws":true},{"text":"at","start":67,"end":69,"id":16,"ws":true},{"text":"6-h","start":70,"end":73,"id":17,"ws":true},{"text":"intervals","start":74,"end":83,"id":18,"ws":true},{"text":",","start":84,"end":85,"id":19,"ws":true},{"text":"charcoal","start":86,"end":94,"id":20,"ws":true},{"text":"shortened","start":95,"end":104,"id":21,"ws":true},{"text":"the","start":105,"end":108,"id":22,"ws":true},{"text":"serum","start":109,"end":114,"id":23,"ws":true},{"text":"half-life","start":115,"end":124,"id":24,"ws":true},{"text":"of","start":125,"end":127,"id":25,"ws":true},{"text":"amitriptyline","start":128,"end":141,"id":26,"ws":true},{"text":"by","start":142,"end":144,"id":27,"ws":true},{"text":"20","start":145,"end":147,"id":28,"ws":true},{"text":"%","start":148,"end":149,"id":29,"ws":true},{"text":"and","start":150,"end":153,"id":30,"ws":true},{"text":"that","start":154,"end":158,"id":31,"ws":true},{"text":"of","start":159,"end":161,"id":32,"ws":true},{"text":"nortriptyline","start":162,"end":175,"id":33,"ws":true},{"text":"by","start":176,"end":178,"id":34,"ws":true},{"text":"35","start":179,"end":181,"id":35,"ws":true},{"text":"%","start":182,"end":183,"id":36,"ws":true},{"text":"(","start":184,"end":185,"id":37,"ws":true},{"text":"p","start":186,"end":187,"id":38,"ws":true},{"text":"less","start":188,"end":192,"id":39,"ws":true},{"text":"than","start":193,"end":197,"id":40,"ws":true},{"text":"0.05","start":198,"end":202,"id":41,"ws":true},{"text":")","start":203,"end":204,"id":42,"ws":true},{"text":".","start":205,"end":206,"id":43,"ws":false}],"spans":[{"start":128,"end":141,"token_start":26,"token_end":26,"label":"DRUG"},{"start":162,"end":175,"token_start":33,"token_end":33,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/3015809/","_input_hash":1971499379,"_task_hash":889539826,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"The molecular subtypes of breast cancer can predict responses to the combinational treatment of doxorubicin with docetaxel , and ERBB2","paragraph":"<h3><u>Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer.</u></h3>The aim of this study is to characterize the effect of chemotherapy drug <b style='color:Tomato;'><i>doxorubicin</i></b> with neoadjuvant drug <b style='color:Tomato;'><i>docetaxel</i></b> for different molecular subtypes. ### methods A total of 83 patients with late-stage breast cancer were chosen to undergo treatment and compared to these patients to the combinational treatment to identify the molecular characteristics that can predict the responses. ### results Total response rate is 81.9% (68/83 patients). Among them, 7 patients show pathological complete response of 8.4%, 12 patients show clinical complete response of 14.5%, 49 patients show partial response of 59%, and 15 patients show stable disease of 18.1%. The comparison among different subtypes of breast cancer, including luminal A, luminal B, basal-like, and ERBB2 ### conclusion <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>molecular</i></b> <b style='color:DodgerBlue;'><i>subtypes</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>predict</i></b> <b style='color:DodgerBlue;'><i>responses</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>combinational</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>doxorubicin</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>ERBB2</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"molecular","start":4,"end":13,"id":1,"ws":true},{"text":"subtypes","start":14,"end":22,"id":2,"ws":true},{"text":"of","start":23,"end":25,"id":3,"ws":true},{"text":"breast","start":26,"end":32,"id":4,"ws":true},{"text":"cancer","start":33,"end":39,"id":5,"ws":true},{"text":"can","start":40,"end":43,"id":6,"ws":true},{"text":"predict","start":44,"end":51,"id":7,"ws":true},{"text":"responses","start":52,"end":61,"id":8,"ws":true},{"text":"to","start":62,"end":64,"id":9,"ws":true},{"text":"the","start":65,"end":68,"id":10,"ws":true},{"text":"combinational","start":69,"end":82,"id":11,"ws":true},{"text":"treatment","start":83,"end":92,"id":12,"ws":true},{"text":"of","start":93,"end":95,"id":13,"ws":true},{"text":"doxorubicin","start":96,"end":107,"id":14,"ws":true},{"text":"with","start":108,"end":112,"id":15,"ws":true},{"text":"docetaxel","start":113,"end":122,"id":16,"ws":true},{"text":",","start":123,"end":124,"id":17,"ws":true},{"text":"and","start":125,"end":128,"id":18,"ws":true},{"text":"ERBB2","start":129,"end":134,"id":19,"ws":false}],"spans":[{"start":96,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},{"start":113,"end":122,"token_start":16,"token_end":16,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32508292/","_input_hash":2029760008,"_task_hash":37814328,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":14,"child":16,"head_span":{"start":96,"end":107,"token_start":14,"token_end":14,"label":"DRUG"},"child_span":{"start":113,"end":122,"token_start":16,"token_end":16,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"The median overall survival time was 22.7 months in the docetaxel arm and 22.4 months in the paclitaxel arm .","paragraph":"<h3><u>A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis.</u></h3>The purpose of the study is to compare two taxanes/cisplatin combinations for metastatic breast cancer in terms of time to disease progression, response rates and toxicity. ### methods Between April 2000 and December 2002, 101 patients with advanced breast carcinoma, previously treated with an anthracycline but not with a taxane, were enrolled. Fifty patients were treated with <b style='color:Tomato;'><i>docetaxel</i></b> 60 mg/m2 and cisplatin 50 mg/m2, and 51 patients were treated with <b style='color:Tomato;'><i>paclitaxel</i></b> 175 mg/m2 and cisplatin 50 mg/m2. Each cycle repeated every 3 weeks. ### results The overall response rate was 62.5 and 42.6% in the <b style='color:Tomato;'><i>docetaxel</i></b> and palcitaxel groups respectively (P = 0.06). Median time to disease progression was 9.8 and 6.5 months in <b style='color:Tomato;'><i>docetaxel</i></b> and <b style='color:Tomato;'><i>paclitaxel</i></b> groups respectively (P = 0.15). <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>median</i></b> <b style='color:DodgerBlue;'><i>overall</i></b> <b style='color:DodgerBlue;'><i>survival</i></b> <b style='color:DodgerBlue;'><i>time</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>22.7</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>22.4</i></b> <b style='color:DodgerBlue;'><i>months</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:MediumOrchid;'><i>paclitaxel</i></b> <b style='color:DodgerBlue;'><i>arm</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Grade 3/4 arthralgia/myalgia, sensory neuropathy and anemia occurred more frequently in the <b style='color:Tomato;'><i>paclitaxel</i></b> arm, while more mucositis, fatigue and neutropenia occurred in the <b style='color:Tomato;'><i>docetaxel</i></b> arm. ### conclusion Taxane/cisplatin combinations were active for advanced breast cancer, while there appeared to be evidence in favor of a <b style='color:Tomato;'><i>docetaxel</i></b>/cisplatin combination. The toxicity in favor of <b style='color:Tomato;'><i>docetaxel</i></b>/cisplatin warrants future first-line clinical trials.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"median","start":4,"end":10,"id":1,"ws":true},{"text":"overall","start":11,"end":18,"id":2,"ws":true},{"text":"survival","start":19,"end":27,"id":3,"ws":true},{"text":"time","start":28,"end":32,"id":4,"ws":true},{"text":"was","start":33,"end":36,"id":5,"ws":true},{"text":"22.7","start":37,"end":41,"id":6,"ws":true},{"text":"months","start":42,"end":48,"id":7,"ws":true},{"text":"in","start":49,"end":51,"id":8,"ws":true},{"text":"the","start":52,"end":55,"id":9,"ws":true},{"text":"docetaxel","start":56,"end":65,"id":10,"ws":true},{"text":"arm","start":66,"end":69,"id":11,"ws":true},{"text":"and","start":70,"end":73,"id":12,"ws":true},{"text":"22.4","start":74,"end":78,"id":13,"ws":true},{"text":"months","start":79,"end":85,"id":14,"ws":true},{"text":"in","start":86,"end":88,"id":15,"ws":true},{"text":"the","start":89,"end":92,"id":16,"ws":true},{"text":"paclitaxel","start":93,"end":103,"id":17,"ws":true},{"text":"arm","start":104,"end":107,"id":18,"ws":true},{"text":".","start":108,"end":109,"id":19,"ws":false}],"spans":[{"start":56,"end":65,"token_start":10,"token_end":10,"label":"DRUG"},{"start":93,"end":103,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/17172351/","_input_hash":307082636,"_task_hash":1430457115,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We hypothesized that Aurora A kinase ( AK ) contributes to castrate resistance in prostate cancer ( PCa ) and that inhibiting AK with alisertib can resensitize PCa cells to androgen receptor ( AR ) inhibitor abiraterone .","paragraph":"<h3><u>A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.</u></h3>Patients with metastatic castration-resistant prostate cancer did not tolerate the combination of <b style='color:Tomato;'><i>alisertib</i></b> with <b style='color:Tomato;'><i>abiraterone</i></b> and <b style='color:Tomato;'><i>prednisone</i></b>.There was no clear signal indicating that adding <b style='color:Tomato;'><i>alisertib</i></b> might be beneficial for those patients progressing on <b style='color:Tomato;'><i>abiraterone</i></b>. ### background <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>hypothesized</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>Aurora</i></b> <b style='color:DodgerBlue;'><i>A</i></b> <b style='color:DodgerBlue;'><i>kinase</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AK</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>contributes</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>castrate</i></b> <b style='color:DodgerBlue;'><i>resistance</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>PCa</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>inhibiting</i></b> <b style='color:DodgerBlue;'><i>AK</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>alisertib</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>resensitize</i></b> <b style='color:DodgerBlue;'><i>PCa</i></b> <b style='color:DodgerBlue;'><i>cells</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>androgen</i></b> <b style='color:DodgerBlue;'><i>receptor</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>AR</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>inhibitor</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods This was a phase I/II trial to determine the safety and efficacy of <b style='color:Tomato;'><i>alisertib</i></b> when given in combination with <b style='color:Tomato;'><i>abiraterone</i></b> plus <b style='color:Tomato;'><i>prednisone</i></b> (AP). Metastatic castration-resistant prostate cancer (mCRPC) patients were treated with dose escalation (<b style='color:Tomato;'><i>alisertib</i></b> at 30, 40, and 50 mg orally b.i.d., days 1-7 every 21 days) per standard 3+3 design. ### results Nine of 43 planned subjects were enrolled. The maximum tolerated dose (MTD) was not reached, and the dose-limiting toxicities (DLTs) included neutropenic fever (1 of 9), neutropenia (1 of 9), fatigue with memory impairment (1 of 9), and diarrhea/mucositis (1 of 9). No prostate-specific antigen (PSA) decrease or circulating tumor cell (CTC) changes were observed during the study. Pharmacodynamically, adding <b style='color:Tomato;'><i>alisertib</i></b> did not affect total testosterone or <b style='color:Tomato;'><i>dehydroepiandrosterone</i></b> (DHEA) levels. There was some change in neuroendocrine markers after therapy. Mean duration on study was 2.5 months. The trial was terminated early. ### conclusion A tolerable dose of <b style='color:Tomato;'><i>alisertib</i></b> in combination with AP in mCRPC was not established in this study. There was no clear signal indicating that <b style='color:Tomato;'><i>alisertib</i></b> might be beneficial for patients with mCRPC progressing on <b style='color:Tomato;'><i>abiraterone</i></b>.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"hypothesized","start":3,"end":15,"id":1,"ws":true},{"text":"that","start":16,"end":20,"id":2,"ws":true},{"text":"Aurora","start":21,"end":27,"id":3,"ws":true},{"text":"A","start":28,"end":29,"id":4,"ws":true},{"text":"kinase","start":30,"end":36,"id":5,"ws":true},{"text":"(","start":37,"end":38,"id":6,"ws":true},{"text":"AK","start":39,"end":41,"id":7,"ws":true},{"text":")","start":42,"end":43,"id":8,"ws":true},{"text":"contributes","start":44,"end":55,"id":9,"ws":true},{"text":"to","start":56,"end":58,"id":10,"ws":true},{"text":"castrate","start":59,"end":67,"id":11,"ws":true},{"text":"resistance","start":68,"end":78,"id":12,"ws":true},{"text":"in","start":79,"end":81,"id":13,"ws":true},{"text":"prostate","start":82,"end":90,"id":14,"ws":true},{"text":"cancer","start":91,"end":97,"id":15,"ws":true},{"text":"(","start":98,"end":99,"id":16,"ws":true},{"text":"PCa","start":100,"end":103,"id":17,"ws":true},{"text":")","start":104,"end":105,"id":18,"ws":true},{"text":"and","start":106,"end":109,"id":19,"ws":true},{"text":"that","start":110,"end":114,"id":20,"ws":true},{"text":"inhibiting","start":115,"end":125,"id":21,"ws":true},{"text":"AK","start":126,"end":128,"id":22,"ws":true},{"text":"with","start":129,"end":133,"id":23,"ws":true},{"text":"alisertib","start":134,"end":143,"id":24,"ws":true},{"text":"can","start":144,"end":147,"id":25,"ws":true},{"text":"resensitize","start":148,"end":159,"id":26,"ws":true},{"text":"PCa","start":160,"end":163,"id":27,"ws":true},{"text":"cells","start":164,"end":169,"id":28,"ws":true},{"text":"to","start":170,"end":172,"id":29,"ws":true},{"text":"androgen","start":173,"end":181,"id":30,"ws":true},{"text":"receptor","start":182,"end":190,"id":31,"ws":true},{"text":"(","start":191,"end":192,"id":32,"ws":true},{"text":"AR","start":193,"end":195,"id":33,"ws":true},{"text":")","start":196,"end":197,"id":34,"ws":true},{"text":"inhibitor","start":198,"end":207,"id":35,"ws":true},{"text":"abiraterone","start":208,"end":219,"id":36,"ws":true},{"text":".","start":220,"end":221,"id":37,"ws":false}],"spans":[{"start":134,"end":143,"token_start":24,"token_end":24,"label":"DRUG"},{"start":208,"end":219,"token_start":36,"token_end":36,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/28178640/","_input_hash":-849461923,"_task_hash":-275457113,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":24,"child":36,"head_span":{"start":134,"end":143,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":208,"end":219,"token_start":36,"token_end":36,"label":"DRUG"},"color":"#c2f2f6","label":"NEG1"}],"radio":["NEG11"],"answer":"accept"}
{"text":"Tanespimycin plus trastuzumab is well tolerated and has antitumor activity in patients with HER-2 + breast cancer whose tumors have progressed during treatment with trastuzumab .","paragraph":"<h3><u>Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.</u></h3>This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor <b style='color:Tomato;'><i>tanespimycin</i></b> (17-AAG; KOS-953) could be administered safely in combination with <b style='color:Tomato;'><i>trastuzumab</i></b> at a dose that inhibits Hsp90 function in vivo in lymphocytes. ### Patients And Methods Patients with an advanced solid tumor progressing during standard therapy were eligible. Patients were treated with weekly <b style='color:Tomato;'><i>trastuzumab</i></b> followed by intravenous <b style='color:Tomato;'><i>tanespimycin</i></b>, assessed in escalating dose levels. ### results Twenty-five patients were enrolled onto four <b style='color:Tomato;'><i>tanespimycin</i></b> dose levels: 225 (n = 4), 300 (n = 3), 375 (n = 8), and 450 mg/m2 (n = 10). Dose-limiting toxicity (DLT) was observed at the third and fourth cohort (1 patient each): more than 2-week delay for grade 4 fatigue/grade 2 nausea and anorexia (375 mg/m2); more than 2-week delay for thrombocytopenia (450 mg/m2). Drug-related grade 3 toxicity included emesis, increased ALT, hypersensitivity reactions (two patients each), and drug-induced thrombocytopenia (n = 1). Common mild to moderate toxicities included fatigue, nausea, diarrhea, emesis, headache, rash/pruritus, increased AST/ALT, and anorexia. Pharmacokinetic analysis demonstrated no difference in <b style='color:Tomato;'><i>tanespimycin</i></b> kinetics with or without <b style='color:Tomato;'><i>trastuzumab</i></b>. Pharmacodynamic testing showed reactive induction of Hsp70 (a marker of Hsp90 inhibition) in lymphocytes at all dose levels. Antitumor activity was noted (partial response, n = 1; minor response, n = 4; stable disease > or = 4 months, n = 4). Tumor regressions were seen only in patients with human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer. ### conclusion <b style='color:MediumOrchid;'><i>Tanespimycin</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>well</i></b> <b style='color:DodgerBlue;'><i>tolerated</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>has</i></b> <b style='color:DodgerBlue;'><i>antitumor</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>HER-2</i></b> <b style='color:DodgerBlue;'><i>+</i></b> <b style='color:DodgerBlue;'><i>breast</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>whose</i></b> <b style='color:DodgerBlue;'><i>tumors</i></b> <b style='color:DodgerBlue;'><i>have</i></b> <b style='color:DodgerBlue;'><i>progressed</i></b> <b style='color:DodgerBlue;'><i>during</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>trastuzumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> These data suggest that Hsp90 function can be inhibited in vivo to a degree sufficient to cause inhibition of tumor growth.","tokens":[{"text":"Tanespimycin","start":0,"end":12,"id":0,"ws":true},{"text":"plus","start":13,"end":17,"id":1,"ws":true},{"text":"trastuzumab","start":18,"end":29,"id":2,"ws":true},{"text":"is","start":30,"end":32,"id":3,"ws":true},{"text":"well","start":33,"end":37,"id":4,"ws":true},{"text":"tolerated","start":38,"end":47,"id":5,"ws":true},{"text":"and","start":48,"end":51,"id":6,"ws":true},{"text":"has","start":52,"end":55,"id":7,"ws":true},{"text":"antitumor","start":56,"end":65,"id":8,"ws":true},{"text":"activity","start":66,"end":74,"id":9,"ws":true},{"text":"in","start":75,"end":77,"id":10,"ws":true},{"text":"patients","start":78,"end":86,"id":11,"ws":true},{"text":"with","start":87,"end":91,"id":12,"ws":true},{"text":"HER-2","start":92,"end":97,"id":13,"ws":true},{"text":"+","start":98,"end":99,"id":14,"ws":true},{"text":"breast","start":100,"end":106,"id":15,"ws":true},{"text":"cancer","start":107,"end":113,"id":16,"ws":true},{"text":"whose","start":114,"end":119,"id":17,"ws":true},{"text":"tumors","start":120,"end":126,"id":18,"ws":true},{"text":"have","start":127,"end":131,"id":19,"ws":true},{"text":"progressed","start":132,"end":142,"id":20,"ws":true},{"text":"during","start":143,"end":149,"id":21,"ws":true},{"text":"treatment","start":150,"end":159,"id":22,"ws":true},{"text":"with","start":160,"end":164,"id":23,"ws":true},{"text":"trastuzumab","start":165,"end":176,"id":24,"ws":true},{"text":".","start":177,"end":178,"id":25,"ws":false}],"spans":[{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},{"start":18,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},{"start":165,"end":176,"token_start":24,"token_end":24,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/18048823/","_input_hash":-2143703813,"_task_hash":1502847177,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":0,"child":2,"head_span":{"start":0,"end":12,"token_start":0,"token_end":0,"label":"DRUG"},"child_span":{"start":18,"end":29,"token_start":2,"token_end":2,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"It contains data on prophylaxis with mefloquine ( n = 48,264 ) , with chloroquine ( 6,752 ) , with chloroquine plus proguanil ( 19,727 ) , and with no prophylaxis ( 3,871 ) .","paragraph":"<h3><u>Tolerability and Effectiveness of Malaria Chemoprophylaxis with Mefloquine or Chloroquine with or without Co-medication.</u></h3>Background: To determine the relevance of drug interactions with co-medication for effectiveness and tolerability of antimalarial chemoprophylaxis. Method: A database (MALPRO2) on travelers on their flight home from Africa to Europe between July 1988 and December 1991 was reanalyzed. <b style='color:DodgerBlue;'><i>It</i></b> <b style='color:DodgerBlue;'><i>contains</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>prophylaxis</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>mefloquine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>n</i></b> <b style='color:DodgerBlue;'><i>=</i></b> <b style='color:DodgerBlue;'><i>48,264</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>6,752</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>chloroquine</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>proguanil</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>19,727</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>no</i></b> <b style='color:DodgerBlue;'><i>prophylaxis</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>3,871</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The comparison of rates of malaria incidence and adverse events (AEs) between users and nonusers of co-medication was expressed by relative risk (RR). Results: Fifty-three percent of travelers (63% of females, 43% of males) used co-medication in all prophylaxis groups, with an average of 1.35 additional drugs per person and about two AEs reported per person. With the exception of antidiarrheals plus <b style='color:Tomato;'><i>mefloquine</i></b>, malaria incidence with co-medication was lower (RR = 0.8) than without co-medication. In all regimens, the proportion of travelers reporting AEs was about 1.5-fold with co-medication (p<.01); that reporting severe AEs was twice as high as compared to with no co-medication. <b style='color:Tomato;'><i>mefloquine</i></b> AE rates for various classes of co-medication were similar to that of <b style='color:Tomato;'><i>chloroquine</i></b>, with highest AE and severity rates with neuropsychiatric drugs (excluding antiepileptics, RR = 1.9 and 2.9), and lowest rates with cardiovasculars (RR = 1.1 and 1.0). Various co-medications were used with different frequencies in males and females, and the latter reported more AEs. Conclusion: These data suggest that co-medications commonly used by travelers have no significant clinical impact on safety and effectiveness of prophylaxis with <b style='color:Tomato;'><i>mefloquine</i></b> or <b style='color:Tomato;'><i>chloroquine</i></b>. Increased frequency and severity of AEs when using co-medication rather is explained by underlying illness.","tokens":[{"text":"It","start":0,"end":2,"id":0,"ws":true},{"text":"contains","start":3,"end":11,"id":1,"ws":true},{"text":"data","start":12,"end":16,"id":2,"ws":true},{"text":"on","start":17,"end":19,"id":3,"ws":true},{"text":"prophylaxis","start":20,"end":31,"id":4,"ws":true},{"text":"with","start":32,"end":36,"id":5,"ws":true},{"text":"mefloquine","start":37,"end":47,"id":6,"ws":true},{"text":"(","start":48,"end":49,"id":7,"ws":true},{"text":"n","start":50,"end":51,"id":8,"ws":true},{"text":"=","start":52,"end":53,"id":9,"ws":true},{"text":"48,264","start":54,"end":60,"id":10,"ws":true},{"text":")","start":61,"end":62,"id":11,"ws":true},{"text":",","start":63,"end":64,"id":12,"ws":true},{"text":"with","start":65,"end":69,"id":13,"ws":true},{"text":"chloroquine","start":70,"end":81,"id":14,"ws":true},{"text":"(","start":82,"end":83,"id":15,"ws":true},{"text":"6,752","start":84,"end":89,"id":16,"ws":true},{"text":")","start":90,"end":91,"id":17,"ws":true},{"text":",","start":92,"end":93,"id":18,"ws":true},{"text":"with","start":94,"end":98,"id":19,"ws":true},{"text":"chloroquine","start":99,"end":110,"id":20,"ws":true},{"text":"plus","start":111,"end":115,"id":21,"ws":true},{"text":"proguanil","start":116,"end":125,"id":22,"ws":true},{"text":"(","start":126,"end":127,"id":23,"ws":true},{"text":"19,727","start":128,"end":134,"id":24,"ws":true},{"text":")","start":135,"end":136,"id":25,"ws":true},{"text":",","start":137,"end":138,"id":26,"ws":true},{"text":"and","start":139,"end":142,"id":27,"ws":true},{"text":"with","start":143,"end":147,"id":28,"ws":true},{"text":"no","start":148,"end":150,"id":29,"ws":true},{"text":"prophylaxis","start":151,"end":162,"id":30,"ws":true},{"text":"(","start":163,"end":164,"id":31,"ws":true},{"text":"3,871","start":165,"end":170,"id":32,"ws":true},{"text":")","start":171,"end":172,"id":33,"ws":true},{"text":".","start":173,"end":174,"id":34,"ws":false}],"spans":[{"start":37,"end":47,"token_start":6,"token_end":6,"label":"DRUG"},{"start":70,"end":81,"token_start":14,"token_end":14,"label":"DRUG"},{"start":99,"end":110,"token_start":20,"token_end":20,"label":"DRUG"},{"start":116,"end":125,"token_start":22,"token_end":22,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9815496/","_input_hash":-419400048,"_task_hash":1005784915,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"We hypothesized that the brain damage mitigating effect of mild hypothermia after cardiac arrest can be enhanced with thiopental loading , and even more so with the further addition of phenytoin and methylprednisolone .","paragraph":"<h3><u>Thiopental combination treatments for cerebral resuscitation after prolonged cardiac arrest in dogs. Exploratory outcome study.</u></h3>We postulate that mitigating the multifactorial pathogenesis of postischemic encephalopathy requires multifaceted treatments. In preparation for expensive definitive studies, we are reporting here the results of small exploratory series, compared with historic controls with the same model. <b style='color:DodgerBlue;'><i>We</i></b> <b style='color:DodgerBlue;'><i>hypothesized</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>brain</i></b> <b style='color:DodgerBlue;'><i>damage</i></b> <b style='color:DodgerBlue;'><i>mitigating</i></b> <b style='color:DodgerBlue;'><i>effect</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>mild</i></b> <b style='color:DodgerBlue;'><i>hypothermia</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:DodgerBlue;'><i>cardiac</i></b> <b style='color:DodgerBlue;'><i>arrest</i></b> <b style='color:DodgerBlue;'><i>can</i></b> <b style='color:DodgerBlue;'><i>be</i></b> <b style='color:DodgerBlue;'><i>enhanced</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>thiopental</i></b> <b style='color:DodgerBlue;'><i>loading</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>even</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>so</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>further</i></b> <b style='color:DodgerBlue;'><i>addition</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>phenytoin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>methylprednisolone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Twenty-four dogs (four groups of six dogs each) received VF 12.5 min no-flow, reversed with brief cardiopulmonary bypass (CPB), controlled ventilation to 20 h, and intensive care to 96 h. Group 1 with normothermia throughout and randomized group 2 with mild hypothermia (from reperfusion to 2 h) were controls. Then, group 3 received in addition, thiopental 90 mg/kg i.v. over the first 6 h. Then, group 4 received, in addition to group 2 treatment, thiopental 30 mg/kg i.v. over the first 90 min (because the larger dose had produced cardiopulmonary complications), plus <b style='color:Tomato;'><i>phenytoin</i></b> 15 mg/kg i.v. at 15 min after reperfusion, and <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b> 130 mg/kg i.v. over 20 h. All dogs survived. Best overall performance categories (OPC) achieved (OPC 1 = normal, OPC 5 = brain death) were better in group 2 than group 1 (< 0.05) and numerically better in groups 3 or 4 than in groups 1 or 2. Good cerebral outcome (OPC 1 or 2) was achieved by all six dogs only in group 4 (P < 0.05 group 4 vs. 2). Best NDS were 44 +/- 3% in group 1; 20 +/- 14% in group 2 (P = 0.002); 21 +/- 15% in group 3 (NS vs. group 2); and 7 +/- 8% in group 4 (P = 0.08 vs. group 2). Total brain histologic damage scores (HDS) at 96 h were 156 +/- 38 in group 1; 81 +/- 12 in group 2 (P < 0.001 vs. group 1); 53 +/- 25 in group 3 (P = 0.02 vs. group 2); and 48 +/- 5 in group 4 (P = 0.02 vs. group 2). We conclude that after prolonged cardiac arrest, the already established brain damage mitigating effect of mild immediate postarrest hypothermia might be enhanced by thiopental, and perhaps then further enhanced by adding <b style='color:Tomato;'><i>phenytoin</i></b> and <b style='color:Tomato;'><i>methyl<b style='color:Tomato;'><i>prednisolone</i></b></i></b>.","tokens":[{"text":"We","start":0,"end":2,"id":0,"ws":true},{"text":"hypothesized","start":3,"end":15,"id":1,"ws":true},{"text":"that","start":16,"end":20,"id":2,"ws":true},{"text":"the","start":21,"end":24,"id":3,"ws":true},{"text":"brain","start":25,"end":30,"id":4,"ws":true},{"text":"damage","start":31,"end":37,"id":5,"ws":true},{"text":"mitigating","start":38,"end":48,"id":6,"ws":true},{"text":"effect","start":49,"end":55,"id":7,"ws":true},{"text":"of","start":56,"end":58,"id":8,"ws":true},{"text":"mild","start":59,"end":63,"id":9,"ws":true},{"text":"hypothermia","start":64,"end":75,"id":10,"ws":true},{"text":"after","start":76,"end":81,"id":11,"ws":true},{"text":"cardiac","start":82,"end":89,"id":12,"ws":true},{"text":"arrest","start":90,"end":96,"id":13,"ws":true},{"text":"can","start":97,"end":100,"id":14,"ws":true},{"text":"be","start":101,"end":103,"id":15,"ws":true},{"text":"enhanced","start":104,"end":112,"id":16,"ws":true},{"text":"with","start":113,"end":117,"id":17,"ws":true},{"text":"thiopental","start":118,"end":128,"id":18,"ws":true},{"text":"loading","start":129,"end":136,"id":19,"ws":true},{"text":",","start":137,"end":138,"id":20,"ws":true},{"text":"and","start":139,"end":142,"id":21,"ws":true},{"text":"even","start":143,"end":147,"id":22,"ws":true},{"text":"more","start":148,"end":152,"id":23,"ws":true},{"text":"so","start":153,"end":155,"id":24,"ws":true},{"text":"with","start":156,"end":160,"id":25,"ws":true},{"text":"the","start":161,"end":164,"id":26,"ws":true},{"text":"further","start":165,"end":172,"id":27,"ws":true},{"text":"addition","start":173,"end":181,"id":28,"ws":true},{"text":"of","start":182,"end":184,"id":29,"ws":true},{"text":"phenytoin","start":185,"end":194,"id":30,"ws":true},{"text":"and","start":195,"end":198,"id":31,"ws":true},{"text":"methylprednisolone","start":199,"end":217,"id":32,"ws":true},{"text":".","start":218,"end":219,"id":33,"ws":false}],"spans":[{"start":185,"end":194,"token_start":30,"token_end":30,"label":"DRUG"},{"start":199,"end":217,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/10950320/","_input_hash":-209864772,"_task_hash":1917055471,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Caspase-independent mechanisms , mainly based on increased oxidative stress , result from 2-methoxyestradiol , Artesunate , ascorbic acid , Dihydroartemisinin , Evodiamine , b-AP15 , VLX1570 , Erw-ASNase , and TAK-242 .","paragraph":"<h3><u>Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma.</u></h3>Multiple myeloma (MM) remains an incurable tumor due to the high rate of relapse that still occurs. Acquired drug resistance represents the most challenging obstacle to the extension of survival and several studies have been conducted to understand the mechanisms of this phenomenon. Mitochondrial pathways have been extensively investigated, demonstrating that cancer cells become resistant to drugs by reprogramming their metabolic assessment. MM cells acquire resistance to proteasome inhibitors (PIs), activating protection programs, such as a reduction in oxidative stress, down-regulating pro-apoptotic, and up-regulating anti-apoptotic signals. Knowledge of the mechanisms through which tumor cells escape control of the immune system and acquire resistance to drugs has led to the creation of new compounds that can restore the response by leading to cell death. In this scenario, based on all literature data available, our review represents the first collection of anti-mitochondrial compounds able to overcome drug resistance in MM. <b style='color:DodgerBlue;'><i>Caspase-independent</i></b> <b style='color:DodgerBlue;'><i>mechanisms</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>mainly</i></b> <b style='color:DodgerBlue;'><i>based</i></b> <b style='color:DodgerBlue;'><i>on</i></b> <b style='color:DodgerBlue;'><i>increased</i></b> <b style='color:DodgerBlue;'><i>oxidative</i></b> <b style='color:DodgerBlue;'><i>stress</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>result</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>2-methoxyestradiol</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Artesunate</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>ascorbic</i></b> <b style='color:DodgerBlue;'><i>acid</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Dihydroartemisinin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Evodiamine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>b-AP15</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>VLX1570</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Erw-ASNase</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>TAK-242</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Other agents restore PIs' efficacy through caspase-dependent tools, such as CDDO-Im, NOXA-inhibitors, FTY720, GCS-100, LBH589, a derivative of ellipticine, AT-101, KD5170, SMAC-mimetics, glutaminase-1 (GLS1)-inhibitors, and thenoyltrifluoroacetone. Each of these substances improved the efficacy rates when employed in combination with the most frequently used antimyeloma drugs.","tokens":[{"text":"Caspase-independent","start":0,"end":19,"id":0,"ws":true},{"text":"mechanisms","start":20,"end":30,"id":1,"ws":true},{"text":",","start":31,"end":32,"id":2,"ws":true},{"text":"mainly","start":33,"end":39,"id":3,"ws":true},{"text":"based","start":40,"end":45,"id":4,"ws":true},{"text":"on","start":46,"end":48,"id":5,"ws":true},{"text":"increased","start":49,"end":58,"id":6,"ws":true},{"text":"oxidative","start":59,"end":68,"id":7,"ws":true},{"text":"stress","start":69,"end":75,"id":8,"ws":true},{"text":",","start":76,"end":77,"id":9,"ws":true},{"text":"result","start":78,"end":84,"id":10,"ws":true},{"text":"from","start":85,"end":89,"id":11,"ws":true},{"text":"2-methoxyestradiol","start":90,"end":108,"id":12,"ws":true},{"text":",","start":109,"end":110,"id":13,"ws":true},{"text":"Artesunate","start":111,"end":121,"id":14,"ws":true},{"text":",","start":122,"end":123,"id":15,"ws":true},{"text":"ascorbic","start":124,"end":132,"id":16,"ws":true},{"text":"acid","start":133,"end":137,"id":17,"ws":true},{"text":",","start":138,"end":139,"id":18,"ws":true},{"text":"Dihydroartemisinin","start":140,"end":158,"id":19,"ws":true},{"text":",","start":159,"end":160,"id":20,"ws":true},{"text":"Evodiamine","start":161,"end":171,"id":21,"ws":true},{"text":",","start":172,"end":173,"id":22,"ws":true},{"text":"b-AP15","start":174,"end":180,"id":23,"ws":true},{"text":",","start":181,"end":182,"id":24,"ws":true},{"text":"VLX1570","start":183,"end":190,"id":25,"ws":true},{"text":",","start":191,"end":192,"id":26,"ws":true},{"text":"Erw-ASNase","start":193,"end":203,"id":27,"ws":true},{"text":",","start":204,"end":205,"id":28,"ws":true},{"text":"and","start":206,"end":209,"id":29,"ws":true},{"text":"TAK-242","start":210,"end":217,"id":30,"ws":true},{"text":".","start":218,"end":219,"id":31,"ws":false}],"spans":[{"start":111,"end":121,"token_start":14,"token_end":14,"label":"DRUG"},{"start":140,"end":158,"token_start":19,"token_end":19,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33669515/","_input_hash":442754413,"_task_hash":392199556,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"In the xenograft model , more augmented effects were achieved when bortezomib was combined with gemcitabine than gemcitabine alone .","paragraph":"<h3><u>Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.</u></h3>Earlier studies that dealt with the combination therapy of <b style='color:Tomato;'><i>gemcitabine</i></b> and histone deacetylation inhibitors for pancreatic cancer revealed unsatisfactory results. The activation of nuclear factor \u03baB (NF-\u03baB) was referred as one of the attributable causes, and we attempted to overcome this resistance by the addition of a proteasome inhibitor. ### methods The influences of suberoylanilide hydroxamic acid (<b style='color:Tomato;'><i>vorinostat</i></b>, SAHA), a histone deacetylase inhibitor, and <b style='color:Tomato;'><i>bortezomib</i></b>, a novel selective antagonist of 26S proteasome, with or without <b style='color:Tomato;'><i>gemcitabine</i></b> on cell growth and apoptosis and the expressions of related proteins were observed in pancreatic cancer cell lines (MiaPaCa-2 and ASPC-1). The xenograft model of pancreatic cancer was used to notice effects in vivo. ### results <b style='color:Tomato;'><i>vorinostat</i></b> and <b style='color:Tomato;'><i>bortezomib</i></b> had independent inhibitory effects and potentiated the antitumor property of <b style='color:Tomato;'><i>gemcitabine</i></b> in vitro. <b style='color:DodgerBlue;'><i>In</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>xenograft</i></b> <b style='color:DodgerBlue;'><i>model</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>more</i></b> <b style='color:DodgerBlue;'><i>augmented</i></b> <b style='color:DodgerBlue;'><i>effects</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>achieved</i></b> <b style='color:DodgerBlue;'><i>when</i></b> <b style='color:MediumOrchid;'><i>bortezomib</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>combined</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:MediumOrchid;'><i>gemcitabine</i></b> <b style='color:DodgerBlue;'><i>alone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The down-regulation of pAkt and suppression of NF-\u03baB activity was induced by the triple combination. ### conclusions The triple combination of <b style='color:Tomato;'><i>vorinostat</i></b>, <b style='color:Tomato;'><i>bortezomib</i></b>, and <b style='color:Tomato;'><i>gemcitabine</i></b> resulted in the strongest antitumor effects both in vitro and in vivo and pAkt and NF-\u03baB seems to be involved in this process.","tokens":[{"text":"In","start":0,"end":2,"id":0,"ws":true},{"text":"the","start":3,"end":6,"id":1,"ws":true},{"text":"xenograft","start":7,"end":16,"id":2,"ws":true},{"text":"model","start":17,"end":22,"id":3,"ws":true},{"text":",","start":23,"end":24,"id":4,"ws":true},{"text":"more","start":25,"end":29,"id":5,"ws":true},{"text":"augmented","start":30,"end":39,"id":6,"ws":true},{"text":"effects","start":40,"end":47,"id":7,"ws":true},{"text":"were","start":48,"end":52,"id":8,"ws":true},{"text":"achieved","start":53,"end":61,"id":9,"ws":true},{"text":"when","start":62,"end":66,"id":10,"ws":true},{"text":"bortezomib","start":67,"end":77,"id":11,"ws":true},{"text":"was","start":78,"end":81,"id":12,"ws":true},{"text":"combined","start":82,"end":90,"id":13,"ws":true},{"text":"with","start":91,"end":95,"id":14,"ws":true},{"text":"gemcitabine","start":96,"end":107,"id":15,"ws":true},{"text":"than","start":108,"end":112,"id":16,"ws":true},{"text":"gemcitabine","start":113,"end":124,"id":17,"ws":true},{"text":"alone","start":125,"end":130,"id":18,"ws":true},{"text":".","start":131,"end":132,"id":19,"ws":false}],"spans":[{"start":67,"end":77,"token_start":11,"token_end":11,"label":"DRUG"},{"start":96,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},{"start":113,"end":124,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/21487323/","_input_hash":-559122592,"_task_hash":-1979398455,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":11,"child":15,"head_span":{"start":67,"end":77,"token_start":11,"token_end":11,"label":"DRUG"},"child_span":{"start":96,"end":107,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"The effectiveness of combination therapy with afatinib and bevacizumab may provide a new therapeutic option for these patients .","paragraph":"<h3><u>Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification: A case report.</u></h3>Acquired resistance to reversible EGFR tyrosine kinase inhibitors remains a significant obstacle, and acquired ERBB2 amplification is the most common \"bypass\" mechanism. For patients with sensitizing EGFR mutation who experience resistance via ERBB2 amplification, no targeted drug has been demonstrated to be effective. ### Patient Concerns A 56-year-old female nonsmoker suffered from left leg paralysis and low back pain. Imaging examination revealed a mass in the anterior segment of the right upper lobe lung and possible multiple metastases in the right hilar, mediastinal lymph nodes, bone metastases, and soft tissue invasion. ### diagnosis Transbronchial lung biopsy revealed a moderately differentiated adenocarcinoma (cT4N2M1c, stage IV). An EGFR exon 19 deletion was identified using amplification refractory mutation system. ### interventions After the patient was treated with <b style='color:Tomato;'><i>gefitinib</i></b> initiation (250\u200amg/d) for 15\u200amonths, the tumor progressed with ERBB2 amplification revealed by next-generation sequencing test. Then, the patient was started on <b style='color:Tomato;'><i>afatinib</i></b> (40\u200amg/d) plus <b style='color:Tomato;'><i>bevacizumab</i></b> (7.5\u200amg/kg every 3\u200aweeks). ### outcomes The combination therapy of <b style='color:Tomato;'><i>afatinib</i></b> and <b style='color:Tomato;'><i>bevacizumab</i></b> in this patient was effective with some slight side effects. Computed tomography scans showed the tumor shrinkage and the pleural effusion disappeared in the right lung. The overall survival was 23.5\u200amonths. ### conclusion To date, there is no targeted therapy approved and demonstrated to be effective for non-small cell lung cancer patients with EGFR sensitizing mutations, and ERBB2 amplification. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>effectiveness</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>therapy</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>afatinib</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>may</i></b> <b style='color:DodgerBlue;'><i>provide</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>new</i></b> <b style='color:DodgerBlue;'><i>therapeutic</i></b> <b style='color:DodgerBlue;'><i>option</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>.</i></b>","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"effectiveness","start":4,"end":17,"id":1,"ws":true},{"text":"of","start":18,"end":20,"id":2,"ws":true},{"text":"combination","start":21,"end":32,"id":3,"ws":true},{"text":"therapy","start":33,"end":40,"id":4,"ws":true},{"text":"with","start":41,"end":45,"id":5,"ws":true},{"text":"afatinib","start":46,"end":54,"id":6,"ws":true},{"text":"and","start":55,"end":58,"id":7,"ws":true},{"text":"bevacizumab","start":59,"end":70,"id":8,"ws":true},{"text":"may","start":71,"end":74,"id":9,"ws":true},{"text":"provide","start":75,"end":82,"id":10,"ws":true},{"text":"a","start":83,"end":84,"id":11,"ws":true},{"text":"new","start":85,"end":88,"id":12,"ws":true},{"text":"therapeutic","start":89,"end":100,"id":13,"ws":true},{"text":"option","start":101,"end":107,"id":14,"ws":true},{"text":"for","start":108,"end":111,"id":15,"ws":true},{"text":"these","start":112,"end":117,"id":16,"ws":true},{"text":"patients","start":118,"end":126,"id":17,"ws":true},{"text":".","start":127,"end":128,"id":18,"ws":false}],"spans":[{"start":46,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},{"start":59,"end":70,"token_start":8,"token_end":8,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/33663050/","_input_hash":-1094798157,"_task_hash":-258752655,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":6,"child":8,"head_span":{"start":46,"end":54,"token_start":6,"token_end":6,"label":"DRUG"},"child_span":{"start":59,"end":70,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone .","paragraph":"<h3><u><b style='color:DodgerBlue;'><i>Clinical</i></b> <b style='color:DodgerBlue;'><i>activity</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>enzalutamide</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>docetaxel</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>men</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>castration-resistant</i></b> <b style='color:DodgerBlue;'><i>prostate</i></b> <b style='color:DodgerBlue;'><i>cancer</i></b> <b style='color:DodgerBlue;'><i>progressing</i></b> <b style='color:DodgerBlue;'><i>after</i></b> <b style='color:MediumOrchid;'><i>abiraterone</i></b> <b style='color:DodgerBlue;'><i>.</i></b></u></h3>The optimal sequencing of the multiple active agents now available for metastatic castration-resistant prostate cancer (mCRPC) is unclear. Prior reports have suggested diminished responses to sequential lines of androgen receptor (AR)-targeted therapies, but it is unknown whether subsequent taxane-based chemotherapy may be more effective than sequential AR-targeting treatment. We sought to evaluate the clinical activity of <b style='color:Tomato;'><i>enzalutamide</i></b> versus <b style='color:Tomato;'><i>docetaxel</i></b> in men with mCRPC who progressed on <b style='color:Tomato;'><i>abiraterone</i></b>. ### methods We performed a single-institution retrospective analysis of consecutive mCRPC patients who had progressed on <b style='color:Tomato;'><i>abiraterone</i></b> therapy and subsequently received either <b style='color:Tomato;'><i>enzalutamide</i></b> (n=30) or <b style='color:Tomato;'><i>docetaxel</i></b> (n=31). We evaluated clinical outcomes including prostate-specific antigen decline of >30% (PSA30) or >50% (PSA50), PSA-progression-free survival (PSA-PFS), and clinical/radiographic PFS. We performed multivariable modeling to control for baseline and on-treatment differences between groups. ### results Compared to subjects who received <b style='color:Tomato;'><i>enzalutamide</i></b> post-<b style='color:Tomato;'><i>abiraterone</i></b>, subjects who received <b style='color:Tomato;'><i>docetaxel</i></b> post-<b style='color:Tomato;'><i>abiraterone</i></b> had more bone metastases, more visceral metastases, higher baseline PSA, and had more frequent PSA tests while on-treatment. There were no significant differences in PSA30 (41% for <b style='color:Tomato;'><i>enzalutamide</i></b> vs. 53% for <b style='color:Tomato;'><i>docetaxel</i></b>) or PSA50 (34% vs. 40%) response rates between the two groups; there remained no difference after stratifying by presence/absence of prior response to <b style='color:Tomato;'><i>abiraterone</i></b>. Median PSA-PFS was 4.1 versus 4.1 months for the <b style='color:Tomato;'><i>enzalutamide</i></b> and <b style='color:Tomato;'><i>docetaxel</i></b> cohorts, respectively (HR 1.35, 95% CI, 0.53-3.66, P=0.502). Median PFS was 4.7 versus 4.4 months, respectively (HR 1.44, 95% CI, 0.77-2.71, P=0.257). PSA-PFS and PFS did not differ after stratifying by prior response to <b style='color:Tomato;'><i>abiraterone</i></b>. In multivariable analyses, there were no significant differences in PSA-PFS or PFS between the two groups. ### conclusions Treatment with either <b style='color:Tomato;'><i>enzalutamide</i></b> or <b style='color:Tomato;'><i>docetaxel</i></b> produced modest PSA responses and PFS intervals in this <b style='color:Tomato;'><i>abiraterone</i></b>-pretreated mCRPC population. In this retrospective study with small sample size, no significant differences in outcomes were observed between groups. Therefore, either <b style='color:Tomato;'><i>enzalutamide</i></b> or <b style='color:Tomato;'><i>docetaxel</i></b> may be a reasonable option in men who have progressed on <b style='color:Tomato;'><i>abiraterone</i></b>.","tokens":[{"text":"Clinical","start":0,"end":8,"id":0,"ws":true},{"text":"activity","start":9,"end":17,"id":1,"ws":true},{"text":"of","start":18,"end":20,"id":2,"ws":true},{"text":"enzalutamide","start":21,"end":33,"id":3,"ws":true},{"text":"versus","start":34,"end":40,"id":4,"ws":true},{"text":"docetaxel","start":41,"end":50,"id":5,"ws":true},{"text":"in","start":51,"end":53,"id":6,"ws":true},{"text":"men","start":54,"end":57,"id":7,"ws":true},{"text":"with","start":58,"end":62,"id":8,"ws":true},{"text":"castration-resistant","start":63,"end":83,"id":9,"ws":true},{"text":"prostate","start":84,"end":92,"id":10,"ws":true},{"text":"cancer","start":93,"end":99,"id":11,"ws":true},{"text":"progressing","start":100,"end":111,"id":12,"ws":true},{"text":"after","start":112,"end":117,"id":13,"ws":true},{"text":"abiraterone","start":118,"end":129,"id":14,"ws":true},{"text":".","start":130,"end":131,"id":15,"ws":false}],"spans":[{"start":21,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},{"start":41,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},{"start":118,"end":129,"token_start":14,"token_end":14,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/25053178/","_input_hash":-60183356,"_task_hash":-289039574,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":3,"child":14,"head_span":{"start":21,"end":33,"token_start":3,"token_end":3,"label":"DRUG"},"child_span":{"start":118,"end":129,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":5,"child":14,"head_span":{"start":41,"end":50,"token_start":5,"token_end":5,"label":"DRUG"},"child_span":{"start":118,"end":129,"token_start":14,"token_end":14,"label":"DRUG"},"color":"#ffd882","label":"POS2"}],"radio":["POS11","POS21"],"answer":"accept"}
{"text":"The use of cyclophosphamide in patients with NSVN is controversial , but recent retrospective data suggest that those treated with prednisone and cyclophosphamide from the outset fare better than those initially treated only with prednisone .","paragraph":"<h3><u>Therapy for vasculitic neuropathies.</u></h3>The term vasculitis refers to a pathologic condition defined by inflammatory cell infiltration and destruction of blood vessels. Systemic vasculitis is classified as primary (eg, polyarteritis nodosa, Churg-Strauss syndrome) or secondary, the latter associated with connective tissue disorders, infections, medications, and rarely, as a paraneoplastic phenomenon. Neuropathy is a common complication of systemic vasculitis and is related to ischemic nerve fiber damage with axon loss. Peripheral neuropathy may be the sole manifestation of vasculitis, a condition termed nonsystemic vasculitic neuropathy (NSVN). Treatment of vasculitic neuropathy requires long-term immunosuppressive therapies with potential side effects. The diagnosis of vasculitis should be established by tissue (preferably nerve) biopsy. High-dose <b style='color:Tomato;'><i>prednisone</i></b> is the standard platform therapy for patients with systemic and NSVN; for those with systemic vasculitis, at least 3 to 12 months of treatment with <b style='color:Tomato;'><i>cyclophosphamide</i></b> (monthly intravenous pulse or daily oral therapy) is also necessary to sustain remission and allow successful <b style='color:Tomato;'><i>prednisone</i></b> tapering. <b style='color:DodgerBlue;'><i>The</i></b> <b style='color:DodgerBlue;'><i>use</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>patients</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>NSVN</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>controversial</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>but</i></b> <b style='color:DodgerBlue;'><i>recent</i></b> <b style='color:DodgerBlue;'><i>retrospective</i></b> <b style='color:DodgerBlue;'><i>data</i></b> <b style='color:DodgerBlue;'><i>suggest</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>from</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>outset</i></b> <b style='color:DodgerBlue;'><i>fare</i></b> <b style='color:DodgerBlue;'><i>better</i></b> <b style='color:DodgerBlue;'><i>than</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>initially</i></b> <b style='color:DodgerBlue;'><i>treated</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:MediumOrchid;'><i>prednisone</i></b> <b style='color:DodgerBlue;'><i>.</i></b> If <b style='color:Tomato;'><i>prednisone</i></b> is administered as monotherapy, <b style='color:Tomato;'><i>cyclophosphamide</i></b> should be added after several months if there is no improvement or relapse occurs with tapering of <b style='color:Tomato;'><i>prednisone</i></b>. Intravenous pulse and daily oral <b style='color:Tomato;'><i>cyclophosphamide</i></b> probably offer similar efficacy, although the risk of complications is greater with oral therapy. <b style='color:Tomato;'><i>azathioprine</i></b> can be safely substituted for <b style='color:Tomato;'><i>cyclophosphamide</i></b> after 3 months without an increased relapse rate. <b style='color:Tomato;'><i>azathioprine</i></b>, <b style='color:Tomato;'><i>methotrexate</i></b>, intravenous immune globulin, <b style='color:Tomato;'><i>mycophenolate</i></b> mofetil, plasma exchange, and <b style='color:Tomato;'><i>rituximab</i></b> can be offered to patients who are intolerant or have a contraindication to <b style='color:Tomato;'><i>cyclophosphamide</i></b>. However, efficacy is unproven for any of these therapies. Interferon-alpha, sometimes combined with plasma exchange, is used to treat vasculitis associated with hepatitis B infection. Some patients also may improve with corticosteroids. The classification of diabetic lumbosacral radiculoplexus neuropathy as a vasculitic disorder remains controversial. However, there is compelling pathological evidence that this condition represents a T-cell-mediated microvasculitis. Some patients treated with intravenous corticosteroids may have greater recovery and improved pain control.","tokens":[{"text":"The","start":0,"end":3,"id":0,"ws":true},{"text":"use","start":4,"end":7,"id":1,"ws":true},{"text":"of","start":8,"end":10,"id":2,"ws":true},{"text":"cyclophosphamide","start":11,"end":27,"id":3,"ws":true},{"text":"in","start":28,"end":30,"id":4,"ws":true},{"text":"patients","start":31,"end":39,"id":5,"ws":true},{"text":"with","start":40,"end":44,"id":6,"ws":true},{"text":"NSVN","start":45,"end":49,"id":7,"ws":true},{"text":"is","start":50,"end":52,"id":8,"ws":true},{"text":"controversial","start":53,"end":66,"id":9,"ws":true},{"text":",","start":67,"end":68,"id":10,"ws":true},{"text":"but","start":69,"end":72,"id":11,"ws":true},{"text":"recent","start":73,"end":79,"id":12,"ws":true},{"text":"retrospective","start":80,"end":93,"id":13,"ws":true},{"text":"data","start":94,"end":98,"id":14,"ws":true},{"text":"suggest","start":99,"end":106,"id":15,"ws":true},{"text":"that","start":107,"end":111,"id":16,"ws":true},{"text":"those","start":112,"end":117,"id":17,"ws":true},{"text":"treated","start":118,"end":125,"id":18,"ws":true},{"text":"with","start":126,"end":130,"id":19,"ws":true},{"text":"prednisone","start":131,"end":141,"id":20,"ws":true},{"text":"and","start":142,"end":145,"id":21,"ws":true},{"text":"cyclophosphamide","start":146,"end":162,"id":22,"ws":true},{"text":"from","start":163,"end":167,"id":23,"ws":true},{"text":"the","start":168,"end":171,"id":24,"ws":true},{"text":"outset","start":172,"end":178,"id":25,"ws":true},{"text":"fare","start":179,"end":183,"id":26,"ws":true},{"text":"better","start":184,"end":190,"id":27,"ws":true},{"text":"than","start":191,"end":195,"id":28,"ws":true},{"text":"those","start":196,"end":201,"id":29,"ws":true},{"text":"initially","start":202,"end":211,"id":30,"ws":true},{"text":"treated","start":212,"end":219,"id":31,"ws":true},{"text":"only","start":220,"end":224,"id":32,"ws":true},{"text":"with","start":225,"end":229,"id":33,"ws":true},{"text":"prednisone","start":230,"end":240,"id":34,"ws":true},{"text":".","start":241,"end":242,"id":35,"ws":false}],"spans":[{"start":11,"end":27,"token_start":3,"token_end":3,"label":"DRUG"},{"start":131,"end":141,"token_start":20,"token_end":20,"label":"DRUG"},{"start":146,"end":162,"token_start":22,"token_end":22,"label":"DRUG"},{"start":230,"end":240,"token_start":34,"token_end":34,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/16464407/","_input_hash":1157918086,"_task_hash":-2064001050,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":20,"child":22,"head_span":{"start":131,"end":141,"token_start":20,"token_end":20,"label":"DRUG"},"child_span":{"start":146,"end":162,"token_start":22,"token_end":22,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS10"],"answer":"accept"}
{"text":"This was a multi-center randomized , two-armed , double-blinded phase II study comparing cediranib plus gefitinib versus cediranib plus placebo in subjects with first relapse/first progression of glioblastoma following surgery and chemoradiotherapy .","paragraph":"<h3><u>Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.</u></h3><b style='color:Tomato;'><i>cediranib</i></b>, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, failed to show benefit over <b style='color:Tomato;'><i>lomustine</i></b> in relapsed glioblastoma. One resistance mechanism for <b style='color:Tomato;'><i>cediranib</i></b> is up-regulation of epidermal growth factor receptor (EGFR). This study aimed to determine if dual therapy with <b style='color:Tomato;'><i>cediranib</i></b> and the oral EGFR inhibitor <b style='color:Tomato;'><i>gefitinib</i></b> improved outcome in recurrent glioblastoma. ### Methods And Findings <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>was</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>multi-center</i></b> <b style='color:DodgerBlue;'><i>randomized</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>two-armed</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>double-blinded</i></b> <b style='color:DodgerBlue;'><i>phase</i></b> <b style='color:DodgerBlue;'><i>II</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>comparing</i></b> <b style='color:MediumOrchid;'><i>cediranib</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:MediumOrchid;'><i>gefitinib</i></b> <b style='color:DodgerBlue;'><i>versus</i></b> <b style='color:MediumOrchid;'><i>cediranib</i></b> <b style='color:DodgerBlue;'><i>plus</i></b> <b style='color:DodgerBlue;'><i>placebo</i></b> <b style='color:DodgerBlue;'><i>in</i></b> <b style='color:DodgerBlue;'><i>subjects</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>first</i></b> <b style='color:DodgerBlue;'><i>relapse/first</i></b> <b style='color:DodgerBlue;'><i>progression</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>glioblastoma</i></b> <b style='color:DodgerBlue;'><i>following</i></b> <b style='color:DodgerBlue;'><i>surgery</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>chemoradiotherapy</i></b> <b style='color:DodgerBlue;'><i>.</i></b> The primary outcome measure was progression free survival (PFS). Secondary outcome measures included overall survival (OS) and radiologic response rate. Recruitment was terminated early following suspension of the <b style='color:Tomato;'><i>cediranib</i></b> program. 38 subjects (112 planned) were enrolled with 19 subjects in each treatment arm. Median PFS with <b style='color:Tomato;'><i>cediranib</i></b> plus <b style='color:Tomato;'><i>gefitinib</i></b> was 3.6 months compared to 2.8 months for <b style='color:Tomato;'><i>cediranib</i></b> plus placebo (HR; 0.72, 90% CI; 0.41 to 1.26). Median OS was 7.2 months with <b style='color:Tomato;'><i>cediranib</i></b> plus <b style='color:Tomato;'><i>gefitinib</i></b> and 5.5 months with <b style='color:Tomato;'><i>cediranib</i></b> plus placebo (HR; 0.68, 90% CI; 0.39 to 1.19). Eight subjects (42%) had a partial response in the <b style='color:Tomato;'><i>cediranib</i></b> plus <b style='color:Tomato;'><i>gefitinib</i></b> arm versus five patients (26%) in the <b style='color:Tomato;'><i>cediranib</i></b> plus placebo arm. ### conclusions <b style='color:Tomato;'><i>cediranib</i></b> and <b style='color:Tomato;'><i>gefitinib</i></b> in combination is tolerated in patients with glioblastoma. Incomplete recruitment led to the study being underpowered. However, a trend towards improved survival and response rates with the addition of <b style='color:Tomato;'><i>gefitinib</i></b> to <b style='color:Tomato;'><i>cediranib</i></b> was observed. Further studies of the combination incorporating EGFR and VEGF inhibition are warranted. ### Trial Registration ClinicalTrials.gov NCT01310855.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"was","start":5,"end":8,"id":1,"ws":true},{"text":"a","start":9,"end":10,"id":2,"ws":true},{"text":"multi-center","start":11,"end":23,"id":3,"ws":true},{"text":"randomized","start":24,"end":34,"id":4,"ws":true},{"text":",","start":35,"end":36,"id":5,"ws":true},{"text":"two-armed","start":37,"end":46,"id":6,"ws":true},{"text":",","start":47,"end":48,"id":7,"ws":true},{"text":"double-blinded","start":49,"end":63,"id":8,"ws":true},{"text":"phase","start":64,"end":69,"id":9,"ws":true},{"text":"II","start":70,"end":72,"id":10,"ws":true},{"text":"study","start":73,"end":78,"id":11,"ws":true},{"text":"comparing","start":79,"end":88,"id":12,"ws":true},{"text":"cediranib","start":89,"end":98,"id":13,"ws":true},{"text":"plus","start":99,"end":103,"id":14,"ws":true},{"text":"gefitinib","start":104,"end":113,"id":15,"ws":true},{"text":"versus","start":114,"end":120,"id":16,"ws":true},{"text":"cediranib","start":121,"end":130,"id":17,"ws":true},{"text":"plus","start":131,"end":135,"id":18,"ws":true},{"text":"placebo","start":136,"end":143,"id":19,"ws":true},{"text":"in","start":144,"end":146,"id":20,"ws":true},{"text":"subjects","start":147,"end":155,"id":21,"ws":true},{"text":"with","start":156,"end":160,"id":22,"ws":true},{"text":"first","start":161,"end":166,"id":23,"ws":true},{"text":"relapse/first","start":167,"end":180,"id":24,"ws":true},{"text":"progression","start":181,"end":192,"id":25,"ws":true},{"text":"of","start":193,"end":195,"id":26,"ws":true},{"text":"glioblastoma","start":196,"end":208,"id":27,"ws":true},{"text":"following","start":209,"end":218,"id":28,"ws":true},{"text":"surgery","start":219,"end":226,"id":29,"ws":true},{"text":"and","start":227,"end":230,"id":30,"ws":true},{"text":"chemoradiotherapy","start":231,"end":248,"id":31,"ws":true},{"text":".","start":249,"end":250,"id":32,"ws":false}],"spans":[{"start":89,"end":98,"token_start":13,"token_end":13,"label":"DRUG"},{"start":104,"end":113,"token_start":15,"token_end":15,"label":"DRUG"},{"start":121,"end":130,"token_start":17,"token_end":17,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/27232884/","_input_hash":1881848093,"_task_hash":-212303019,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":13,"child":15,"head_span":{"start":89,"end":98,"token_start":13,"token_end":13,"label":"DRUG"},"child_span":{"start":104,"end":113,"token_start":15,"token_end":15,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
{"text":"This study aims to compare the biological , molecular , pharmacological , and clinical characteristics of these three treatment modalities for SARS-COV-2 infections , Chloroquine and Hydroxychloroquine , Convalescent Plasma , and Remdesivir .","paragraph":"<h3><u>Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis.</u></h3>The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, also known as COVID-19 pandemic has caused an alarming situation worldwide. Since the first detection, in December 2019, there have been no effective drug therapy options for treating the SARS-CoV-2 pandemic. However, healthcare professionals are using <b style='color:Tomato;'><i>chloroquine</i></b>, hydroxy<b style='color:Tomato;'><i>chloroquine</i></b>, <b style='color:Tomato;'><i>remdesivir</i></b>, convalescent plasma and some other options of treatments. <b style='color:DodgerBlue;'><i>This</i></b> <b style='color:DodgerBlue;'><i>study</i></b> <b style='color:DodgerBlue;'><i>aims</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>compare</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>biological</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>molecular</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>pharmacological</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>clinical</i></b> <b style='color:DodgerBlue;'><i>characteristics</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>these</i></b> <b style='color:DodgerBlue;'><i>three</i></b> <b style='color:DodgerBlue;'><i>treatment</i></b> <b style='color:DodgerBlue;'><i>modalities</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>SARS-COV-2</i></b> <b style='color:DodgerBlue;'><i>infections</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>Chloroquine</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Hydroxychloroquine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>Convalescent</i></b> <b style='color:DodgerBlue;'><i>Plasma</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>Remdesivir</i></b> <b style='color:DodgerBlue;'><i>.</i></b> ### methods A search was conducted in the \"Institute of Science Information (ISI)-Web of Science, PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library databases, Scopus, and Google Scholar\" for peer reviewed, published studies and clinical trials through July 30, 2020. The search was based on keywords \"COVID-19\" SARS-COV-2, <b style='color:Tomato;'><i>chloroquine</i></b>, hydroxy<b style='color:Tomato;'><i>chloroquine</i></b>, convalescent plasma, <b style='color:Tomato;'><i>remdesivir</i></b> and treatment modalities. ### results As of July 30, 2020, a total of 36,640 relevant documents were published. From them 672 peer reviewed, published articles, and clinical trials were screened. We selected 17 relevant published original articles and clinical trials: 05 for <b style='color:Tomato;'><i>chloroquine</i></b> and/or hydroxy<b style='color:Tomato;'><i>chloroquine</i></b> with total sample size (n\u202f=\u202f220), 05 for <b style='color:Tomato;'><i>remdesivir</i></b> (n\u202f=\u202f1,781), and 07 for Convalescent Plasma therapy (n\u202f=\u202f398), with a combined total sample size (n\u202f=\u202f2,399). Based on the available data, convalescent plasma therapy showed clinical advantages in SARS-COV-2 patients. ### conclusions All three treatment modalities have both favorable and unfavorable characteristics, but none showed clear evidence of benefit for early outpatient disease or prophylaxis. Based on the current available data, convalescent plasma therapy appears to show clinical advantages for inpatient use. In the future, ongoing large sample size randomized controlled clinical trials may further clarify the comparative efficacy and safety of these three treatment classes, to conclusively determine whom to treat with which drug and when to treat them.","tokens":[{"text":"This","start":0,"end":4,"id":0,"ws":true},{"text":"study","start":5,"end":10,"id":1,"ws":true},{"text":"aims","start":11,"end":15,"id":2,"ws":true},{"text":"to","start":16,"end":18,"id":3,"ws":true},{"text":"compare","start":19,"end":26,"id":4,"ws":true},{"text":"the","start":27,"end":30,"id":5,"ws":true},{"text":"biological","start":31,"end":41,"id":6,"ws":true},{"text":",","start":42,"end":43,"id":7,"ws":true},{"text":"molecular","start":44,"end":53,"id":8,"ws":true},{"text":",","start":54,"end":55,"id":9,"ws":true},{"text":"pharmacological","start":56,"end":71,"id":10,"ws":true},{"text":",","start":72,"end":73,"id":11,"ws":true},{"text":"and","start":74,"end":77,"id":12,"ws":true},{"text":"clinical","start":78,"end":86,"id":13,"ws":true},{"text":"characteristics","start":87,"end":102,"id":14,"ws":true},{"text":"of","start":103,"end":105,"id":15,"ws":true},{"text":"these","start":106,"end":111,"id":16,"ws":true},{"text":"three","start":112,"end":117,"id":17,"ws":true},{"text":"treatment","start":118,"end":127,"id":18,"ws":true},{"text":"modalities","start":128,"end":138,"id":19,"ws":true},{"text":"for","start":139,"end":142,"id":20,"ws":true},{"text":"SARS-COV-2","start":143,"end":153,"id":21,"ws":true},{"text":"infections","start":154,"end":164,"id":22,"ws":true},{"text":",","start":165,"end":166,"id":23,"ws":true},{"text":"Chloroquine","start":167,"end":178,"id":24,"ws":true},{"text":"and","start":179,"end":182,"id":25,"ws":true},{"text":"Hydroxychloroquine","start":183,"end":201,"id":26,"ws":true},{"text":",","start":202,"end":203,"id":27,"ws":true},{"text":"Convalescent","start":204,"end":216,"id":28,"ws":true},{"text":"Plasma","start":217,"end":223,"id":29,"ws":true},{"text":",","start":224,"end":225,"id":30,"ws":true},{"text":"and","start":226,"end":229,"id":31,"ws":true},{"text":"Remdesivir","start":230,"end":240,"id":32,"ws":true},{"text":".","start":241,"end":242,"id":33,"ws":false}],"spans":[{"start":167,"end":178,"token_start":24,"token_end":24,"label":"DRUG"},{"start":183,"end":201,"token_start":26,"token_end":26,"label":"DRUG"},{"start":230,"end":240,"token_start":32,"token_end":32,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/32921965/","_input_hash":-1164581320,"_task_hash":-1670352699,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":24,"child":26,"head_span":{"start":167,"end":178,"token_start":24,"token_end":24,"label":"DRUG"},"child_span":{"start":183,"end":201,"token_start":26,"token_end":26,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"}],"radio":[],"answer":"accept"}
{"text":"Patients received a mean ( \u00b1standard deviation ) of 8.8 \u00b1 4.9 intravitreal bevacizumab injections prior to the switch to intravitreal ranibizumab .","paragraph":"<h3><u>Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).</u></h3>To evaluate the outcome of second-line intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> treatment in eyes with diabetic macular edema having persistent edema following initial therapy with intravitreal <b style='color:Tomato;'><i>bevacizumab</i></b>. ### Methods Diabetic macular edema treated with <b style='color:Tomato;'><i>ranibizumab</i></b> following <b style='color:Tomato;'><i>bevacizumab</i></b> failure in Israel was a retrospective, multi-center study. Consecutive eyes with persistent diabetic macular edema following at least three previous intravitreal <b style='color:Tomato;'><i>bevacizumab</i></b> injections prior to intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b>, at least three-monthly intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> injections and at least 12\u2009months of follow-up were included. Data collected included demographics, ocular findings, diabetes control, details of intravitreal <b style='color:Tomato;'><i>bevacizumab</i></b> and <b style='color:Tomato;'><i>ranibizumab</i></b> injections, and visual and anatomical measurements before and after intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> treatment. ### Results In total, 202 eyes of 162 patients treated at 11 medical centers across Israel were included. <b style='color:DodgerBlue;'><i>Patients</i></b> <b style='color:DodgerBlue;'><i>received</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>mean</i></b> <b style='color:DodgerBlue;'><i>(</i></b> <b style='color:DodgerBlue;'><i>\u00b1standard</i></b> <b style='color:DodgerBlue;'><i>deviation</i></b> <b style='color:DodgerBlue;'><i>)</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>8.8</i></b> <b style='color:DodgerBlue;'><i>\u00b1</i></b> <b style='color:DodgerBlue;'><i>4.9</i></b> <b style='color:DodgerBlue;'><i>intravitreal</i></b> <b style='color:MediumOrchid;'><i>bevacizumab</i></b> <b style='color:DodgerBlue;'><i>injections</i></b> <b style='color:DodgerBlue;'><i>prior</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>the</i></b> <b style='color:DodgerBlue;'><i>switch</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:DodgerBlue;'><i>intravitreal</i></b> <b style='color:MediumOrchid;'><i>ranibizumab</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A mean of 7.0\u2009\u00b1\u20092.7 intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> injections were given during the 12\u2009months following the switch to intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b>. The median central subfield retinal thickness (\u00b1interquartile range) by spectral-domain optical coherence tomography decreased from 436\u2009\u00b1\u2009162\u2009\u00b5m at baseline to 319\u2009\u00b1\u2009113\u2009\u00b5m at month 12 (p\u2009<\u20090.001). Median logMAR visual acuity (\u00b1interquartile range) improved from 0.40\u2009\u00b1\u20090.48 at baseline to 0.38\u2009\u00b1\u20090.40 at month 12 (p\u2009=\u20090.001). Linear regression suggested that higher number of intravitreal <b style='color:Tomato;'><i>ranibizumab</i></b> injections and higher pre-switch central subfield retinal thickness were associated with favorable visual outcome. Higher number of intravitreal <b style='color:Tomato;'><i>bevacizumab</i></b> injections and the presence of intraretinal fluid before the switch lessened the odds of favorable outcome. ### Conclusion Switching from <b style='color:Tomato;'><i>bevacizumab</i></b> to <b style='color:Tomato;'><i>ranibizumab</i></b> in persistent diabetic macular edema was associated with anatomical improvement in the majority of eyes and \u2a7e2 lines of vision improvement in 22% of eyes.","tokens":[{"text":"Patients","start":0,"end":8,"id":0,"ws":true},{"text":"received","start":9,"end":17,"id":1,"ws":true},{"text":"a","start":18,"end":19,"id":2,"ws":true},{"text":"mean","start":20,"end":24,"id":3,"ws":true},{"text":"(","start":25,"end":26,"id":4,"ws":true},{"text":"\u00b1standard","start":27,"end":36,"id":5,"ws":true},{"text":"deviation","start":37,"end":46,"id":6,"ws":true},{"text":")","start":47,"end":48,"id":7,"ws":true},{"text":"of","start":49,"end":51,"id":8,"ws":true},{"text":"8.8","start":52,"end":55,"id":9,"ws":true},{"text":"\u00b1","start":56,"end":57,"id":10,"ws":true},{"text":"4.9","start":58,"end":61,"id":11,"ws":true},{"text":"intravitreal","start":62,"end":74,"id":12,"ws":true},{"text":"bevacizumab","start":75,"end":86,"id":13,"ws":true},{"text":"injections","start":87,"end":97,"id":14,"ws":true},{"text":"prior","start":98,"end":103,"id":15,"ws":true},{"text":"to","start":104,"end":106,"id":16,"ws":true},{"text":"the","start":107,"end":110,"id":17,"ws":true},{"text":"switch","start":111,"end":117,"id":18,"ws":true},{"text":"to","start":118,"end":120,"id":19,"ws":true},{"text":"intravitreal","start":121,"end":133,"id":20,"ws":true},{"text":"ranibizumab","start":134,"end":145,"id":21,"ws":true},{"text":".","start":146,"end":147,"id":22,"ws":false}],"spans":[{"start":75,"end":86,"token_start":13,"token_end":13,"label":"DRUG"},{"start":134,"end":145,"token_start":21,"token_end":21,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/29916263/","_input_hash":571835589,"_task_hash":1057049130,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[],"radio":[],"answer":"accept"}
{"text":"Combinations of penicillin and streptomycin and penicillin and amikacin were synergistic only against those strains that were not highly resistant to streptomycin and kanamycin , respectively .","paragraph":"<h3><u>Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis.</u></h3>Combinations of penicillin with various aminoglycosidic aminocyclitols were tested against a collection of clinical isolates of Streptococcus faecium in vitro and were used to treat endocarditis caused by S. faecium in the rabbit model. S. faecium proved more resistant to penicillin than Streptococcus faecalis. Even more striking, however, was the resistance to in vitro synergism by combinations of penicillin and various aminoglycosides. At clinically achievable concentrations, penicillin-<b style='color:Tomato;'><i>gentamicin</i></b> was the only combination that was synergistic against all strains that were tested. <b style='color:DodgerBlue;'><i>Combinations</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:DodgerBlue;'><i>penicillin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>amikacin</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>synergistic</i></b> <b style='color:DodgerBlue;'><i>only</i></b> <b style='color:DodgerBlue;'><i>against</i></b> <b style='color:DodgerBlue;'><i>those</i></b> <b style='color:DodgerBlue;'><i>strains</i></b> <b style='color:DodgerBlue;'><i>that</i></b> <b style='color:DodgerBlue;'><i>were</i></b> <b style='color:DodgerBlue;'><i>not</i></b> <b style='color:DodgerBlue;'><i>highly</i></b> <b style='color:DodgerBlue;'><i>resistant</i></b> <b style='color:DodgerBlue;'><i>to</i></b> <b style='color:MediumOrchid;'><i>streptomycin</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>kanamycin</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>respectively</i></b> <b style='color:DodgerBlue;'><i>.</i></b> Combinations of penicillin with <b style='color:Tomato;'><i>kanamycin</i></b>, <b style='color:Tomato;'><i>tobramycin</i></b>, <b style='color:Tomato;'><i>sisomicin</i></b>, or <b style='color:Tomato;'><i>netilmicin</i></b> failed to produce synergism against any of these strains. The possible clinical significance of these findings was verified by use of the rabbit model of endocarditis. Combinations of penicillin with <b style='color:Tomato;'><i>gentamicin</i></b> or <b style='color:Tomato;'><i>streptomycin</i></b> were synergistic in the therapy of endocarditis that was produced by a strain of S. faecium that did not have a high level of resistance to aminoglycosides. However, the combination of penicillin and <b style='color:Tomato;'><i>netilmicin</i></b> was no more effective than penicillin alone.","tokens":[{"text":"Combinations","start":0,"end":12,"id":0,"ws":true},{"text":"of","start":13,"end":15,"id":1,"ws":true},{"text":"penicillin","start":16,"end":26,"id":2,"ws":true},{"text":"and","start":27,"end":30,"id":3,"ws":true},{"text":"streptomycin","start":31,"end":43,"id":4,"ws":true},{"text":"and","start":44,"end":47,"id":5,"ws":true},{"text":"penicillin","start":48,"end":58,"id":6,"ws":true},{"text":"and","start":59,"end":62,"id":7,"ws":true},{"text":"amikacin","start":63,"end":71,"id":8,"ws":true},{"text":"were","start":72,"end":76,"id":9,"ws":true},{"text":"synergistic","start":77,"end":88,"id":10,"ws":true},{"text":"only","start":89,"end":93,"id":11,"ws":true},{"text":"against","start":94,"end":101,"id":12,"ws":true},{"text":"those","start":102,"end":107,"id":13,"ws":true},{"text":"strains","start":108,"end":115,"id":14,"ws":true},{"text":"that","start":116,"end":120,"id":15,"ws":true},{"text":"were","start":121,"end":125,"id":16,"ws":true},{"text":"not","start":126,"end":129,"id":17,"ws":true},{"text":"highly","start":130,"end":136,"id":18,"ws":true},{"text":"resistant","start":137,"end":146,"id":19,"ws":true},{"text":"to","start":147,"end":149,"id":20,"ws":true},{"text":"streptomycin","start":150,"end":162,"id":21,"ws":true},{"text":"and","start":163,"end":166,"id":22,"ws":true},{"text":"kanamycin","start":167,"end":176,"id":23,"ws":true},{"text":",","start":177,"end":178,"id":24,"ws":true},{"text":"respectively","start":179,"end":191,"id":25,"ws":true},{"text":".","start":192,"end":193,"id":26,"ws":false}],"spans":[{"start":16,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},{"start":31,"end":43,"token_start":4,"token_end":4,"label":"DRUG"},{"start":63,"end":71,"token_start":8,"token_end":8,"label":"DRUG"},{"start":150,"end":162,"token_start":21,"token_end":21,"label":"DRUG"},{"start":167,"end":176,"token_start":23,"token_end":23,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/113469/","_input_hash":175357667,"_task_hash":-1271017010,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":2,"child":4,"head_span":{"start":16,"end":26,"token_start":2,"token_end":2,"label":"DRUG"},"child_span":{"start":31,"end":43,"token_start":4,"token_end":4,"label":"DRUG"},"color":"#96e8ce","label":"COMB1"},{"head":6,"child":8,"head_span":{"start":48,"end":58,"token_start":6,"token_end":6,"label":null},"child_span":{"start":63,"end":71,"token_start":8,"token_end":8,"label":"DRUG"},"color":"#ffd1b2","label":"COMB2"}],"radio":[],"answer":"accept"}
{"text":"Treatment with a combination chemotherapeutic regimen consisting of cyclophosphamide , vincristine , and dacarbazine for malignant paraganglioma with hepatic metastasis is reported .","paragraph":"<h3><u>Combination chemotherapy for malignant paraganglioma.</u></h3> <b style='color:DodgerBlue;'><i>Treatment</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>a</i></b> <b style='color:DodgerBlue;'><i>combination</i></b> <b style='color:DodgerBlue;'><i>chemotherapeutic</i></b> <b style='color:DodgerBlue;'><i>regimen</i></b> <b style='color:DodgerBlue;'><i>consisting</i></b> <b style='color:DodgerBlue;'><i>of</i></b> <b style='color:MediumOrchid;'><i>cyclophosphamide</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:MediumOrchid;'><i>vincristine</i></b> <b style='color:DodgerBlue;'><i>,</i></b> <b style='color:DodgerBlue;'><i>and</i></b> <b style='color:MediumOrchid;'><i>dacarbazine</i></b> <b style='color:DodgerBlue;'><i>for</i></b> <b style='color:DodgerBlue;'><i>malignant</i></b> <b style='color:DodgerBlue;'><i>paraganglioma</i></b> <b style='color:DodgerBlue;'><i>with</i></b> <b style='color:DodgerBlue;'><i>hepatic</i></b> <b style='color:DodgerBlue;'><i>metastasis</i></b> <b style='color:DodgerBlue;'><i>is</i></b> <b style='color:DodgerBlue;'><i>reported</i></b> <b style='color:DodgerBlue;'><i>.</i></b> A 51-year-old male presented with tumors in the retroperitoneal space and liver. The patient was diagnosed as having paraganglioma based on elevated levels of serum neuron-specific enolase, urinary catecholamine and vanillylmandelic acid, and on histological findings of the liver specimen. The patient was treated with this combination chemotherapy in repeated 21-day cycles. Temporary improvement in laboratory findings and a 20% reduction in the size of the hepatic masses were observed without severe adverse effects.","tokens":[{"text":"Treatment","start":0,"end":9,"id":0,"ws":true},{"text":"with","start":10,"end":14,"id":1,"ws":true},{"text":"a","start":15,"end":16,"id":2,"ws":true},{"text":"combination","start":17,"end":28,"id":3,"ws":true},{"text":"chemotherapeutic","start":29,"end":45,"id":4,"ws":true},{"text":"regimen","start":46,"end":53,"id":5,"ws":true},{"text":"consisting","start":54,"end":64,"id":6,"ws":true},{"text":"of","start":65,"end":67,"id":7,"ws":true},{"text":"cyclophosphamide","start":68,"end":84,"id":8,"ws":true},{"text":",","start":85,"end":86,"id":9,"ws":true},{"text":"vincristine","start":87,"end":98,"id":10,"ws":true},{"text":",","start":99,"end":100,"id":11,"ws":true},{"text":"and","start":101,"end":104,"id":12,"ws":true},{"text":"dacarbazine","start":105,"end":116,"id":13,"ws":true},{"text":"for","start":117,"end":120,"id":14,"ws":true},{"text":"malignant","start":121,"end":130,"id":15,"ws":true},{"text":"paraganglioma","start":131,"end":144,"id":16,"ws":true},{"text":"with","start":145,"end":149,"id":17,"ws":true},{"text":"hepatic","start":150,"end":157,"id":18,"ws":true},{"text":"metastasis","start":158,"end":168,"id":19,"ws":true},{"text":"is","start":169,"end":171,"id":20,"ws":true},{"text":"reported","start":172,"end":180,"id":21,"ws":true},{"text":".","start":181,"end":182,"id":22,"ws":false}],"spans":[{"start":68,"end":84,"token_start":8,"token_end":8,"label":"DRUG"},{"start":87,"end":98,"token_start":10,"token_end":10,"label":"DRUG"},{"start":105,"end":116,"token_start":13,"token_end":13,"label":"DRUG"}],"article_link":"https://pubmed.ncbi.nlm.nih.gov/9058098/","_input_hash":-1922423655,"_task_hash":-164068088,"_session_id":"drug_drug_pilot_split2c-hagit","_view_id":"blocks","relations":[{"head":8,"child":10,"head_span":{"start":68,"end":84,"token_start":8,"token_end":8,"label":"DRUG"},"child_span":{"start":87,"end":98,"token_start":10,"token_end":10,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"},{"head":10,"child":13,"head_span":{"start":87,"end":98,"token_start":10,"token_end":10,"label":"DRUG"},"child_span":{"start":105,"end":116,"token_start":13,"token_end":13,"label":"DRUG"},"color":"#c5bdf4","label":"POS1"}],"radio":["POS11"],"answer":"accept"}
